Glycosidic dual-cleavage linkers for antibody-drug conjugates

JP2023551203A5Pending Publication Date: 2024-11-26R P SCHERER TECH INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023530743
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-01-20
Filing Date
2021-11-19
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Existing antibody-drug conjugates lack efficient enzymatic cleavage mechanisms for targeted drug release, leading to potential off-target effects and reduced specificity.

Method used

Development of antibody-drug conjugates with a cleavable linker system that includes a first enzymatically cleavable moiety and a second enzymatically cleavable glycoside, such as galactosides, glucosides, mannosides, fucosides, O-GlcNAc, or O-GalNAc, to enhance targeted drug release and reduce off-target activity.

Benefits of technology

The cleavable linker system enables precise drug delivery by enzymatic cleavage, improving the specificity and efficacy of antibody-drug conjugates, reducing side effects and enhancing therapeutic potency.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present disclosure provides antibody-drug conjugate structures, the antibody-drug conjugate structures comprising a cleavable linker linking the antibody to the drug and having a first enzymatically cleavable moiety and a second enzymatically cleavable moiety comprising a glycoside selected from a galactoside, a glucoside, a mannoside, a fucoside, O-GlcNAc, and O-GalNAc. The present disclosure also encompasses compounds and methods for producing such conjugates, as well as methods of using the conjugates.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Cross-reference of related applications This application claims the interests of U.S. Provisional Application No. 63 / 116,632, filed November 20, 2020, and U.S. Provisional Application No. 63 / 139,685, filed January 20, 2021, the disclosures thereof incorporated herein by reference.

[0002] Introduction The field of protein-small molecule conjugate therapy has evolved significantly and is offering many clinically beneficial drugs, with the expectation that more drugs will be available in the coming years. Protein-conjugate therapies can offer several advantages, for example, due to their specificity, functional diversity, and relatively low off-target activity, as well as fewer side effects. Chemical modification of proteins can extend these advantages by making them more potent, stable, or diverse. [Overview of the project]

[0003] This disclosure provides an antibody-drug conjugate structure comprising an antibody linked to a drug and a cleavable linker having a first enzymatically cleavable moiety and a second enzymatically cleavable moiety containing a glycoside selected from galactosides, glucosides, mannosides, fucosides, O-GlcNAc, and O-GalNAc. This disclosure also includes compounds and methods for producing such conjugates, as well as methods for using the conjugates.

[0004] Aspects of the present disclosure include a conjugate comprising an antibody, a drug, and a cleavable linker that links the antibody to the drug and has a first enzymatically cleavable portion and a second enzymatically cleavable portion comprising a glycoside selected from galactosides, glucosides, mannosides, fucosides, O-GlcNAc, and O-GalNAc.

[0005] In some embodiments, the conjugate is a conjugate of formula (I),

Chemical formula

[0006] In some embodiments, k is 2, and the conjugate is the conjugate of formula (Ia). [ka]

[0007] In some embodiments, the second enzymatically cleavable portion comprises a galactoside. In some embodiments, the second enzymatically cleavable portion comprises a glucoside. In some embodiments, the second enzymatically cleavable portion comprises a mannoside. In some embodiments, the second enzymatically cleavable portion comprises a fucisode. In some embodiments, the second enzymatically cleavable portion comprises O-GlcNAc. In some embodiments, the second enzymatically cleavable portion comprises O-GalNAc.

[0008] In some embodiments, the conjugate is the conjugate of formula (Ib). [ka]

[0009] In some embodiments, the conjugate is the conjugate of expression (Ic). [ka]

[0010] In some embodiments, the conjugate is the conjugate of expression (Id). [ka]

[0011] In some embodiments, the conjugate is the conjugate of formula (Ie). [ka]

[0012] In some embodiments, the conjugate is a conjugate of the expression (If). [ka]

[0013] In some embodiments, the conjugate is the conjugate of formula (Ig). [ka]

[0014] In some embodiments, L 1 teeth, -(T 1 -V 1 ) a -(T 2 -V 2 ) b -(T 3 -V 3 ) c -(T 4 -V 4 ) d - Includes, During the ceremony, a, b, c, and d are each independently either 0 or 1. T 1 , T 2 , T 3 , and T 4 However, each is independent, and covalent, (C1~C 12 ) alkyl, substituted (C1~C 12 ) alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl, (EDA) w (PEG) n , (AA) p ,-(CR 13 OH) m - Selected from 4-amino-piperidine (4AP), acetal group, hydrazine, disulfide, and ester, where EDA is the ethylenediamine moiety, PEG is polyethylene glycol, AA is an amino acid residue or amino acid analog, each w is an integer from 1 to 20, each n is an integer from 1 to 30, each p is an integer from 1 to 20, and each m is an integer from 1 to 12. V 1 , V 2 , V 3 , and V 4 However, each operates independently as a covalent bond, -CO-, -NR. 15 -, -NR 15 (CH2) q -, -NR 15 (C6H4)-, -CONR 15 -, -NR 15 CO-, -C(O)O-, -OC(O)-, -O-, -S-, -S(O)-, -SO2-, -SO2NR 15 -, -NR 15 Selected from the group consisting of SO2- and -P(O)OH-, where each q is an integer from 1 to 6. Each R 13 However, they are independently selected from hydrogen, alkyl, substituted alkyl, aryl, and substituted aryl. Each R 15However, these are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, carboxyl, carboxyl ester, acyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl.

[0015] In some embodiments, L 2 teeth, -(T 5 -V 5 ) e -(T 6 -V 6 ) f -(T 7 -V 7 ) g -(T 8 -V 8 ) h - Includes, During the ceremony, e, f, g, and h are each independently either 0 or 1. T 5 , T 6 , T 7 , and T 8 However, each is independent, and covalent, (C1~C 12 ) alkyl, substituted (C1~C 12 ) alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl, (EDA) w (PEG) n , (AA) p ,-(CR 13 OH) m - Selected from 4-amino-piperidine (4AP), acetal group, hydrazine, disulfide, and ester, where EDA is the ethylenediamine moiety, PEG is polyethylene glycol, AA is an amino acid residue or amino acid analog, each w is an integer from 1 to 20, each n is an integer from 1 to 30, each p is an integer from 1 to 20, and each m is an integer from 1 to 12. V 5 , V 6 , V7 and V 8 is, independently of each other, a covalent bond, -CO-, -NR 15 -, -NR 15 (CH2) q -, -NR 15 (C6H4)-, -CONR 15 -, -NR 15 CO-, -C(O)O-, -OC(O)-, -O-, -S-, -S(O)-, -SO2-, -SO2NR 15 -, -NR 15 SO2-, and -P(O)OH- and is selected from the group consisting of, each q is an integer from 1 to 6, each R 13 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, and substituted aryl, each R 15 is independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, carboxyl, carboxyl ester, acyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl.

[0016] In some embodiments, L 1 is as described herein, where T 1 is selected from (C1-C 12 ) alkyl and substituted (C1-C 12 ) alkyl, T 2 , T 3 , and T 4 are each independently aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl, (EDA) w , (PEG) n , (C1-C 12 ) alkyl, substituted (C1-C 12 ) alkyl, (AA) p , -(CR 13 OH) m- Selected from 4-amino-piperidine (4AP), acetal group, hydrazine, and ester, V 1 , V 2 , V 3 , and V 4 However, each operates independently as a covalent bond, -CO-, -NR. 15 -, -NR 15 (CH2) q -, -NR 15 (C6H4)-, -CONR 15 -, -NR 15 CO-, -C(O)O-, -OC(O)-, -O-, -S-, -S(O)-, -SO2-, -SO2NR 15 -, -NR 15 Selected from the group consisting of SO2- and -P(O)OH-, During the ceremony, (PEG) n but, [ka] In the formula, n is an integer between 1 and 30. EDA has the following structure [ka] The ethylenediamine moiety has the following characteristics, where y is an integer from 1 to 6, and r is 0 or 1. 4-amino-piperidine (4AP) [ka] And, Each R 12 and R 15 However, independently selected from hydrogen, alkyl, substituted alkyl, polyethylene glycol moiety, aryl, and substituted aryl, any two adjacent R 12 The groups may be linked in a ring to form a piperazinyl ring. R 13 However, it is selected from hydrogen, alkyl, substituted alkyl, aryl, and substituted aryl.

[0017] In some embodiments, L 1 This is as described herein, and here, T 1 However, (C1~C 12 ) is alkyl, V 1 However, it is -CO-, T 2 However, it is an amino acid analog, V 2 However, it is -NH-, T 3 However, (PEG) n V 3 However, it is -CO-, d is 0.

[0018] In some embodiments, L 2 This is as described herein, and here, T 5 However, it is a covalent bond, V 5 However, it is -CO-, f, g, and h are 0.

[0019] In some embodiments, L 2 This is as described herein, and here, T 5 However, it is a covalent bond, V 5 However, -CONR 15 -and, T 6 However, (C1~C 12 ) is alkyl, V 6 However, it is -CO-, g and h are 0.

[0020] In some embodiments, the drug is selected from cytotoxins, kinase inhibitors, immunostimulants, Toll-like receptor (TLR) agonists, oligonucleotides, aptamers, cytokines, steroids, and peptides. In some embodiments, the drug is selected from auristatin, mytansin, and duocalmycin. In some embodiments, the drug is selected from tubulisin M, calichemycin, SN-38, exatecan, STAT3 inhibitors, alpha-amanitin, aurora kinase inhibitors, berotecan, 9-aminocamptothecin (9-AC), and anthracyclines.

[0021] Aspects of the present disclosure include compounds comprising a cleavable linker for linking an antibody to a drug, wherein the cleavable linker comprises a first enzymatically cleavable moiety and a second enzymatically cleavable moiety having a glycoside selected from galactosides, glucosides, mannosides, fucosides, O-GlcNAc, and O-GalNAc.

[0022] In some embodiments, the compound is a compound of formula (II), [ka] During the ceremony, Z, CR 4 or N, X is O or NR 4 And, R 2 and R 3 However, each is independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, acyl, acyloxy, acylamino, aminoacyl, alkylamide, substituted alkylamide, sulfonyl, thioalkoxy, substituted thioalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl, or R 2 and R 3However, they are optionally linked in a ring, forming a 5- or 6-membered heterocycline. Each R 4 However, independently selected from hydrogen, halogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, acyl, acyloxy, acylamino, aminoacyl, alkylamide, substituted alkylamide, sulfonyl, thioalkoxy, substituted thioalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl, Each R 5 However, they are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl. Each R 6 However, they are independently selected from alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl. k is an integer between 1 and 10. R 7 However, it contains a second enzymatically cleavable portion, L 1 However, it was the first linker, L 2 However, it is the second linker, W 1 However, it is a drug.

[0023] In some embodiments, k is 2, and the compound is the compound of formula (IIa). [ka]

[0024] In some embodiments, the second cleavable portion comprises a galactoside. In some embodiments, the second cleavable portion comprises a glucoside. In some embodiments, the second cleavable portion comprises a mannoside. In some embodiments, the second enzymatically cleavable portion comprises a fucisode. In some embodiments, the second enzymatically cleavable portion comprises O-GlcNAc. In some embodiments, the second enzymatically cleavable portion comprises O-GalNAc.

[0025] In some embodiments, the compound is the compound of formula (IIb). [ka]

[0026] In some embodiments, the compound is a compound of formula (IIc). [ka]

[0027] In some embodiments, the compound is the compound of formula (IId). [ka]

[0028] In some embodiments, the compound is a compound of formula (IIe). [ka]

[0029] In some embodiments, the compound is a compound of formula (IIf). [ka]

[0030] In some embodiments, the compound is the compound of formula (IIg). [ka]

[0031] In some embodiments, L 1 teeth, -(T 1 -V 1 ) a -(T 2 -V 2 ) b -(T 3 -V 3 ) c -(T 4 -V 4 ) d - Includes, During the ceremony, a, b, c, and d are each independently either 0 or 1. T 1 , T 2 , T 3 , and T 4 However, each is independent, and covalent, (C1~C 12 ) alkyl, substituted (C1~C 12 ) alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl, (EDA) w (PEG) n , (AA) p ,-(CR 13 OH) m - Selected from 4-amino-piperidine (4AP), acetal group, hydrazine, disulfide, and ester, where EDA is the ethylenediamine moiety, PEG is polyethylene glycol, AA is an amino acid residue or amino acid analog, each w is an integer from 1 to 20, each n is an integer from 1 to 30, each p is an integer from 1 to 20, and each m is an integer from 1 to 12. V 1 , V 2 , V 3 , and V 4 However, each operates independently as a covalent bond, -CO-, -NR. 15 -, -NR 15 (CH2) q-, -NR 15 (C6H4)-, -CONR 15 -, -NR 15 CO-, -C(O)O-, -OC(O)-, -O-, -S-, -S(O)-, -SO2-, -SO2NR 15 -, -NR 15 Selected from the group consisting of SO2- and -P(O)OH-, where each q is an integer from 1 to 6. Each R 13 However, they are independently selected from hydrogen, alkyl, substituted alkyl, aryl, and substituted aryl. Each R 15 However, these are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, carboxyl, carboxyl ester, acyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl.

[0032] In some embodiments, L 2 teeth, -(T 5 -V 5 ) e -(T 6 -V 6 ) f -(T 7 -V 7 ) g -(T 8 -V 8 ) h - Includes, During the ceremony, e, f, g, and h are each independently either 0 or 1. T 5 , T 6 , T 7 , and T 8 However, each is independent, and covalent, (C1~C 12 ) alkyl, substituted (C1~C 12 ) alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl, (EDA) w (PEG) n, (AA) p ,-(CR 13 OH) m - Selected from 4-amino-piperidine (4AP), acetal group, hydrazine, disulfide, and ester, where EDA is the ethylenediamine moiety, PEG is polyethylene glycol, AA is an amino acid residue or amino acid analog, each w is an integer from 1 to 20, each n is an integer from 1 to 30, each p is an integer from 1 to 20, and each m is an integer from 1 to 12. V 5 , V 6 , V 7 , and V 8 However, each operates independently as a covalent bond, -CO-, -NR. 15 -, -NR 15 (CH2) q -, -NR 15 (C6H4)-, -CONR 15 -, -NR 15 CO-, -C(O)O-, -OC(O)-, -O-, -S-, -S(O)-, -SO2-, -SO2NR 15 -, -NR 15 Selected from the group consisting of SO2- and -P(O)OH-, where each q is an integer from 1 to 6. Each R 13 However, they are independently selected from hydrogen, alkyl, substituted alkyl, aryl, and substituted aryl. Each R 15 However, these are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, carboxyl, carboxyl ester, acyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl.

[0033] In some embodiments, L 1 This is as described herein, and here, T 1 However, (C1~C 12 ) Alkyl and substituted (C1~C 12 ) Selected from alkyl groups, T 2 , T3 , and T 4 However, each independently includes aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl (EDA) w (PEG) n , (C1~C 12 ) alkyl, substituted (C1~C 12 ) alkyl, (AA) p ,-(CR 13 OH) m - Selected from 4-amino-piperidine (4AP), acetal group, hydrazine, and ester, V 1 , V 2 , V 3 , and V 4 However, each operates independently as a covalent bond, -CO-, -NR. 15 -, -NR 15 (CH2) q -, -NR 15 (C6H4)-, -CONR 15 -, -NR 15 CO-, -C(O)O-, -OC(O)-, -O-, -S-, -S(O)-, -SO2-, -SO2NR 15 -, -NR 15 Selected from the group consisting of SO2- and -P(O)OH-, During the ceremony, (PEG) n but, [ka] In the formula, n is an integer between 1 and 30. EDA has the following structure [ka] The ethylenediamine moiety has the following characteristics, where y is an integer from 1 to 6, and r is 0 or 1. 4-amino-piperidine (4AP) [ka] And, Each R12 and R 15 However, independently selected from hydrogen, alkyl, substituted alkyl, polyethylene glycol moiety, aryl, and substituted aryl, any two adjacent R 12 The groups may be linked in a ring to form a piperazinyl ring. R 13 However, it is selected from hydrogen, alkyl, substituted alkyl, aryl, and substituted aryl.

[0034] In some embodiments, L 1 This is as described herein, and here, T 1 However, (C1~C 12 ) is alkyl, V 1 However, it is -CO-, T 2 However, it is an amino acid analog, V 2 However, it is -NH-, T 3 However, (PEG) n V 3 However, it is -CO-, d is 0.

[0035] In some embodiments, L 2 This is as described herein, and here, T 5 However, it is a covalent bond, V 5 However, it is -CO-, f, g, and h are 0.

[0036] In some embodiments, L 2 This is as described herein, and here, T 5 However, it is a covalent bond, V 5 However, -CONR 15 -and, T 6 However, (C1~C 12 ) is alkyl, V 6 However, it is -CO-, g and h are 0.

[0037] In some embodiments, the drug is selected from cytotoxins, kinase inhibitors, immunostimulants, Toll-like receptor (TLR) agonists, oligonucleotides, aptamers, cytokines, steroids, and peptides. In some embodiments, the drug is selected from auristatin, mytansin, and duocalmycin. In some embodiments, the drug is selected from tubulisin M, calichemycin, SN-38, exatecan, STAT3 inhibitors, alpha-amanitin, aurora kinase inhibitors, berotecan, 9-aminocamptothecin (9-AC), and anthracyclines.

[0038] Aspects of this disclosure include pharmaceutical compositions comprising a conjugate described herein and a pharmaceutically acceptable excipient.

[0039] Aspects of this disclosure include methods for administering a conjugate to a subject, wherein the method comprises administering the conjugate described herein to the subject.

[0040] Aspects of the present disclosure include a method for treating cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a conjugate described herein, wherein the administration is effective in treating cancer in the subject. [Brief explanation of the drawing]

[0041] [Figure 1] This diagram shows cytotoxins commonly used to generate therapeutic antibody-drug conjugates. Arrows indicate base instability groups. [Figure 2] This document describes HIPS ligation for the synthesis of antibody-drug conjugates (ADCs). Antibodies containing an aldehyde moiety were reacted with a Hydrazino-iso-Pictet-Spengler (HIPS) linker and payload to generate site-specifically conjugated ADCs with stable azacarborin binding. [Figure 3]The hydrophobic interaction column (HIC) trace of construct 30 trastuzumab conjugate is shown, and the DAR was 1.7 as determined by HIC. [Figure 4] The analytical size exclusion chromatography (SEC) trace of construct 30 trastuzumab conjugate is shown, indicating that the conjugate was 97.1% monomer, as determined by analytical SEC. [Figure 5] The HIC trace of construct 33 trustuzumab conjugate is shown, and the DAR was 1.66 when determined by HIC. [Figure 6] The analytical SEC trace of construct 33 trastuzumab conjugate is shown, which indicated that the conjugate was 97.6% monomer, as determined by analytical SEC. [Figure 7] The HIC trace of construct 30 polatuzumab conjugate is shown, and the DAR was 1.78 when determined by HIC. [Figure 8] The analytical SEC trace of construct 30 polatuzumab conjugate is shown, which indicated that the conjugate was 95.4% monomer, as determined by analytical SEC. [Figure 9] The HIC trace of construct 33, polatuzumab conjugate, is shown, and the DAR was 1.6 as determined by HIC. [Figure 10] The analytical SEC trace of construct 33 polatuzumab conjugate is shown, which indicated that the conjugate was 96.8% monomer, as determined by analytical SEC. [Figure 11] The structures of comparative molecules 35 (single-cleavage mytansine construct) and 34 (glucuronide double-cleavage MMAE construct) are shown. [Figure 12] The graph shows the in vitro efficacy of ADCs conjugated with mytansin possessing a single cleavage (35) or a galactosid-modified double cleavage linker (30) against Granta-519 cells. [Figure 13]The graph shows the in vitro efficacy of ADCs conjugated with mytansin possessing a single cleavage (35) or a galactosid-modified double cleavage linker (30) against Ramos-RA cells. [Figure 14] The graph shows the in vitro efficacy of ADCs conjugated with mytansin possessing a single cleavage (35) or a galactosid-modified double cleavage linker (30) against NCI-N87 cells. [Figure 15] The graph shows the in vitro efficacy of ADCs conjugated with mytansin possessing a single cleavage (35) or a galactosid-modified double cleavage linker (30) against Sk-Br-3 cells. [Figure 16] This graph shows the in vitro efficacy of ADCs conjugated with MMAEs possessing glucuronide-modified double-cleavage linkers (34) or galactoside-modified double-cleavage linkers (33) against Ramos-RA cells. [Figure 17] The graph shows the in vitro efficacy of ADCs conjugated with MMAEs possessing glucuronide-modified double-cleavage linkers (34) or galactoside-modified double-cleavage linkers (33) against NCI-N87 cells. [Figure 18] The graph shows the in vitro efficacy of ADCs conjugated with MMAEs possessing glucuronide-modified double-cleavage linkers (34) or galactoside-modified double-cleavage linkers (33) against Sk-Br-3 cells. [Figure 19] The PLRP trace of the 46 anti-FITC conjugate structure is shown, and the DAR was 1.70 as determined by the PLRP. [Figure 20] The analytical SEC trace of construct 46 anti-FITC conjugate is shown, and as determined by analytical SEC, 95.9% were monomers. [Figure 21] The PLRP trace for construct 46 trastuzumab conjugate is shown, and the DAR was 1.79 when determined by PLRP. [Figure 22]The analytical SEC trace of construct 46 trastuzumab conjugate is shown, and as determined by analytical SEC, 96.2% was monomer. [Figure 23] The PLRP trace of construct 46, the sacizumab conjugate, was shown, and the DAR was 1.15 as determined by PLRP. [Figure 24] The analytical SEC trace of construct 46 sacituzumab conjugate is shown, and as determined by analytical SEC, 94.4% was monomer. [Figure 25] The PLRP trace of the 44 anti-FITC conjugate structure is shown, and the DAR was 1.68 as determined by the PLRP. [Figure 26] The analytical SEC trace of construct 44 anti-FITC conjugate is shown, and as determined by analytical SEC, 96.0% were monomers. [Figure 27] The PLRP trace for construct 44 trustuzumab conjugate is shown, and the DAR was 1.78 when determined by PLRP. [Figure 28] The analytical SEC trace of construct 44 trastuzumab conjugate is shown, and as determined by analytical SEC, 96.0% was monomer. [Figure 29] The PLRP trace of construct 44 sacizumab conjugate is shown, and the DAR was 1.16 when determined by PLRP. [Figure 30] The analytical SEC trace of construct 44 sacituzumab conjugate is shown, and as determined by analytical SEC, 94.5% was monomer. [Figure 31] This graph shows the in vitro efficacy of ADCs conjugated with mytansin possessing glucoside modification (44) or galactoside modification double cleavage linker (30) against MDA-MB-468 cells. [Figure 32] The graph shows the in vitro efficacy of ADCs conjugated with mytansin possessing glucoside modification (44) or galactoside modification double cleavage linker (30) against BxPC3 cells. [Figure 33] The graph shows the in vitro efficacy of ADCs conjugated with mytansin possessing glucoside modification (44) or galactoside modification double cleavage linker (30) against SKBR3 cells. [Figure 34] This graph shows the in vitro efficacy of ADCs conjugated with mytansin possessing glucoside modification (44) or galactoside modification double cleavage linker (30) against NCI-N87 cells. [Figure 35] This graph shows the in vitro efficacy of ADCs conjugated with MMAEs possessing glucuronide modification (34) or glucoside modification double-cleavage linkers (46) against MDA-MB-468 cells. [Figure 36] The graph shows the in vitro efficacy of ADCs conjugated with MMAEs possessing glucuronide modification (34) or glucoside modification double-cleavage linkers (46) against BxPC3 cells.

[0042] definition The following terms have the meanings set forth below unless otherwise indicated. Any undefined terms have the meanings recognized in the art.

[0043] "Alkyl" refers to a monovalent saturated aliphatic hydrocarbyl group having 1 to 10 carbon atoms, for example, 1 to 6 carbon atoms, or 1 to 5, or 1 to 4, or 1 to 3 carbon atoms. This term includes, by example, linear and branched hydrocarbyl groups, such as methyl (CH3-), ethyl (CH3CH2-), n-propyl (CH3CH2CH2-), isopropyl ((CH3)2CH-), n-butyl (CH3CH2CH2CH2-), isobutyl ((CH3)2CHCH2-), sec-butyl ((CH3)(CH3CH2)CH-), t-butyl ((CH3)3C-), n-pentyl (CH3CH2CH2CH2CH2-), and neopentyl ((CH3)3CCH2-).

[0044] The term "substituted alkyl" refers to a group in which one or more carbon atoms (excluding the C1 carbon atom) in the alkyl chain are optionally -O-, -N-, -S-, or -S(O). n -(wherein n is 0 to 2), -NR-(wherein R is hydrogen or alkyl), etc. are replaced by heteroatoms, and include alkoxy, substituted alkoxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, acyl, acylamino, acyloxy, amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azide, cyano, halogen, hydroxyl, oxo, thioketo, carboxyl, carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-aryl, -SO-heteroaryl, -SO2-alkyl, -SO2-aryl, -SO2-heteroaryl, and -NR a R b Having 1 to 5 substituents selected from the group consisting of R ’ and R ” However, these may be the same or different and refer to alkyl groups as defined herein, selected from hydrogen, optionally substituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl, and heterocyclic groups.

[0045] "Alkylene" is a divalent aliphatic hydrocarbyl group, preferably having 1 to 6 carbon atoms in either a linear or branched chain, more preferably 1 to 3 carbon atoms, and optionally -O-, -NR 10 -, -NR 10 C(O)-, -C(O)NR 10- Refers to a group interrupted by one or more groups selected from the following. Examples of this term include methylene (-CH2-), ethylene (-CH2CH2-), n-propylene (-CH2CH2CH2-), iso-propylene (-CH2CH(CH3)-), (-C(CH3)2CH2CH2-), (-C(CH3)2CH2C(O)-), (-C(CH3)2CH2C(O)NH-), (-CH(CH3)CH2-), etc.

[0046] "Substitutive alkylene" refers to an alkylene group having 1 to 3 hydrogen atoms replaced by substituents, as described in the definition of "substitution" below for carbon.

[0047] The term "alkane" refers to alkyl and alkylene groups as defined herein.

[0048] The terms "alkylaminoalkyl," "alkylaminoalkenyl," and "alkylaminoalkynyl" refer to an R'NHR"- group in which R' is an alkyl group as defined herein and R'' is an alkylene, alkenylene, or alkynylene group as defined herein.

[0049] The terms "alkaryl" or "aralkyl" refer to alkylene-aryl and substituted alkylene-aryl groups, where alkylene, substituted alkylene, and aryl are as defined herein.

[0050] "Alkoxy" refers to an -O-alkyl group, where alkyl is as defined herein. Examples of alkoxys include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, t-butoxy, sec-butoxy, n-pentoxy, and the like. The term "alkoxy" also refers to alkenyl-O-, cycloalkyl-O-, cycloalkenyl-O-, and alkynyl-O- groups, where alkenyl, cycloalkyl, cycloalkenyl, and alkynyl are as defined herein.

[0051] The term "substituted alkoxy" refers to a substituted alkyl-O-, substituted alkenyl-O-, substituted cycloalkyl-O-, substituted cycloalkenyl-O-, and substituted alkynyl-O- group, where substituted alkyl, substituted alkenyl, substituted cycloalkyl, substituted cycloalkenyl, and substituted alkynyl are as defined herein.

[0052] The term "alkoxyamino" refers to an -NH-alkoxy group in which alkoxy is as defined herein.

[0053] The term "haloalkoxy" refers to an alkyl-O- group in which one or more hydrogen atoms on the alkyl group are substituted with a halo group, and examples include groups such as trifluoromethoxy.

[0054] The term "haloalkyl" refers to the aforementioned substituted alkyl groups in which one or more hydrogen atoms on the alkyl group are replaced by a halo group. Examples of such groups include, but are not limited to, fluoroalkyl groups, such as trifluoromethyl, difluoromethyl, and trifluoroethyl.

[0055] The term "alkylalkoxy" refers to alkylene-O-alkyl, alkylene-O-substituted alkyl, substituted alkylene-O-alkyl, and substituted alkylene-O-substituted alkyl groups, wherein alkyl, substituted alkyl, alkyl, alkylene and substituted alkylene are as defined herein.

[0056] The term "alkylthioalkoxy" refers to alkylene-S-alkyl, alkylene-S-substituted alkyl, substituted alkylene-S-alkyl, and substituted alkylene-S-substituted alkyl groups, wherein alkyl, substituted alkyl, alkyl, and substituted alkylene are as defined herein.

[0057] "Alkenyl" refers to a linear or branched hydrocarbyl group having 2 to 6 carbon atoms, preferably 2 to 4 carbon atoms, and at least 1, preferably 1 to 2 double bond unsaturated sites. Examples of this term include bivinyl, allyl, and buta-3-en-1-yl. This term includes cis and trans isomers, or mixtures thereof.

[0058] The term "substituted alkenyl" refers to an alkenyl group as defined herein, having 1 to 5 substituents selected from alkoxy, substituted alkoxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azide, cyano, halogen, hydroxyl, oxo, thioketo, carboxyl, carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-substituted alkyl, -SO-aryl, -SO-heteroaryl, -SO2-alkyl, -SO2-substituted alkyl, -SO2-aryl, and -SO2-heteroaryl, or having 1 to 3 substituents.

[0059] "Alkynyl" refers to a monovalent hydrocarbyl group, either linear or branched, having 2 to 6 carbon atoms, preferably 2 to 3 carbon atoms, and at least 1, preferably 1 to 2 triple-bond unsaturated sites. Examples of such alkynyl groups include acetylenyl (-C≡CH) and propargyl (-CH2C≡CH).

[0060] The term "substituted alkynyl" refers to an alkynyl group as defined herein, having 1 to 5 substituents selected from alkoxy, substituted alkoxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azide, cyano, halogen, hydroxyl, oxo, thioketo, carboxyl, carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-substituted alkyl, -SO-aryl, -SO-heteroaryl, -SO2-alkyl, -SO2-substituted alkyl, -SO2-aryl, and -SO2-heteroaryl, or having 1 to 3 substituents.

[0061] "Alkynyloxy" refers to an -O-alkynyl group, where alkynyl is as defined herein. Examples of alkynyloxy include ethynyloxy and propynyloxy.

[0062] "Acyl" refers to a group which is HC(O)-, alkyl-C(O)-, substituted alkyl-C(O)-, alkenyl-C(O)-, substituted alkenyl-C(O)-, alkynyl-C(O)-, substituted alkynyl-C(O)-, cycloalkyl-C(O)-, substituted cycloalkyl-C(O)-, cycloalkenyl-C(O)-, substituted cycloalkenyl-C(O)-, aryl-C(O)-, substituted aryl-C(O)-, heteroaryl-C(O)-, substituted heteroaryl-C(O)-, heterocyclyl-C(O)-, and substituted heterocyclyl-C(O)-, wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, and substituted heterocycle as defined herein. For example, acyls contain the "acetyl" group CH3C(O)-.

[0063] "Acylamino" is -NR 20 C(O)alkyl, -NR 20 C(O) substituted alkyl, NR 20 C(O) cycloalkyl, -NR 20 C(O) substituted cycloalkyl, -NR 20 C(O)cycloalkenyl, -NR 20 C(O)-substituted cycloalkenyl, -NR 20 C(O) alkenyl, -NR 20 C(O) substituted alkenyl, -NR 20 C(O)alkynyl, -NR 20 C(O) substituted alkynyl, -NR 20 C(O)aryl, -NR 20 C(O) substituted aryl, -NR 20 C(O) heteroaryl, -NR 20 C(O) substituted heteroaryl, -NR 20 C(O) heterocycle and -NR 20 A C(O) substituted heterocyclic group, R 20The group is hydrogen or alkyl, and is an alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, and substituted heterocycle as defined herein.

[0064] The terms "aminocarbonyl" or "aminoacyl" are defined as -C(O)NR 21 R 22 It is a base, R 21 and R 22 However, independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heteroaryl, substituted heteroaryl, heterocycle, and substituted heterocycle, R 21 and R 22 However, it refers to a group which optionally connects with nitrogen to which it is bound, forming a heterocycle or substituted heterocycle group, wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, and substituted heterocycle are as defined herein.

[0065] "Aminocarbonylamino" is -NR 21 C(O)NR 22 R 23 It is a base, R 21 , R 22 , and R 23 However, it independently refers to a group selected from hydrogen, alkyl, aryl, or cycloalkyl, or a group in which two R groups are linked to form a heterocycline group.

[0066] The term "alkoxycarbonylamino" refers to a -NRC(O)OR group in which each R is independently hydrogen, alkyl, substituted alkyl, aryl, heteroaryl, or heterocyclyl, where alkyl, substituted alkyl, aryl, heteroaryl, and heterocyclyl are as defined herein.

[0067] The term "acyloxy" refers to alkyl-C(O)O-, substituted alkyl-C(O)O-, cycloalkyl-C(O)O-, substituted cycloalkyl-C(O)O-, aryl-C(O)O-, heteroaryl-C(O)O-, and heterocyclyl-C(O)O- groups, where alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, heteroaryl, and heterocyclyl are as defined herein.

[0068] "Aminosulfonyl" is -SO2NR 21 R 22 It is a base, R 21 and R 22 However, independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heteroaryl, substituted heteroaryl, heterocycle, and substituted heterocycle, R 21 and R 22 However, it refers to a group which optionally connects with nitrogen to which it is bound, forming a heterocycle or substituted heterocycle group, wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, and substituted heterocycle are as defined herein.

[0069] "Sulfonylamino" is -NR 21 SO2R 22 It is a base, R 21 and R 22However, independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heteroaryl, substituted heteroaryl, heterocycle, and substituted heterocycle, R 21 and R 22 However, it refers to a group which is optionally bonded to an atom, forming a heterocycle or substituted heterocycle group, wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, and substituted heterocycle are as defined herein.

[0070] "Aryl" or "Ar" refers to a monovalent aromatic carbocyclic group of 6 to 18 carbon atoms having a monocyclic ring (e.g., present in a phenyl group) or a ring system having multiple fused rings (examples of such aromatic ring systems include naphthyl, anthryl, and indanyl), where the fused ring may or may not be aromatic, provided that the connection point is through an atom of an aromatic ring. This term includes, by example, phenyl and naphthyl. Unless otherwise restricted by the definition of aryl substituents, such aryl groups may be optionally substituted with 1 to 5 substituents selected from acyloxy, hydroxy, thiol, acyl, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, substituted alkyl, substituted alkoxy, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted cycloalkenyl, amino, substituted amino, aminoacyl, acylamino, alkaryl, aryloxy, azide, carboxyl, carboxylalkyl, cyano, halogen, nitro, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclooxy, aminoacyloxy, oxyacylamino, thioalkoxy, substituted thioalkoxy, thioaryloxy, thioheteroaryloxy, -SO-alkyl, -SO-substituted alkyl, -SO-aryl, -SO-heteroaryl, -SO2-alkyl, -SO2-substituted alkyl, -SO2-aryl, -SO2-heteroaryl, and trihalomethyl, or 1 to 3 substituents.

[0071] "Aryloxy" refers to an -O-aryl group in which aryl is as defined herein, and includes, for example, phenoxy, naphthoxy, and also includes optionally substituted aryl groups as defined herein.

[0072] "Amino" refers to the -NH2 group.

[0073] The term "substituted amino" refers to a -NRR group in which each R is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, cycloalkenyl, substituted cycloalkenyl, alkynyl, substituted alkynyl, aryl, heteroaryl, and heterocyclyl, provided that at least one R is not hydrogen.

[0074] The term "azide" refers to the -N3 group.

[0075] "Carboxyl," "carboxy," or "carboxylate" refers to -CO2H or its salts.

[0076] The terms "carboxyl ester" or "carboxyester," or "carboxyalkyl" or "carboxylalkyl" refer to -C(O)O-alkyl, -C(O)O-substituted alkyl, -C(O)O-alkenyl, -C(O)O-substituted alkenyl, -C(O)O-alkynyl, -C(O)O-substituted alkynyl, -C(O)O-aryl, -C(O)O-substituted aryl, -C(O)O-cycloalkyl, -C(O)O-substituted cycloalkyl, -C(O)O-cycloalkenyl, -C( The group is an O)O-substituted cycloalkenyl, -C(O)O-heteroaryl, -C(O)O-substituted heteroaryl, -C(O)O-heterocyclic, and -C(O)O-substituted heterocyclic group, wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic group as defined herein.

[0077] "(carboxyl ester)oxy" or "carbonate" refers to -OC(O)O-alkyl, -OC(O)O-substituted alkyl, -OC(O)O-alkenyl, -OC(O)O-substituted alkenyl, -OC(O)O-alkynyl, -OC(O)O-substituted alkynyl, -OC(O)O-aryl, -OC(O)O-substituted aryl, -OC(O)O-cycloalkyl, -OC(O)O-substituted cycloalkyl, -OC(O)O-cycloalkenyl, -OC(O)O-substituted cycloalkeny The group is an alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, and substituted heterocycle as defined herein.

[0078] "Cyano" or "nitrile" refers to the -CN group.

[0079] "Cycloalkyl" refers to a cyclic alkyl group of 3 to 10 hydrocarbon atoms having a monocyclic or polycyclic ring, including fused ring systems, crosslinked ring systems, and spirocyclic systems. Suitable examples of cycloalkyl groups include, for example, adamantyl, cyclopropyl, cyclobutyl, cyclopentyl, and cyclooctyl. Such cycloalkyl groups include, for example, monocyclic structures such as cyclopropyl, cyclobutyl, cyclopentyl, and cyclooctyl, or polycyclic structures such as adamantanyl.

[0080] The term "substituted cycloalkyl" refers to a cycloalkyl group having 1 to 5 substituents selected from alkyl, substituted alkyl, alkoxy, substituted alkoxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azide, cyano, halogen, hydroxyl, oxo, thioketo, carboxyl, carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-substituted alkyl, -SO-aryl, -SO-heteroaryl, -SO2-alkyl, -SO2-substituted alkyl, -SO2-aryl, and -SO2-heteroaryl, or having 1 to 3 substituents.

[0081] "Cycloalkenyl" refers to a non-aromatic cyclic alkyl group having 3 to 10 carbon atoms, having a monocyclic or polycyclic structure and at least one double bond, preferably one to two double bonds.

[0082] The term "substituted cycloalkenyl" refers to a cycloalkenyl group having 1 to 5 substituents selected from alkoxy, substituted alkoxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azide, cyano, halogen, hydroxyl, keto, thioketo, carboxyl, carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-substituted alkyl, -SO-aryl, -SO-heteroaryl, -SO2-alkyl, -SO2-substituted alkyl, -SO2-aryl, and -SO2-heteroaryl, or having 1 to 3 substituents.

[0083] "Cycloalkynyl" refers to a non-aromatic cycloalkyl group consisting of 5 to 10 carbon atoms, having a monocyclic or polycyclic structure and at least one triple bond.

[0084] "Cycloalkoxy" refers to -O-cycloalkyl.

[0085] "Cycloalkenyloxy" refers to -O-cycloalkenyl.

[0086] "Halo" or "halogen" refers to fluoro, chloro, bromo, and iodine.

[0087] "Hydroxy" or "hydroxyl" refers to the -OH group.

[0088] A "heteroaryl" refers to an aromatic group consisting of 1 to 15 carbon atoms, for example, 1 to 10 carbon atoms and 1 to 10 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur in the ring. Such a heteroaryl group may be monocyclic (e.g., pyridinyl, imidazolyl, or furyl) or may have multiple fused rings in its ring system (e.g., in groups such as indolidinyl, quinolinyl, benzofuran, benzimidazolyl, or benzothienyl), and at least one ring in the ring system is aromatic. To satisfy the valency requirements, any heteroatom in such a heteroaryl ring may or may not be bonded to H or a substituent, for example, an alkyl group or other substituent as described herein. In certain embodiments, the nitrogen and / or sulfur ring atoms of the heteroaryl group are optionally oxidized to provide an N-oxide (N→O), sulfinyl, or sulfonyl moiety. Examples of this term include pyridinyl, pyrrolyl, indolyl, thiophenyl, and furanyl. Unless otherwise restricted by the definition of heteroaryl substituents, such heteroaryl groups may be optionally substituted with 1 to 5 substituents, or 1 to 3 substituents, selected from acyloxy, hydroxy, thiol, acyl, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, substituted alkyl, substituted alkoxy, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted cycloalkenyl, amino, substituted amino, aminoacyl, acylamino, alkaryl, aryl, aryloxy, azide, carboxyl, carboxylalkyl, cyano, halogen, nitro, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclooxy, aminoacyloxy, oxyacylamino, thioalkoxy, substituted thioalkoxy, thioaryloxy, thioheteroaryloxy, -SO-alkyl, -SO-substituted alkyl, -SO-aryl, -SO-heteroaryl, -SO2-alkyl, -SO2-substituted alkyl, -SO2-aryl, and -SO2-heteroaryl, as well as trihalomethyl.

[0089] The term "heteroaralkyl" refers to an alkylene-heteroaryl group in which alkylene and heteroaryl are as defined herein. Examples of this term include pyridylmethyl, pyridylethyl, indolylmethyl, and the like.

[0090] "Heteroaryloxy" refers to -O-heteroaryl.

[0091] "Heterocycle," "heterocyclic," "heterocycloalkyl," and "heterocyclyl" refer to saturated or unsaturated groups having a monocyclic or multiple fused rings, including fused ring systems, bridging ring systems, and spiro-ring systems, and having 3 to 20 ring atoms containing 1 to 10 heteroatoms. These ring atoms are selected from nitrogen, sulfur, or oxygen, and in fused ring systems, one or more of the rings may be cycloalkyl, aryl, or heteroaryl, provided that the connection point is via a non-aromatic ring. In certain embodiments, the nitrogen and / or sulfur atoms of the heterocyclic group are optionally oxidized to provide an N-oxide, -S(O)-, or -SO2- moiety. To satisfy valency requirements, any heteroatom in such heterocyclic rings may or may not be bonded to one or more H atoms or one or more substituents, such as alkyl groups or other substituents described herein.

[0092] Examples of heterocyclic and heteroaryl compounds include, but are not limited to, azetidine, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, indidine, isoindole, indole, dihydroindole, indazole, purine, quinoridine, isoquinoline, quinoline, phthalazine, naphthylpyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carborin, phenanthridine, acridine, phenanthroline, isothiazole, and phenazine. Examples include isoxazole, phenoxazine, phenothiazine, imidazolidine, imidazoline, piperidine, piperazine, indoline, phthalimide, 1,2,3,4-tetrahydroisoquinoline, 4,5,6,7-tetrahydrobenzo[b]thiophene, thiazole, thiazolidine, thiophene, benzo[b]thiophene, morpholinil, thiomorpholinil (also called thiamorpholinil), 1,1-dioxothiomorpholinil, piperidinil, pyrrolidine, and tetrahydrofuranil.

[0093] Unless otherwise restricted by the definition of heterocyclic substituents, such heterocyclic groups may be optionally substituted with 1 to 5 or 1 to 3 substituents selected from alkoxy, substituted alkoxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azide, cyano, halogen, hydroxyl, oxo, thioketo, carboxyl, carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-substituted alkyl, -SO-aryl, -SO-heteroaryl, -SO2-alkyl, -SO2-substituted alkyl, -SO2-aryl, -SO2-heteroaryl, and condensed heterocyclic groups.

[0094] "Heterocyclyloxy" refers to the -O-heterocyclyl group.

[0095] The term "heterocyclilthio" refers to a heterocyclic -S-group.

[0096] The term "heterocyclene" refers to a diradical group formed from a heterocycle, as defined herein.

[0097] The term "hydroxyamino" refers to the -NHOH group.

[0098] "Nitro" refers to the -NO2 group.

[0099] "Oxo" refers to an atom (=O).

[0100] "Sulfonyl" refers to groups of the form -SO2-alkyl, -SO2-substituted alkyl, -SO2-alkenyl, -SO2-substituted alkenyl, -SO2-cycloalkyl, -SO2-substituted cycloalkyl, -SO2-cycloalkenyl, -SO2-substituted cycloalkenyl, -SO2-substituted aryl, -SO2-substituted aryl, -SO2-heteroaryl, -SO2-substituted heteroaryl, -SO2-heterocyclic, and -SO2-substituted heterocyclic, wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic are as defined herein. Examples of sulfonyls include methyl-SO2-, phenyl-SO2-, and 4-methylphenyl-SO2-.

[0101] "Sulfonyloxy" refers to a group which is -OSO2-alkyl, -OSO2-substituted alkyl, -OSO2-alkenyl, -OSO2-substituted alkenyl, -OSO2-cycloalkyl, -OSO2-substituted cycloalkyl, -OSO2-cycloalkenyl, -OSO2-substituted cycloalkenyl, -OSO2-aryl, -OSO2-substituted aryl, -OSO2-heteroaryl, -OSO2-substituted heteroaryl, -OSO2-heterocyclic, and -OSO2-substituted heterocyclic, wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic are as defined herein.

[0102] "Sulfate" or "sulfate ester" refers to -O-SO2-OH, -O-SO2-O-alkyl, -O-SO2-O-substituted alkyl, -O-SO2-O-alkenyl, -O-SO2-O-substituted alkenyl, -O-SO2-O-cycloalkyl, -O-SO2-O-substituted cycloalkyl, -O-SO2-O-cycloalkenyl, -O-SO2-O-substituted cycloalkenyl, -O-SO2-O-aryl, -O-SO2-O-substituted aryl, -O-SO2-O- Telolaryl, -O-SO2-O-substituted heteroaryl, -O-SO2-O-heterocyclic, and -O-SO2-O-substituted heterocyclic groups, wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic groups are as defined herein.

[0103] The term "aminocarbonyloxy" refers to an -OC(O)NRR group in which each R is independently hydrogen, alkyl, substituted alkyl, aryl, heteroaryl, or heterocycle, where alkyl, substituted alkyl, aryl, heteroaryl, and heterocycle are as defined herein.

[0104] "Thiol" refers to the -SH group.

[0105] The terms "thioxo" or "thioketo" refer to an atom (=S).

[0106] The terms "alkylthio" or "thioalkoxy" refer to an -S-alkyl group, where alkyl is as defined herein. In certain embodiments, sulfur may be oxidized to -S(O)-. The sulfoxide may exist as one or more stereoisomers.

[0107] The term "substituted thioalkoxy" refers to an -S-substituted alkyl group.

[0108] The term "thioaryloxy" refers to an aryl-S- group, wherein the aryl group is as defined herein and also includes an aryl group that is optionally substituted as defined herein.

[0109] The term "thioheteroaryloxy" refers to a heteroaryl-S-group, wherein the heteroaryl group is as defined herein and includes an aryl group that is optionally substituted, as also defined herein.

[0110] The term "thioheterocyclooxy" refers to a heterocyclyl-S-group, where the heterocyclyl group is as defined herein and also contains a heterocyclyl group that is optionally substituted as defined herein.

[0111] In addition to the disclosure herein, the term “substitution” may also mean, when used to modify a designated group or radical, that one or more hydrogen atoms of that designated group or radical are replaced, each independently of the others, by the same or different substituents as defined below.

[0112] In addition to the groups disclosed with respect to individual terms herein, substituents for substituting one or more hydrogens on a saturated carbon atom in a particular group or radical (where any two hydrogens on a single carbon are =O, =NR) 70 、=N-OR 70 (which may be replaced with =N2 or =S) is -R unless otherwise specified. 60 , halo, =O, -OR 70 , -SR 70 , -NR 80 R 80 , trihalomethyl, -CN, -OCN, -SCN, -NO, -NO2, =N2, -N3, -SO2R 70 , -SO2O - M + , -SO2OR 70 , -OSO2R 70 , -OSO2O - M + , -OSO2OR 70 ,-P(O)(O - )2(M + )2, -P(O)(OR 70 )O - M + , -P(O)(OR 70 )2, -C(O)R 70 ,-C(S)R 70 -C(NR 70 )R 70 ,-C(O)O - M + , -C(O)OR 70 , -C(S)OR 70 -C(O)NR 80 R 80 -C(NR 70 )NR 80 R 80 ,-OC(O)R 70 ,-OC(S)R 70 , -OC(O)O - M + -OC(O)OR 70 , -OC(S)OR 70 , -NR 70 C(O)R 70 , -NR 70 C(S)R 70 , -NR 70 CO2 - M+ , -NR 70 CO2R 70 , -NR 70 C(S)OR 70 , -NR 70 C(O)NR 80 R 80 , -NR 70 C(NR 70 )R 70 , and -NR 70 C(NR 70 )NR 80 R 80 And R 60 However, each R is selected from the group consisting of alkyl, cycloalkyl, heteroalkyl, heterocycloalkylalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl, which are optionally substituted. 70 However, independently, hydrogen or R 60 And each R 80 However, R is independent 70 Either or, two R's 80 However, along with the nitrogen atom to which they are bonded, they may optionally contain 1 to 4 additional heteroatoms, either the same or different, selected from the group consisting of O, N, and S, where the N may have a -H or C1-C3 alkyl substitution, forming a 5-membered, 6-membered, or 7-membered heterocycloalkyl group, and each M + However, each M is a counterion with a single positive charge. + These are independent, for example, alkaline ions, for example, K + na + Li + ; Ammonium ions, for example, + N(R 60 )4; or alkaline earth ions, for example, [Ca 2+ ] 0.5 [Mg 2+ ] 0.5 , or [Ba 2+ ] 0.5(The subscript 0.5 means that one of the counterions for such divalent alkaline earth ions may be the ionized form of the compound of the present invention, the other may be a typical counterion such as a chloride, or the two ionized compounds disclosed herein may function as counterions for such divalent alkaline earth ions, or the doubly ionized compound of the present invention may function as a counterion for such divalent alkaline earth ions.) For example, -NR 80 R 80 This means that it contains -NH2, -NH-alkyl, N-pyrrolidinyl, N-piperazinyl, 4N-methylpiperazin-1-yl, and N-morpholinyl.

[0113] In addition to the disclosures herein, the substituents of hydrogen on unsaturated carbon atoms in "substituted" alkenes, alkynes, aryls, and heteroaryl groups are -R unless otherwise specified. 60 Hello, -O - M + , -OR 70 , -SR 70 , -S - M + , -NR 80 R 80 , trihalomethyl, -CF3, -CN, -OCN, -SCN, -NO, -NO2, -N3, -SO2R 70 , -SO3 - M + , -SO3R 70 , -OSO2R 70 , -OSO3 - M + , -OSO3R 70 , -PO3 -2 (M + )2, -P(O)(OR 70 )O - M + , -P(O)(OR 70 )2, -C(O)R 70 ,-C(S)R 70 -C(NR 70 )R 70 , -CO2 - M + , -CO2R 70, -C(S)OR 70 -C(O)NR 80 R 80 -C(NR 70 )NR 80 R 80 ,-OC(O)R 70 ,-OC(S)R 70 , -OCO2 - M + , -OCO2R 70 , -OC(S)OR 70 , -NR 70 C(O)R 70 , -NR 70 C(S)R 70 , -NR 70 CO2 - M + , -NR 70 CO2R 70 , -NR 70 C(S)OR 70 , -NR 70 C(O)NR 80 R 80 , -NR 70 C(NR 70 )R 70 , and -NR 70 C(NR 70 )NR 80 R 80 And R 60 , R 70 , R 80 , and M + This is as previously defined, except in the case of substituted alkenes or alkynes, the substituent is -O - M + , -OR 70 , -SR 70 , or -S - M + isn't it.

[0114] In addition to the groups disclosed with respect to the individual terms herein, substituents on the hydrogen atom of the nitrogen atom in "substituted" heteroalkyl and cycloheteralkyl groups are, unless otherwise specified, -R 60 , -O - M + , -OR 70 , -SR 70 , -S - M +, -NR 80 R 80 , trihalomethyl, -CF3, -CN, -NO, -NO2, -S(O)2R 70 , -S(O)2O - M + , -S(O)2OR 70 , -OS(O)2R 70 , -OS(O)2O - M + , -OS(O)2OR 70 , -P(O)(O - )2(M + , -P(O)(OR 70 )O - M + , -P(O)(OR 70 )(OR 70 , -C(O)R 70 , -C(S)R 70 , -C(NR 70 )R 70 , -C(O)OR 70 , -C(S)OR 70 , -C(O)NR 80 R 80 , -C(NR 70 )NR 80 R 80 , -OC(O)R 70 , -OC(S)R 70 , -OC(O)OR 70 , -OC(S)OR 70 , -NR 70 C(O)R 70 , -NR 70 C(S)R 70 , -NR 70 C(O)OR 70 , -NR 70 C(S)OR 70 , -NR 70 C(O)NR 80 R 80 , -NR 70 C(NR 70 )R 70 , and -NR 70 C(NR 70 )NR 80 R 80 and R 60 , R 70 , R 80 , and M+ This is as already defined.

[0115] In addition to the disclosures herein, in certain embodiments, the substituted group has one, two, three, or four substituents, one, two, or three substituents, one or two substituents, or one substituent.

[0116] It is understood that polymers obtained by defining substituents having further substituents on themselves (e.g., substituted aryls having substituted aryl groups as substituents, which themselves are substituted with substituted aryl groups and further substituted with substituted aryl groups) for all the substituted groups defined above are not intended to be included herein. In such cases, the maximum number of such substitutions is 3. For example, the sequential substitution of substituted aryl groups specifically intended herein is limited to substituted aryl-(substituted aryl)-substituted aryl.

[0117] Unless otherwise specified, the nomenclature of substituents not explicitly defined herein is achieved by naming the terminal portion of the functional group followed by adjacent functional groups toward the connection point. For example, the substituent "arylalkyloxycarbonyl" refers to the (aryl)-(alkyl)-OC(O)- group.

[0118] With respect to any of the groups disclosed herein that contain one or more substituents, it should be understood that such groups naturally do not contain any substitutions or substitution patterns that are sterically unfeasible and / or synthetically unfeasible. In addition, the compounds of the subject matter include all stereochemical isomers resulting from the substitutions of these compounds.

[0119] The term “pharmaceutically acceptable salt” means a salt that is acceptable for administration to a patient, e.g., a mammal (a salt having a counterion that has mammalian safety acceptable for a given drug regimen). Such salts may be derived from pharmaceutically acceptable inorganic or organic bases, and pharmaceutically acceptable inorganic or organic acids. “pharmaceutically acceptable salt” refers to a pharmaceutically acceptable salt of a compound, the salt being derived from a variety of organic and inorganic counterions well known in the art, including, but not limited to, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, etc., and, if the molecule contains basic functionality, salts of organic or inorganic acids such as hydrochloride, hydrobromide, formate, tartrate, besylate, mesylate, acetate, maleate, oxalate, etc.

[0120] The term "salt" refers to a compound formed when a proton of an acid is replaced by a cation, such as a metal cation or an organic cation. Where applicable, the salt is pharmaceutically acceptable, although this is not required for salts of intermediate compounds not intended for administration to patients. As an example, salts of the compounds of the present invention include those in which a conjugate base of an inorganic or organic acid is used as the anionic component of the salt, and the compound is protonated by the inorganic or organic acid to form a cation.

[0121] A "solvate" refers to a complex formed by a combination of solvent molecules and solute molecules or ions. The solvent can be an organic compound, an inorganic compound, or a mixture of both. Some examples of solvents, though not limited to them, include methanol, N,N-dimethylformamide, tetrahydrofuran, dimethyl sulfoxide, and water. When the solvent is water, the solvate formed is a hydrate.

[0122] "Stereoisomers" refer to compounds that have the same atomic bonding but different atomic arrangements in space. Stereoiomers include cis-trans isomers, E and Z isomers, enantiomers, and diastereomers.

[0123] "Tautomers" refer to alternative molecular forms that differ only in the electron bonding of atoms and / or the position of protons, such as enol-keto and imine-enamine tautomers, or tautomer forms of heteroaryl groups containing the -N=C(H)-NH-ring atomic configuration, such as pyrazole, imidazole, benzimidazole, triazole, and tetrazole. Those skilled in the art will recognize that other tautomer ring atomic configurations are possible.

[0124] It should be understood that the term “or its salts, solvates, or stereoisomers” is intended to include all permutations of salts, solvates, and stereoisomers, such as solvates of pharmaceutically acceptable salts of the stereoisomers of the compound in question.

[0125] "Pharmacologically effective dose" and "therapeutic dose" refer to the amount of a compound sufficient to treat one or more of a specific disorder or disease, or its symptoms, and / or to prevent the onset of that disease or disorder. With respect to tumorigenic proliferative disorders, the pharmaceutically effective dose or therapeutic dose includes, in particular, an amount sufficient to shrink the tumor or reduce the rate of tumor growth.

[0126] The term "patient" refers to both human and non-human subjects, particularly mammals.

[0127] As used herein, the terms “to treat” or “to treat” mean treating or treating a disease or medical condition in a patient, for example, a mammal (in particular human), and include (a) preventing the occurrence of a disease or medical condition, for example, prophylactic treatment of the subject; (b) mitigating a disease or medical condition, for example, eliminating or reversing the disease or medical condition in a patient; (c) suppressing a disease or medical condition, for example, by slowing or halting its progression in a patient; or (d) alleviating the symptoms of a disease or medical condition in a patient.

[0128] The terms “polypeptide,” “peptide,” and “protein” are used interchangeably herein to refer to polymeric forms of amino acids of any length. Unless otherwise indicated, “polypeptide,” “peptide,” and “protein” may include genetically encoded and unencoded amino acids, chemically or biochemically modified or derivatized amino acids, and polypeptides having a modified peptide backbone. The term includes fusion proteins, which include, but are not limited to, fusion proteins having heterologous amino acid sequences, fusions having heterologous and homologous leader sequences, proteins containing at least one N-terminal methionine residue (e.g., to facilitate production in recombinant host cells), immunotagged proteins, and the like.

[0129] "Natural amino acid sequence" or "parent amino acid sequence" are used interchangeably herein and refer to the amino acid sequence of the polypeptide before modification, such as the sequence containing modified amino acid residues.

[0130] The terms "amino acid analog" and "non-natural amino acid" may be used interchangeably and include amino acid-like compounds that are structurally and / or in shape similar to one or more amino acids commonly found in naturally occurring proteins (e.g., Ala or A, Cys or C, Asp or D, Glu or E, Phe or F, Gly or G, His or H, Ile or I, Lys or K, Leu or L, Met or M, Asn or N, Pro or P, Gln or Q, Arg or R, Ser or S, Thr or T, Val or V, Trp or W, Tyr or Y). Amino acid analogs also include natural amino acids with modified side chains or backbone. Amino acid analogs also include amino acid analogs that have the same stereochemistry as the naturally occurring D form, as well as the L form of amino acid analogs. In some cases, amino acid analogs share the backbone structure and / or side chain structure of one or more natural amino acids, the difference being one or more modifying groups in the molecule. Such modifications, though not limited to, include substitution of an atom (e.g., N) with a related atom (e.g., S), addition of a group (e.g., methyl or hydroxyl) or an atom (e.g., Cl or Br), deletion of a group, substitution of a covalent bond (e.g., changing a single bond to a double bond), or combinations thereof. For example, amino acid analogs may include α-hydroxy acids and α-amino acids.

[0131] Terms such as "amino acid side chain" or "side chain of amino acids" may be used to refer to substituents attached to the α-carbon of an amino acid residue, including natural amino acids, unnatural amino acids, and amino acid analogs. Amino acid side chains may also include amino acid side chains described herein in the context of modified amino acids and / or conjugates.

[0132] The term "carbohydrate" may be used to refer to monomeric units and / or polymers of monosaccharides, disaccharides, oligosaccharides, and polysaccharides. The term "sugar" may be used to refer to smaller carbohydrates such as monosaccharides and disaccharides. The term "carbohydrate derivative" includes compounds in which one or more functional groups of the carbohydrate of interest are substituted (replaced by any convenient substituent), modified (converted to another group using any convenient chemical), or absent (e.g., removed or replaced by H). A variety of carbohydrates and carbohydrate derivatives are available and may be suitable for use in the subject compound and conjugate.

[0133] The terms "glycoside" or "glycosyl" refer to a sugar molecule or group linked to a part via a glycosidic bond. For example, the part to which the glycoside is linked may be a cleavable linker as described herein. Glycosidic bonds can link a glycoside to another part via various types of bonds, such as, but not limited to, O-glycosidic bonds (O-glycosides), N-glycosidic bonds (glycosylamines), S-glycosidic bonds (thioglycosides), or C-glycosidic bonds (C-glycosides or C-glycosyls). In some cases, glycosides can be cleaved from the part to which they are linked by, for example, chemically mediated hydrolysis or enzymatically mediated hydrolysis.

[0134] The term "antibody" is used in its broadest sense and includes monoclonal antibodies (including full-length monoclonal antibodies), polyclonal antibodies, and multispecific antibodies (e.g., bispecific antibodies), humanized antibodies, single-chain antibodies, chimeric antibodies, antibody fragments (e.g., Fab fragments), etc. Antibodies can bind to target antigens. (Janeway, C., Travers, P., Walport, M., Shlomchik (2001) Immuno Biology, 5th Ed., Garland Publishing, New York). Target antigens may have one or more binding sites, also called epitopes, that are recognized by complementarity-determining regions (CDRs) formed by one or more variable regions of the antibody.

[0135] The term "natural antibody" refers to an antibody in which the heavy and light chains have been produced and which is paired by the immune system of a multicellular organism. The spleen, lymph nodes, bone marrow, and serum are examples of tissues that produce natural antibodies. For example, antibodies produced by antibody-producing cells isolated from a first animal immunized with an antigen are natural antibodies.

[0136] The terms "humanized antibody" or "humanized immunoglobulin" refer to a non-human (e.g., mouse or rabbit) antibody derived from a human antibody that contains one or more amino acids (e.g., in the framework region, constant region, or CDR) that are substituted with correspondingly positioned amino acids. Generally, humanized antibodies produce a reduced immune response in the human host compared to the non-humanized form of the same antibody. Antibodies can be humanized using various techniques known in the art, including, for example, CDR grafting (EP239,400, PCT Publication No. WO91 / 09967, U.S. Patents No. 5,225,539, 5,530,101, and 5,585,089), veneering or resurfacing (EP592,106, EP519,596, Padlan, Molecular Immunology 28(4 / 5):489-498 (1991), Studnicka et al., Protein Engineering 7(6):805-814 (1994), Roguska et al., PNAS 91:969-973 (1994)), and chain shuffling (U.S. Patent No. 5,565,332). In certain embodiments, framework substitutions are identified by modeling the interaction between CDRs and framework residues to identify framework residues important for antigen binding and sequence comparison, and to identify abnormal framework residues at specific positions (see, for example, U.S. Patent No. 5,585,089, Riechmann et al., Nature 332:323 (1988)). Additional methods for humanizing antibodies intended for use in the present invention are described in U.S. Patents No. 5,750,078, 5,502,167, 5,705,154, 5,770,403, 5,698,417, 5,693,493, 5,558,864, 4,935,496, and 4,816,567, as well as PCT Publications WO98 / 45331 and WO98 / 45332. In certain embodiments, the subject rabbit antibody may be humanized according to the methods described in US2004 / 0086979 and US2005 / 0033031. Thus, the antibody described above may be humanized using methods well known in the art.

[0137] The term "chimeric antibody" refers to an antibody typically constructed through genetic engineering, in which the light and heavy chain genes are derived from the variable and constant regions of antibodies belonging to different species. For example, the variable segment of a gene from a mouse monoclonal antibody can bind to human constant segments such as gamma 1 and gamma 3. An example of a therapeutic chimeric antibody is a hybrid protein composed of a variable domain or antigen-binding domain derived from a mouse antibody and a constant domain or effector domain derived from a human antibody, although domains from other mammalian species may also be used.

[0138] The immunoglobulin light chain or heavy chain variable region of an immunoglobulin polypeptide consists of a framework region (FR) interrupted by three hypervariable regions, also called "complementarity-determining regions" or "CDRs." The extent of the framework region and CDRs is defined (see "Sequences of Proteins of Immunological Interest," E. Kabat et al., USD Department of Health and Human Services, 1991). The antibody framework region, which is the combined framework region of its constituent light and heavy chains, helps to locate and align the CDRs. The CDRs primarily contribute to the binding of the antigen to the epitope.

[0139] The "parent Ig polypeptide" is a polypeptide comprising an amino acid sequence lacking the aldehyde-tagged constant region described herein. The parent polypeptide may include a natural sequence constant region, or it may include a constant region having existing amino acid sequence modifications (addition, deletion, and / or substitution, etc.).

[0140] As used herein, the term “isolated” means describing a compound of interest that is in an environment different from that in which it naturally occurs. “Isolated” means including a compound in a sample in which the compound of interest is substantially concentrated and / or partially or substantially purified.

[0141] As used herein, the term “substantially purified” means a compound that has been removed from its natural environment and contains at least 60%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or more than 98% of other components associated with its natural origin.

[0142] The term "physiological conditions" means those conditions that are compatible with living cells, such as temperature, pH, salinity, and other primarily aqueous conditions that are compatible with living cells.

[0143] A “reactive partner” means a molecule or molecular part that specifically reacts with another reactive partner to produce a reaction product. An exemplary reactive partner comprises cysteine ​​or serine of a sulfatase motif and formylglycine-producing enzyme (FGE), which react to form a reaction product of a converted aldehyde tag containing formylglycine (FGly) instead of cysteine ​​or serine in the motif. Another exemplary reactive partner comprises an “aldehyde-reactive reactive partner” comprising the aldehyde (e.g., a reactive aldehyde group) of the fGly residue of the converted aldehyde tag, as well as an aldehyde-reactive group and the moiety of interest, which react to form a reaction product of a modified aldehyde-tagged polypeptide having the moiety of interest conjugated to the modified polypeptide via a modified fGly residue.

[0144] The "N-terminus" refers to the terminal amino acid residue of a polypeptide that has a free amine group, and the amine group in the non-N-terminal amino acid residue usually forms part of the covalent backbone of the polypeptide.

[0145] The "C-terminus" refers to the terminal amino acid residue of a polypeptide that has a free carboxyl group, while carboxyl groups in non-C-terminal amino acid residues typically form part of the polypeptide's covalent backbone.

[0146] When used in reference to polypeptides or the amino acid sequences of polypeptides, the term "internal region" refers to the region of the polypeptide that is neither N-terminus nor C-terminus.

[0147] Before further describing the present invention, it should be understood that the present invention is not limited to the specific embodiments described and is therefore naturally subject to change. Furthermore, since the scope of the present invention is limited only by the appended claims, it should also be understood that the terms used herein are merely for describing specific embodiments and are not intended to limit them.

[0148] Where a range of values ​​is provided, unless the context explicitly indicates otherwise, each intervening value up to one-tenth of the lower limit between the upper and lower limits of that range, and any other stated or intervening values ​​within the stated range, are understood to be included within the present invention. The upper and lower limits of these smaller ranges may be independently included within the smaller ranges and, according to any specifically excluded boundaries within the stated range, are also included in this disclosure. Where a stated range includes one or both of the boundaries, ranges excluding either or both of the boundaries that they include are also included in the present invention.

[0149] For clarity, it is understood that certain features of the Invention described in the context of separate embodiments may also be provided in combination in a single embodiment. Conversely, for brevity, various features of the Disclosure described in the context of a single embodiment may also be provided separately or in any preferred subcombination. All combinations of embodiments relating to the Invention are specifically encompassed by the Disclosure and are disclosed herein as if each and all combinations were individually and explicitly disclosed to the extent that such combinations encompass the subject matter of the Invention, which is, for example, a stable compound (i.e., a compound that can be prepared, isolated, characterized, and tested for biological activity). In addition, all subcombinations of various embodiments and their elements (e.g., elements of chemical groups enumerated in embodiments describing such variables) are also specifically encompassed by the Disclosure and are disclosed herein as if each and all such subcombinations were individually and explicitly disclosed herein.

[0150] Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present invention pertains. Any methods and materials similar to or equivalent to those described herein may also be used in the implementation or testing of the present invention, but preferred methods and materials are described herein. All publications referenced herein are incorporated herein by reference to disclose and explain methods and / or materials relating to the cited publications.

[0151] It should be noted that, as used herein and in the appended claims, the singular forms "a," "an," and "the" refer to multiple subjects unless the context explicitly indicates otherwise. It should also be noted that claims may be written to exclude any optional elements. Therefore, this statement is intended to serve as an antecedent for the use of exclusive terms such as "simply," "only," or "negative" limitations relating to the description of elements of the claims.

[0152] For clarity, it is understood that certain features of the present invention described in the context of separate embodiments may also be provided in combination in a single embodiment. Conversely, for brevity, various features of the present disclosure described in the context of a single embodiment may also be provided separately or in any preferred subcombination.

[0153] The publications discussed herein were made available solely for their disclosure prior to the filing date of this application. Nothing herein should be construed as acknowledging that the present invention does not have prior rights to such disclosure by prior art. Furthermore, the dates of the publications provided may differ from the actual publication dates which may need to be independently verified. [Modes for carrying out the invention]

[0154] This disclosure provides an antibody-drug conjugate structure comprising a cleavable linker that links an antibody to a drug. The cleavable linker comprises a first enzymatically cleavable moiety and a second enzymatically cleavable moiety comprising a glycoside selected from galactosides, glucosides, mannosides, fucosides, O-GlcNAc, and O-GalNAc. This disclosure also includes methods for producing such conjugates and methods for using such conjugates.

[0155] Antibody-drug conjugates This disclosure provides conjugates, such as antibody-drug conjugates (ADCs). “Conjugate” means a first part (e.g., an antibody) that stably associates with a second part (e.g., a drug or active agent). For example, an antibody-drug conjugate includes a drug or active agent that stably associates with another part (e.g., an antibody). “Stable association” means that one part binds to another part or structure under standard conditions. In certain embodiments, the first and second parts are linked to each other via one or more functional groups and covalent bonds. For example, one or more functional groups and covalent bonds may include cleavable linkers as described herein.

[0156] In certain embodiments, the conjugate is a polypeptide conjugate comprising a polypeptide (e.g., an antibody) conjugated to a second portion. In certain embodiments, the portion conjugated to the polypeptide may be any of various purposes, but is not limited to, a drug, an active agent, a detectable label, a water-soluble polymer, or a portion for immobilizing the polypeptide onto a membrane or surface. In certain embodiments, the conjugate is a drug conjugate, where the polypeptide is an antibody, and therefore provides an antibody-drug conjugate. For example, the conjugate may be a drug conjugate in which the polypeptide is conjugated to a drug or active agent. Various types of drugs or active agents may be used in the conjugate, as described in more detail below.

[0157] In certain embodiments, the conjugate is an antibody-drug conjugate in which an antibody and a drug are linked together by a linker. In some cases, the linker is a cleavable linker. A cleavable linker is a linker comprising one or more cleavable moieties, each comprising one or more bonds that can dissociate under certain conditions, and thus separate the cleavable linker into two or more separable parts. For example, the cleavable moieties may comprise one or more covalent bonds, each of which can dissociate or separate under certain conditions to separate the cleavable linker into two or more parts. Such a cleavable linker may be contained in an antibody-drug conjugate, and as a result, under appropriate conditions, the cleavable linker is cleaved, separating or releasing the drug from the antibody at a desired target site of action for that drug.

[0158] In some cases, a cleavable linker includes two cleavable portions, for example, a first cleavable portion and a second cleavable portion. The cleavable portions may be configured such that cleavage of both cleavable portions is required to separate or release the drug from the antibody at a desired target site of action for the drug. For example, cleavage of a cleavable linker can be achieved by first cleaving one of the two cleavable portions and then cleaving the other of the two cleavable portions. In certain embodiments, a cleavable linker includes a first cleavable portion and a second cleavable portion that interferes with the cleavage of the first cleavable portion. "Interfering with cleavage" means that the presence of the uncleaved second cleavable portion reduces the possibility of cleavage of the first cleavable portion or substantially inhibits cleavage, and therefore substantially reduces or prevents cleavage of the cleavable linker. For example, the presence of an uncleaved second cleavable portion can interfere with the cleavage of the first cleavable portion. The presence of a second cleavable portion interferes with the cleavage of the first cleavable portion, thereby substantially reducing or preventing the release of the drug from the antibody. For example, premature release of the drug from the antibody can be substantially reduced or prevented until the antibody-drug conjugate is at or near the desired target site of action for the drug.

[0159] In some cases, the second cleavable portion interferes with the cleavage of the first cleavable portion, so cleavage of the cleavable linker can be achieved by first cleaving the second cleavable portion and then the first cleavable portion. Cleavage of the second cleavable portion can reduce or eliminate the interference with cleavage of the first cleavable portion, and thus enable cleavage of the first cleavable portion. Cleavage of the first cleavable portion allows the cleavable linker to dissociate or separate into two or more portions as described above, thereby releasing the drug from the antibody-drug conjugate. In some cases, cleavage of the first cleavable portion does not substantially occur in the presence of the uncleaved second cleavable portion. "Substantially" means that, in the presence of a second, uncuttable portion, the cutting of the first cleavable portion is less than approximately 10%; for example, in the presence of a second, uncuttable portion, the cutting of the first cleavable portion is less than approximately 9%, or less than approximately 8%, or less than approximately 7%, or less than approximately 6%, or less than approximately 5%, or less than approximately 4%, or less than approximately 3%, or less than approximately 2%, or less than approximately 1%, or less than approximately 0.5%, or less than approximately 0.1%.

[0160] In other words, the second cleavable portion can protect the first cleavable portion from being cleaved. For example, the presence of an uncleaved second cleavable portion can protect the first cleavable portion from being cleaved, and thus substantially reduce or prevent premature release of the drug from the antibody until the antibody-drug conjugate is at or near the desired target site of action for the drug. Thus, cleavage of the second cleavable portion exposes the first cleavable portion (e.g., deprotects the first cleavable portion), and thus enables cleavage of the first cleavable portion, resulting in cleavage of the cleavable linker, and then separation or release of the drug from the antibody at the desired target site of action for the drug. In certain cases, cleavage of the second cleavable portion exposes the first cleavable portion to subsequent cleavage, but the second cleavable portion is not in the cleavable linker and does not cause cleavage of the cleavable linker itself (i.e., cleavage of the first cleavable portion is still required to cleave the cleavable linker).

[0161] Each cleavable portion within a cleavable linker can be an enzymatically cleavable portion. For example, the first cleavable portion may be the first enzymatically cleavable portion, and the second cleavable portion may be the second enzymatically cleavable portion. An enzymatically cleavable portion is a cleavable portion that can be separated into two or more parts as described above by the enzymatic action of an enzyme. An enzymatically cleavable portion can be any cleavable portion that can be cleaved by the enzymatic action of an enzyme, such as, but not limited to, peptides, glycosides, etc. In some cases, the enzyme that cleaves the enzymatically cleavable portion is present at the desired target site of action, such as the desired target site of action of the drug released from the antibody-drug conjugate. In other cases, the enzyme that cleaves the enzymatically cleavable portion is not present in significant amounts in other regions such as whole blood, plasma, or serum. Therefore, cleavage of the enzymatically cleavable portion can be controlled so that substantial cleavage occurs at the desired site of action, while significant cleavage does not occur in other regions or before the antibody-drug conjugate reaches the desired site of action.

[0162] For example, as described herein, the antibody-drug conjugates of this disclosure can be used for the treatment of cancer, for example, for the delivery of cancer-therapeutic drugs to a desired site of action where cancer cells are present. In some cases, an enzyme, for example, the protease enzyme cathepsin B, may be a biomarker for cancer that is overexpressed in cancer cells. The overexpression, and therefore localization, of a specific enzyme in cancer can be used in the context of an enzymatically cleavable moiety contained in the cleavable linker of the antibody-drug conjugate of this disclosure to specifically release a drug at a desired site of action (i.e., the site of cancer (and the overexpressed enzyme)). Thus, in some embodiments, the enzymatically cleavable moiety is a cleavable moiety (e.g., a peptide) that can be cleaved by an enzyme overexpressed in cancer cells. For example, the enzyme may be the protease enzyme cathepsin B. Thus, in some cases, the enzymatically cleavable moiety is a cleavable moiety (e.g., a peptide) that can be cleaved by a protease enzyme (e.g., cathepsin B).

[0163] In certain embodiments, the enzymatically cleavable portion is a peptide. The peptide can be any peptide that is suitable for use in a cleavable linker and can be cleaved by the enzymatic action of an enzyme. Non-limiting examples of peptides that can be used as an enzymatically cleavable portion include, for example, Val-Ala, Phe-Lys, etc. For example, the first cleavable portion described above (i.e., the cleavage portion protected from premature cleavage by the second cleavable portion) may include a peptide. The presence of an uncleaved second cleavable portion can protect the first cleavable portion (peptide) from being cleaved by a protease enzyme (e.g., cathepsin B), and thus substantially reduce or prevent premature release of the drug from the antibody until the antibody-drug conjugate is at or near the desired target site of action for the drug. In some cases, one of the amino acid residues of the peptide containing the first cleavable portion is linked to or contains a substituent, the substituent contains the second cleavable portion. In some cases, the second cleavable portion contains a glycoside.

[0164] In some embodiments, the enzymatically cleavable portion is a sugar portion, such as a glycoside (or glycosyl). In some cases, the glycoside can promote increased hydrophilicity of the cleavable linker compared to a cleavable linker that does not contain a glycoside. The glycoside can be any glycoside that is suitable for use in a cleavable linker and can be cleaved by the enzymatic action of an enzyme. For example, the second cleavable portion (i.e., a cleavable portion that protects the first cleavable portion from premature cleavage) can be a glycoside. For example, in some embodiments, the first cleavable portion comprises a peptide and the second cleavable portion comprises a glycoside. In certain embodiments, the second cleavable portion is a glycoside selected from galactosides, glucosides, mannosides, fucosides, O-GlcNAc, and O-GalNAc. In some cases, the second cleavable portion is a galactoside. In some cases, the second cleavable portion is a glucoside. In some cases, the second cleavable portion is mannoside. In some cases, the second cleavable portion is fucoside. In some cases, the second cleavable portion is O-GlcNAc. In some cases, the second cleavable portion is O-GalNAc.

[0165] Glycosides can be linked (covalently) to cleavable linkers via glycosidic bonds. Glycosidic bonds can link glycosides to cleavable linkers via various types of bonds, including, but are not limited to, O-glycosidic bonds (O-glycosid), N-glycosidic bonds (glycosylamine), S-glycosidic bonds (thioglycoside), or C-glycosidic bonds (C-glycosid or C-glycosyl). In some cases, the glycosidic bond is an O-glycosidic bond (O-glycosid). In other cases, glycosides can be cleaved from cleavable linkers by enzymes (e.g., via enzyme-mediated hydrolysis of the glycosidic bond). Glycosides can be removed or cleaved from cleavable linkers by any convenient enzyme capable of performing the cleavage (hydrolysis) of the glycosidic bond linking the glycoside to the cleavable linker. An example of an enzyme that can be used to mediate the cleavage (hydrolysis) of a glycosidic bond connecting a glycoside to a linker capable of cleaving is a glycosidase, such as galactosidase, glucosidase, mannosidase, or fucosidase. Other suitable enzymes can also be used to mediate the cleavage (hydrolysis) of a glycosidic bond connecting a glycoside to a linker capable of cleaving. In some cases, the enzyme used to mediate the cleavage (hydrolysis) of a glycosidic bond connecting a glycoside to a linker capable of cleaving is found at or near the desired site of action for the drug in the antibody-drug conjugate. For example, the enzyme may be a lysosomal enzyme, such as a lysosomal glycosidase, found in a cell at or near the desired site of action for the drug in the antibody-drug conjugate. In some cases, the enzyme is found at or near the target site where the enzyme mediating the cleavage of the first cleavable portion is found.

[0166] A target portion (e.g., a drug or active agent) can be conjugated to a polypeptide (e.g., an antibody) at any desired site of the polypeptide. Therefore, this disclosure provides, for example, modified polypeptides having a conjugated portion at or near the C-terminus of the polypeptide. Other examples include modified polypeptides having a conjugated portion at or near the N-terminus of the polypeptide. Examples also include modified polypeptides having a conjugated portion between the C-terminus and N-terminus of the polypeptide (e.g., an internal site of the polypeptide). The above combinations are also possible when the modified polypeptide is conjugated to two or more portions.

[0167] In certain embodiments, the conjugates of the Disclosure include drugs or active agents conjugated to amino acid residues of a polypeptide at the α-carbon of an amino acid residue. In other words, the conjugates include polypeptides modified so that the side chains of one or more amino acid residues in the polypeptide are linked to a drug or active agent (for example, via a linker as described herein). For example, the conjugates include polypeptides modified so that the α-carbon of one or more amino acid residues in the polypeptide is linked to a drug or active agent (for example, via a linker as described herein).

[0168] Embodiments of the present disclosure include a conjugate in which a polypeptide is conjugated to one or more parts, for example, two, three, four, five, six, seven, eight, nine, or ten or more parts. A part can be conjugated to a polypeptide at one or more sites in the polypeptide. For example, one or more parts can be conjugated to a single amino acid residue of the polypeptide. In some cases, one part is conjugated to an amino acid residue of the polypeptide. In other embodiments, two parts can be conjugated to the same amino acid residue of the polypeptide. In other embodiments, a first part is conjugated to a first amino acid residue of the polypeptide, and a second part is conjugated to a second amino acid residue of the polypeptide. The above combinations are also possible, for example, the polypeptide is conjugated to a first amino acid residue by a first part and to a second amino acid residue by two other parts. Other combinations are also possible, such as polypeptides in which the first and second portions are conjugated to the first amino acid residue, and the third and fourth portions are conjugated to the second amino acid residue.

[0169] One or more amino acid residues of a polypeptide that are conjugated to one or more parts may be naturally occurring amino acids, unnatural amino acids, or a combination thereof. For example, the conjugate may include a part conjugated to a naturally occurring amino acid residue of the polypeptide. In other cases, the conjugate may include a part conjugated to an unnatural amino acid residue of the polypeptide. One or more parts may be conjugated to the polypeptide with a single natural or unnatural amino acid residue, as described above. One or more natural or unnatural amino acid residues in the polypeptide may be conjugated to one or more parts as described herein. For example, two (or more) amino acid residues (e.g., natural or unnatural amino acid residues) in the polypeptide may each be conjugated to one or two parts, resulting in modification of multiple sites in the polypeptide.

[0170] As described herein, a polypeptide can be conjugated to one or more parts. In certain embodiments, the part of interest is a chemical entity such as a drug, an active agent, or a detectable label. For example, a drug (or active agent) may be conjugated to a polypeptide, or in other embodiments, a detectable label may be conjugated to a polypeptide. Thus, embodiments of this disclosure, for example, include, but are not limited to, conjugates of polypeptides and drugs, conjugates of polypeptides and active agents, conjugates of polypeptides and detectable labels, conjugates of two or more drugs and polypeptides, conjugates of two or more detectable labels and polypeptides, etc.

[0171] In certain embodiments, a polypeptide (e.g., an antibody) and a moiety of interest (e.g., a drug or active agent) are conjugated via a coupling moiety. For example, the polypeptide and the moiety of interest may each be bound (e.g., covalently) to the coupling moiety, and thus indirectly linked together via the coupling moiety. In some cases, the coupling moiety includes a hydrazinyl-indolyl or hydrazinyl-pyrrolo-pyridinyl compound, or a derivative of a hydrazinyl-indolyl or hydrazinyl-pyrrolo-pyridinyl compound. For example, a general scheme for coupling a moiety of interest to a polypeptide via a hydrazinyl-indolyl or hydrazinyl-pyrrolo-pyridinyl coupling moiety is shown in the general reaction scheme below. The hydrazinyl-indolyl or hydrazinyl-pyrrolo-pyridinyl coupling moieties are also referred to herein as the hydrazino-iso-Pictet-Spengler (HIPS) coupling moiety and the aza-hydrazino-iso-Pictet-Spengler (aza-HIPS) coupling moiety, respectively. [ka]

[0172] In the above reaction scheme, R comprises a target portion (e.g., a drug or active agent) to be conjugated to the polypeptide (e.g., conjugated to the polypeptide via a cleavable linker as described herein). As shown in the above reaction scheme, a polypeptide comprising a 2-formylglycine residue (fGly) is reacted with a drug or active agent modified to include a coupling moiety (e.g., a hydrazinyl-indolyl or hydrazinyl-pyrrolo-pyridinyl coupling moiety) to produce a polypeptide conjugate linked to the coupling moiety, thereby linking the drug or active agent to the polypeptide via the coupling moiety.

[0173] As described herein, this part may be any of the following: a variety of parts, for example, a chemical entity, for example, a detectable label, or a drug or active agent. R' and R'' may each independently be any desired substituent, for example, but not limited to hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, acyl, acyloxy, acylamino, aminoacyl, alkylamide, substituted alkylamide, sulfonyl, thioalkoxy, substituted thioalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl. Z is CR 21 , NR 22 It may be N, O, or S, R 21 and R 22 Each of these substituents is independently selected from among the substituents described above for R' and R''.

[0174] Other hydrazinyl-indolyl or hydrazinyl-pyrrolo-pyridinyl coupling moieties are also possible, as shown in the conjugates and compounds described herein. For example, hydrazinyl-indolyl or hydrazinyl-pyrrolo-pyridinyl coupling moieties may be modified to connect to a linker (e.g., covalently). Thus, embodiments of the present disclosure include hydrazinyl-indolyl or hydrazinyl-pyrrolo-pyridinyl coupling moieties connected to a drug or active agent via a linker. Various embodiments of linkers capable of coupling the hydrazinyl-indolyl or hydrazinyl-pyrrolo-pyridinyl coupling moieties to a drug or active agent are described in detail herein. For example, in some cases, the linker is a cleavable linker, e.g., a cleavable linker as described herein.

[0175] In certain embodiments, the polypeptide may be conjugated to a moiety of interest, and the polypeptide is modified before conjugation to the moiety of interest. Modification of the polypeptide may produce a modified polypeptide containing one or more reactive groups suitable for conjugation to the moiety of interest. In some cases, the polypeptide may be modified with one or more amino acid residues to provide one or more reactive groups suitable for conjugation to a moiety of interest (e.g., a moiety containing a coupling moiety such as the hydrazinyl-indolyl or hydrazinyl-pyrrolo-pyridinyl coupling moiety described above). For example, the polypeptide may be modified to contain a reactive aldehyde group (e.g., reactive aldehyde). The reactive aldehyde may be contained in an "aldehyde tag" or "ald-tag," which, as used herein, refer to an amino acid sequence derived from a sulfatase motif (e.g., L(C / S)TPSR) that has been converted to contain a 2-formylglycine residue (referred to herein as "FGly") by the action of formylglycinase (FGE). The FGly residue produced by FGE may also be referred to as “formylglycine.” In other words, the term “aldehyde tag” is used herein to refer to an amino acid sequence containing a “converted” sulfatase motif (i.e., a sulfatase motif in which a cysteine ​​or serine residue has been converted to FGly by the action of FGE, e.g., L(FGly)TPSR). The converted sulfatase motif may originate from an amino acid sequence containing an “unconverted” sulfatase motif (i.e., a sulfatase motif in which a cysteine ​​or serine residue has not been converted to FGly by FGE, but which can be converted, e.g., an unconverted sulfatase motif having the sequence L(C / S)TPSR). “Conversion” as used in the context of the action of formylglycinase (FGE) on a sulfatase motif refers to a biochemical modification from a cysteine ​​or serine residue to a formylglycine (FGly) residue in the sulfatase motif (e.g., Cys to FGly, or Ser to FGly).Further embodiments of aldehyde tags in site-directed protein modification and their use are described in U.S. Patents No. 7,985,783 and No. 8,729,232, the respective disclosures of which are incorporated herein by reference.

[0176] In some cases, a modified polypeptide containing an FGly residue may be conjugated to the desired moiety by a reaction between FGly and a compound (e.g., a compound containing a hydrazinyl-indolyl or hydrazinyl-pyrrolo-pyridinyl coupling moiety, as described above). For example, an FGly-containing polypeptide may be contacted with a drug containing a reactive partner under conditions suitable for providing drug conjugation to a polypeptide. In some cases, the drug containing the reactive partner may contain the hydrazinyl-indolyl or hydrazinyl-pyrrolo-pyridinyl coupling moiety described above. For example, a drug or active agent may be modified to contain a hydrazinyl-indolyl or hydrazinyl-pyrrolo-pyridinyl coupling moiety. In some cases, the drug or active agent may be linked to hydrazinyl-indolyl or hydrazinyl-pyrrolo-pyridinyl and covalently bonded to hydrazinyl-indolyl or hydrazinyl-pyrrolo-pyridinyl via, for example, a linker (e.g., a cleavable linker as described in detail herein).

[0177] In certain embodiments, the conjugate of the present disclosure comprises a polypeptide (e.g., an antibody) having at least one modified amino acid residue. The modified amino acid residue of the polypeptide can be coupled to a drug or active agent containing the hydrazinyl-indolyl or hydrazinyl-pyrrolo-pyridinyl coupling moiety described above. In certain embodiments, the modified amino acid residue of the polypeptide (e.g., an antibody) may be derived from a cysteine ​​or serine residue converted to an FGly residue as described above. In certain embodiments, the FGly residue is conjugated to a drug or active agent containing the hydrazinyl-indolyl or hydrazinyl-pyrrolo-pyridinyl coupling moiety described above, providing the conjugate of the present disclosure in which the drug or active agent is conjugated to the polypeptide via the hydrazinyl-indolyl or hydrazinyl-pyrrolo-pyridinyl coupling moiety. As used herein, the term 'FGly' refers to the modified amino acid residue of the polypeptide (e.g., an antibody) coupled to the moiety of interest (e.g., a drug or active agent).

[0178] In certain embodiments, the conjugate comprises at least one modified amino acid residue as described herein, the modified amino acid residue being connected to a linker (a cleavable linker) as described herein, and then to a drug or active agent. For example, the conjugate may comprise the above-described at least one modified amino acid residue (FGly'). In some embodiments, the conjugate is a conjugate of formula (I), [ka] During the ceremony, Z, CR 4 or N, X is O or NR 4 And, R 1 However, selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl, R2 and R 3 However, each is independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, acyl, acyloxy, acylamino, aminoacyl, alkylamide, substituted alkylamide, sulfonyl, thioalkoxy, substituted thioalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl, or R 2 and R 3 However, they are optionally linked in a ring, forming a 5- or 6-membered heterocycline. Each R 4 However, independently selected from hydrogen, halogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, acyl, acyloxy, acylamino, aminoacyl, alkylamide, substituted alkylamide, sulfonyl, thioalkoxy, substituted thioalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl, Each R 5 However, they are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, and substituted alkynyl, Each R 6 However, they are independently selected from alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl. k is an integer between 1 and 10. R 7 However, it contains a second enzymatically cleavable portion, L 1 However, it was the first linker, L 2 However, it is the second linker, W1 However, it is a drug, W 2 However, it is an antibody.

[0179] In a particular embodiment of equation (I), k is 2, and the conjugate is the conjugate of equation (Ia). [ka]

[0180] In a particular embodiment of formula (I), the conjugate is the conjugate of formula (Ib). [ka]

[0181] In a particular embodiment of formula (I), the conjugate is the conjugate of formula (Ic). [ka]

[0182] In a particular embodiment of formula (I), the conjugate is the conjugate of formula (Id). [ka]

[0183] In a particular embodiment of formula (I), the conjugate is the conjugate of formula (Ie). [ka]

[0184] In a particular embodiment of expression (I), the conjugate is the conjugate of expression (If). [ka]

[0185] In a particular embodiment of formula (I), the conjugate is the conjugate of formula (Ig). [ka]

[0186] The substituents associated with the conjugate of formula (I) are described in more detail below. References to formula (I) are intended to also encompass formulas (Ia), (Ib), (Ic), (Id), (Ie), (If), and (Ig).

[0187] In certain embodiments, Z is CR 4 Or N. In certain embodiments, Z is CR 4 In certain embodiments, Z is N.

[0188] In certain embodiments, X is O or NR 4 In some cases, X is O. In some cases, X is NR 4 In some cases, X is NH.

[0189] In a particular embodiment, R 1 R is selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl. In certain embodiments, R 1 is hydrogen. In a particular embodiment, R 1 is an alkyl or substituted alkyl, for example, C 1~6 Alkyl or C 1~6 Substituting alkyl, or C 1~4 Alkyl or C 1~4 Substituting alkyl, or C 1~3 Alkyl or C 1~3 It is a substituted alkyl. In certain embodiments, R 1 is methyl. In certain embodiments, R 1 This refers to an alkenyl or a substituted alkenyl, for example, C 2~6Alkenil or C 2~6 Substituting alkenyl, or C 2~4 Alkenil or C 2~4 Substituting alkenyl, or C 2~3 Alkenil or C 2~3 It is a substituted alkenyl. In certain embodiments, R 1 This refers to alkynyl or substituted alkynyl, for example, C 2~6 Alkinyl or C 2~6 Substituting alkynyl, or C 2~4 Alkenil or C 2~4 Substituting alkenyl, or C 2~3 Alkenil or C 2~3 It is a substituted alkenyl. In certain embodiments, R 1 is an aryl or substituted aryl, for example, C 5~8 Aryl or C 5~8 Substituting aryls, for example, C5 aryls or C5-substituted aryls, or C6 aryls or C6-substituted aryls. In certain embodiments, R 1 This refers to heteroaryl or substituted heteroaryl, for example, C 5~8 Heteroaryl or C 5~8 Substituting heteroaryls, for example, C5 heteroaryls or C5-substituted heteroaryls, or C6 heteroaryls or C6-substituted heteroaryls. In certain embodiments, R 1 This refers to cycloalkyl or substituted cycloalkyl, for example, C 3~8 Cycloalkyl or C 3~8 Substitutive cycloalkyls, for example, C 3~6 Cycloalkyl or C 3~6 Substituted cycloalkyl, or C 3~5 Cycloalkyl or C 3~5 It is a substituted cycloalkyl. In certain embodiments, R 1 This refers to heterocyclines or substituted heterocyclines, for example, C 3~8 Heterocycline or C 3~8 Substituting heterocyclyls, e.g., C 3~6 Heterocycline or C 3~6 Substituted heterocyclyl, or C 3~5 Heterocycline or C3~5 It is a substituted heterocyclyl.

[0190] In a particular embodiment, R 2 and R 3 Each is independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, acyl, acyloxy, acylamino, aminoacyl, alkylamide, substituted alkylamide, sulfonyl, thioalkoxy, substituted thioalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl, or R 2 and R 3 However, they are optionally linked together in a ring, forming a 5- or 6-membered heterocycline.

[0191] In a particular embodiment, R 2 is selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, acyl, acyloxy, acylamino, aminoacyl, alkylamide, substituted alkylamide, sulfonyl, thioalkoxy, substituted thioalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl. In certain embodiments, R 2 is hydrogen. In a particular embodiment, R 2 is an alkyl or substituted alkyl, for example, C 1~6 Alkyl or C 1~6 Substituting alkyl, or C 1~4 Alkyl or C 1~4 Substituting alkyl, or C 1~3 Alkyl or C 1~3 It is a substituted alkyl. In certain embodiments, R 2 is methyl. In certain embodiments, R 2 This refers to an alkenyl or a substituted alkenyl, for example, C2~6 Alkenil or C 2~6 Substituting alkenyl, or C 2~4 Alkenil or C 2~4 Substituting alkenyl, or C 2~3 Alkenil or C 2~3 It is a substituted alkenyl. In certain embodiments, R 2 is an alkynyl or substituted alkynyl. In certain embodiments, R 2 is an alkoxy or substituted alkoxy. In certain embodiments, R 2 is an amino acid or a substituted amino acid. In certain embodiments, R 2 is a carboxyl or carboxyl ester. In certain embodiments, R 2 is an acyl or acyloxy. In certain embodiments, R 2 is acylamino or aminoacyl. In certain embodiments, R 2 is an alkylamide or a substituted alkylamide. In certain embodiments, R 2 is a sulfonyl. In certain embodiments, R 2 is a thioalkoxy or a substituted thioalkoxy. In certain embodiments, R 2 is an aryl or substituted aryl, for example, C 5~8 Aryl or C 5~8 Substituting aryls, for example, C5 aryls or C5-substituted aryls, or C6 aryls or C6-substituted aryls. In certain embodiments, R 2 This refers to heteroaryl or substituted heteroaryl, for example, C 5~8 Heteroaryl or C 5~8 Substituting heteroaryls, for example, C5 heteroaryls or C5-substituted heteroaryls, or C6 heteroaryls or C6-substituted heteroaryls. In certain embodiments, R 2 This refers to cycloalkyl or substituted cycloalkyl, for example, C 3~8 Cycloalkyl or C 3~8 Substitutive cycloalkyls, for example, C 3~6 Cycloalkyl or C 3~6 Substituted cycloalkyl, or C 3~5Cycloalkyl or C 3~5 It is a substituted cycloalkyl. In certain embodiments, R 2 This refers to heterocyclines or substituted heterocyclines, for example, C 3~6 Heterocycline or C 3~6 Substituted heterocyclyl, or C 3~5 Heterocycline or C 3~5 It is a substituted heterocyclyl.

[0192] In a particular embodiment, R 3 is selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, acyl, acyloxy, acylamino, aminoacyl, alkylamide, substituted alkylamide, sulfonyl, thioalkoxy, substituted thioalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl. In certain embodiments, R 3 is hydrogen. In a particular embodiment, R 3 is an alkyl or substituted alkyl, for example, C 1~6 Alkyl or C 1~6 Substituting alkyl, or C 1~4 Alkyl or C 1~4 Substituting alkyl, or C 1~3 Alkyl or C 1~3 It is a substituted alkyl. In certain embodiments, R 3 is methyl. In certain embodiments, R 3 This refers to an alkenyl or a substituted alkenyl, for example, C 2~6 Alkenil or C 2~6 Substituting alkenyl, or C 2~4 Alkenil or C 2~4 Substituting alkenyl, or C 2~3 Alkenil or C 2~3 It is a substituted alkenyl. In certain embodiments, R 3 is an alkynyl or substituted alkynyl. In certain embodiments, R 3is an alkoxy or substituted alkoxy. In certain embodiments, R 3 is an amino acid or a substituted amino acid. In certain embodiments, R 3 is a carboxyl or carboxyl ester. In certain embodiments, R 3 is an acyl or acyloxy. In certain embodiments, R 3 is acylamino or aminoacyl. In certain embodiments, R 3 is an alkylamide or a substituted alkylamide. In certain embodiments, R 3 is a sulfonyl. In certain embodiments, R 3 is a thioalkoxy or a substituted thioalkoxy. In certain embodiments, R 3 is an aryl or substituted aryl, for example, C 5~8 Aryl or C 5~8 Substituting aryls, for example, C5 aryls or C5-substituted aryls, or C6 aryls or C6-substituted aryls. In certain embodiments, R 3 This refers to heteroaryl or substituted heteroaryl, for example, C 5~8 Heteroaryl or C 5~8 Substituting heteroaryls, for example, C5 heteroaryls or C5-substituted heteroaryls, or C6 heteroaryls or C6-substituted heteroaryls. In certain embodiments, R 3 This refers to cycloalkyl or substituted cycloalkyl, for example, C 3~8 Cycloalkyl or C 3~8 Substitutive cycloalkyls, for example, C 3~6 Cycloalkyl or C 3~6 Substituted cycloalkyl, or C 3~5 Cycloalkyl or C 3~5 It is a substituted cycloalkyl. In certain embodiments, R 3 This refers to heterocyclines or substituted heterocyclines, for example, C 3~8 Heterocycline or C 3~8 Substituting heterocyclyls, e.g., C 3~6 Heterocycline or C 3~6 Substituted heterocyclyl, or C 3~5Heterocycline or C 3~5 It is a substituted heterocyclyl.

[0193] In a particular embodiment, R 2 and R 3 These are optionally linked in a ring to form a 5- or 6-membered heterocycline. In certain embodiments, R 2 and R 3 These are linked in a ring shape, forming a 5- or 6-membered heterocycline. In certain embodiments, R 2 and R 3 These are linked in a ring, forming a 5-membered heterocycline. In certain embodiments, R 2 and R 3 These are linked together in a ring, forming a six-membered heterocycline.

[0194] In a specific method of operation, each R 4 These are independently selected from hydrogen, halogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, acyl, acyloxy, acylamino, aminoacyl, alkylamide, substituted alkylamide, sulfonyl, thioalkoxy, substituted thioalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl.

[0195] Each R 4 Various possibilities regarding this are described in more detail below. In certain embodiments, R 4 is hydrogen. In a particular embodiment, each R 4 is hydrogen. In a particular embodiment, R 4 is a halogen such as F, Cl, Br, or I. In certain embodiments, R 4 is F. In a particular embodiment, R 4 is Cl. In certain embodiments, R 4 is Br. In certain embodiments, R 4 is I. In a particular embodiment, R 4is an alkyl or substituted alkyl, for example, C 1~6 Alkyl or C 1~6 Substituting alkyl, or C 1~4 Alkyl or C 1~4 Substituting alkyl, or C 1~3 Alkyl or C 1~3 It is a substituted alkyl. In certain embodiments, R 4 is methyl. In certain embodiments, R 4 This refers to an alkenyl or a substituted alkenyl, for example, C 2~6 Alkenil or C 2~6 Substituting alkenyl, or C 2~4 Alkenil or C 2~4 Substituting alkenyl, or C 2~3 Alkenil or C 2~3 It is a substituted alkenyl. In certain embodiments, R 4 is an alkynyl or substituted alkynyl. In certain embodiments, R 4 is an alkoxy or substituted alkoxy. In certain embodiments, R 4 is an amino acid or a substituted amino acid. In certain embodiments, R 4 is a carboxyl or carboxyl ester. In certain embodiments, R 4 is an acyl or acyloxy. In certain embodiments, R 4 is acylamino or aminoacyl. In certain embodiments, R 4 is an alkylamide or a substituted alkylamide. In certain embodiments, R 4 is a sulfonyl. In certain embodiments, R 4 is a thioalkoxy or a substituted thioalkoxy. In certain embodiments, R 4 is an aryl or substituted aryl, for example, C 5~8 Aryl or C 5~8 Substituting aryls, for example, C5 aryls or C5-substituted aryls, or C6 aryls or C6-substituted aryls (for example, phenyl or substituted phenyl). In certain embodiments, R 4 This refers to heteroaryl or substituted heteroaryl, for example, C 5~8Heteroaryl or C 5~8 Substituting heteroaryls, for example, C5 heteroaryls or C5-substituted heteroaryls, or C6 heteroaryls or C6-substituted heteroaryls. In certain embodiments, R 4 This refers to cycloalkyl or substituted cycloalkyl, for example, C 3~8 Cycloalkyl or C 3~8 Substitutive cycloalkyls, for example, C 3~6 Cycloalkyl or C 3~6 Substituted cycloalkyl, or C 3~5 Cycloalkyl or C 3~5 It is a substituted cycloalkyl. In certain embodiments, R 4 This refers to heterocyclines or substituted heterocyclines, for example, C 3~8 Heterocycline or C 3~8 Substituting heterocyclyls, e.g., C 3~6 Heterocycline or C 3~6 Substituted heterocyclyl, or C 3~5 Heterocycline or C 3~5 It is a substituted heterocyclyl.

[0196] In a specific method of operation, each R 5 R is independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, and substituted alkynyl. In certain embodiments, R 5 is hydrogen. In a particular embodiment, R 5 is an alkyl or substituted alkyl, for example, C 1~6 Alkyl or C 1~6 Substituting alkyl, or C 1~4 Alkyl or C 1~4 Substituting alkyl, or C 1~3 Alkyl or C 1~3 It is a substituted alkyl. In certain embodiments, R 5 is methyl. In certain embodiments, R 5 is ethyl. In certain embodiments, R 5 is propyl (e.g., n-propyl or isopropyl). In certain embodiments, R 5is butyl (e.g., n-butyl, isobutyl, sec-butyl, or t-butyl). In certain embodiments, R 5 R is pentyl (e.g., n-pentyl or neopentyl). In certain embodiments, R 5 is neopentyl. In certain embodiments, R 5 This refers to an alkenyl or a substituted alkenyl, for example, C 2~6 Alkenil or C 2~6 Substituting alkenyl, or C 2~4 Alkenil or C 2~4 Substituting alkenyl, or C 2~3 Alkenil or C 2~3 It is a substituted alkenyl. In certain embodiments, R 5 This is an alkynyl or substituted alkynyl.

[0197] In a specific method of operation, each R 6 R is independently selected from alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl. In certain embodiments, R 6 is hydrogen. In a particular embodiment, R 6 is an alkyl or substituted alkyl, for example, C 1~6 Alkyl or C 1~6 Substituting alkyl, or C 1~4 Alkyl or C 1~4 Substituting alkyl, or C 1~3 Alkyl or C 1~3 It is a substituted alkyl. In certain embodiments, R 6 is methyl. In certain embodiments, R 6 is ethyl. In certain embodiments, R 6 is propyl (e.g., n-propyl or isopropyl). In certain embodiments, R 6 is butyl (e.g., n-butyl, isobutyl, sec-butyl, or t-butyl). In certain embodiments, R 6R is pentyl (e.g., n-pentyl or neopentyl). In certain embodiments, R 6 is neopentyl. In certain embodiments, R 6 This refers to an alkenyl or a substituted alkenyl, for example, C 2~6 Alkenil or C 2~6 Substituting alkenyl, or C 2~4 Alkenil or C 2~4 Substituting alkenyl, or C 2~3 Alkenil or C 2~3 It is a substituted alkenyl. In certain embodiments, R 6 This is an alkynyl or substituted alkynyl.

[0198] In a particular embodiment, R 6 is an aryl or substituted aryl, for example, C 5~8 Aryl or C 5~8 Substituting aryls, for example, C5 aryls or C5-substituted aryls, or C6 aryls or C6-substituted aryls (for example, phenyl or substituted phenyl). In certain embodiments, R 6 This refers to heteroaryl or substituted heteroaryl, for example, C 5~8 Heteroaryl or C 5~8 Substituting heteroaryls, for example, C5 heteroaryls or C5-substituted heteroaryls, or C6 heteroaryls or C6-substituted heteroaryls. In certain embodiments, R 6 This refers to cycloalkyl or substituted cycloalkyl, for example, C 3~8 Cycloalkyl or C 3~8 Substitutive cycloalkyls, for example, C 3~6 Cycloalkyl or C 3~6 Substituted cycloalkyl, or C 3~5 Cycloalkyl or C 3~5 It is a substituted cycloalkyl. In certain embodiments, R 6 This refers to heterocyclines or substituted heterocyclines, for example, C 3~8 Heterocycline or C 3~8 Substituting heterocyclyls, e.g., C 3~6 Heterocycline or C 3~6Substituted heterocyclyl, or C 3~5 Heterocycline or C 3~5 It is a substituted heterocyclyl.

[0199] In a particular embodiment, R 6 R represents the side chain of an amino acid. For example, R 6 R may represent substituents attached to the α-carbon of an amino acid residue, including natural amino acids, unnatural amino acids, and amino acid analogs. In some cases, R 6 is a side chain of an amino acid found in naturally occurring proteins (e.g., Ala or A, Cys or C, Asp or D, Glu or E, Phe or F, Gly or G, His or H, Ile or I, Lys or K, Leu or L, Met or M, Asn or N, Pro or P, Gln or Q, Arg or R, Ser or S, Thr or T, Val or V, Trp or W, Tyr or Y). In certain embodiments, R 6 This represents the side chain of valine (Val), i.e., R 6 is isopropyl. In certain embodiments, R 6 This represents the side chain of alanine (Ala), i.e., R 6 is methyl. In certain embodiments, R 6 This represents the side chain of phenylalanine (Phe), i.e., R 6 is benzyl. In certain embodiments, R 6 represents the side chain of lysine (Lys), i.e., R 6 It is 4-aminobutyl.

[0200] In certain embodiments, k is an integer between 1 and 10. In certain embodiments, k is 1. In certain embodiments, k is 2. In certain embodiments, k is 3. In certain embodiments, k is 4. In certain embodiments, k is 5. In certain embodiments, k is 6. In certain embodiments, k is 7. In certain embodiments, k is 8. In certain embodiments, k is 9. In certain embodiments, k is 10.

[0201] In certain embodiments, the portion of formula (I) enclosed in parentheses - subscript k represents one or more amino acids (e.g., a peptide). For example, as described above, the conjugate of the present disclosure may include a first enzymatically cleavable moiety, the first enzymatically cleavable moiety being a peptide. As represented in formula (I), one or more amino acids may be a peptide containing the first enzymatically cleavable moiety.

[0202] In a particular embodiment, R 7 R is a second enzymatically cleavable portion as described herein. For example, R 7 This may include glycosides selected from galactosides, glucosides, mannosides, fucosides, O-GlcNAc, and O-GalNAc. In some cases, R 7 It contains galactoside. In some cases, R 7 It contains glucosides. In some cases, R 7 It contains mannoside. In some cases, R 7 It contains fucoside. In some cases, R 7 It contains O-GlcNAc. In some cases, R 7 It contains O-GalNAc.

[0203] In a particular embodiment, L 1 This is the first linker. 1 Suitable linkers are described in more detail below.

[0204] In a particular embodiment, L 2 This is the second linker. 2 Suitable linkers are described in more detail below.

[0205] In a particular embodiment, W 1 is a drug (or active agent). Further descriptions of drugs and active agents suitable for use with the conjugates and compounds described herein can be found in more detail below.

[0206] In a particular embodiment, W 2This is an antibody. Further descriptions of antibodies that find applications in subject conjugates can be found in the disclosure herein.

[0207] In certain embodiments, the conjugate of formula (I) comprises one or more linkers. The linkers can be used to conjugate a coupling moiety to one or more moieties and / or polypeptides of interest. In some embodiments, the linker conjugates the coupling moiety to either a polypeptide or a chemical entity such as a drug. The linker can be conjugated to the coupling moiety at any convenient position (e.g., as described herein) (e.g., covalently). For example, the linker may conjugate a hydrazinyl-indolyl or hydrazinyl-pyrrolo-pyridinyl coupling moiety to a drug (e.g., mytansin or auristatin). The hydrazinyl-indolyl or hydrazinyl-pyrrolo-pyridinyl coupling moiety can be used to conjugate the linker (and therefore the drug) to a polypeptide, such as an antibody. For example, the coupling moiety can be used to conjugate the linker (and therefore the drug) to a modified amino acid residue of a polypeptide, such as an FGly residue (reside) of an antibody.

[0208] In certain embodiments, the linker is one or more linkers, for example, a first linker L 1 and the second linker L 2 This includes. In addition, the linker may include one or more cleavable parts (e.g., a first cleavable part and a second cleavable part) as described herein. In some cases, the linker may include one or more linkers, e.g., a first linker L 1 and the second linker L 2 This includes, for example, a first linker (L) that connects a first severable portion to a coupling portion (e.g., a hydrazinyl-indolyl or hydrazinyl-pyrrolo-pyridinyl coupling portion as described herein). 1 ) and a second linker (L) connecting the first cleavable portion to a chemical entity, for example, a drug or active agent described herein. 2) and may include. Therefore, the linker is a first linker (L) that links the first cleavable portion to the antibody (for example, via the hydrazinyl-indolyl or hydrazinyl-pyrrolo-pyridinyl coupling portion described herein). 1 ) and a second linker (L) connecting the first cleavable portion to a chemical entity, for example, a drug or active agent described herein. 2 ) and may include.

[0209] For example, as shown in equation (I) above, L 1 W 2 Connect to W 2 The first linker L is connected via the coupling portion. 1 It is indirectly connected to W. 2 It is an antibody, and therefore, L 1 It connects to the antibody via a coupling portion, for example, the first linker L 1 It indirectly binds to the antibody via a coupling moiety (for example, via the hydrazinyl-indolyl or hydrazinyl-pyrrolo-pyridinyl coupling moiety described herein). In addition, as shown in formula (I) above, L 1 L 2 Connect to (indirectly), L 2 is, W 1 It is connected to W. As mentioned above, 1 It is a drug, and therefore the second linker L 2 This is the first linker L 1 and via the coupling moiety (for example, the hydrazinyl-indolyl or hydrazinyl-pyrrolo-pyridinyl coupling moiety described herein) antibody W 2 Connect the drug to it.

[0210] Any convenient linker is the first linker (L) in the subject conjugate and compound. 1 ) and the second linker (L 2 ) can be used in a particular embodiment. In a particular embodiment, the first linker (L 1 ) and the second linker (L 2) may each independently contain a group selected from alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, acylamino, alkylamide, substituted alkylamide, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl. In certain embodiments, the first linker (L 1 ) and the second linker (L 2 ) may each independently contain an alkyl or substituted alkyl group. In certain embodiments, the first linker (L 1 ) and the second linker (L 2 ) may each independently contain an alkenyl or substituted alkenyl group. In certain embodiments, the first linker (L 1 ) and the second linker (L 2 ) may each independently contain an alkynyl or substituted alkynyl group. In certain embodiments, the first linker (L 1 ) and the second linker (L 2 ) may each independently contain an alkoxy or substituted alkoxy group. In certain embodiments, the first linker (L 1 ) and the second linker (L 2 ) may each independently contain an amino or substituted amino group. In certain embodiments, the first linker (L 1 ) and the second linker (L 2 ) may each independently contain a carboxyl or carboxyl ester group. In certain embodiments, the first linker (L 1 ) and the second linker (L 2 ) may each independently contain an acylamino group. In certain embodiments, the first linker (L 1 ) and the second linker (L 2 ) may each independently contain an alkylamide or substituted alkylamide group. In certain embodiments, the first linker (L 1 ) and the second linker (L 2 ) may each independently contain an aryl or substituted aryl group. In certain embodiments, the first linker (L1 ) and the second linker (L 2 ) may each independently include a heteroaryl or substituted heteroaryl group. In certain embodiments, the first linker (L 1 ) and the second linker (L 2 ) may each independently include a cycloalkyl or substituted cycloalkyl group. In certain embodiments, the first linker (L 1 ) and the second linker (L 2 ) may each independently include a heterocyclyl or substituted heterocyclyl group.

[0211] In certain embodiments, the first linker (L 1 ) and the second linker (L 2 ) may each independently include a polymer. For example, the polymer may include polyalkylene glycols and derivatives thereof, such as polyethylene glycol, methoxypolyethylene glycol, polyethylene glycol homopolymers, polypropylene glycol homopolymers, copolymers of ethylene glycol and propylene glycol (e.g., homopolymers and copolymers that are unsubstituted or substituted at one end with an alkyl group), polyvinyl alcohol, polyvinyl ethyl ether, polyvinyl pyrrolidone, combinations thereof, etc. In certain embodiments, the polymer is a polyalkylene glycol. In certain embodiments, the polymer is polyethylene glycol. Other linkers are also possible, as shown in the conjugates and compounds described in more detail below.

[0212] In some embodiments, L 1 is the first linker described by the formula -(L 11 ) a -(L 12 ) b -(L 13 ) c -(L 14 ) d - wherein L 11 , L 12 , L 13 , and L 14Each of these is independently a first linker subunit, and each of a, b, c, and d is independently 0 or 1, and the sum of a, b, c, and d is between 1 and 4.

[0213] In certain embodiments, the sum of a, b, c, and d is 1. In certain embodiments, the sum of a, b, c, and d is 2. In certain embodiments, the sum of a, b, c, and d is 3. In certain embodiments, the sum of a, b, c, and d is 4. In certain embodiments, a, b, c, and d are each 1. In certain embodiments, a, b, and c are each 1, and d is 0. In certain embodiments, a and b are each 1, and c and d are each 0. In certain embodiments, a is 1, and b, c, and d are each 0.

[0214] In a particular embodiment, L 11 L is connected to a hydrazinyl-indolyl or hydrazinyl-pyrrolo-pyridinyl coupling portion (for example, as shown in formula (I) above). In certain embodiments, L 12 If present, it is connected to the first detachable portion. In certain embodiments, L 13 If present, it is connected to the first detachable portion. In certain embodiments, L 14 If present, it is connected to the first detachable portion.

[0215] Any convenient linker subunit, the first linker L 1 It can be used for the following. The target linker subunit is not limited to polyethylene glycol, polyethylene and polyacrylate, amino acid residues, carbohydrate polymers or their carbohydrate residues and derivatives, polynucleotides, alkyl groups, aryl groups, heterocyclic groups, and other polymer units, combinations thereof, and substitutions thereof. In some embodiments, L 11 , L 12 , L 13 , and L 14Each of these (if present) comprises one or more groups independently selected from polyethylene glycol, modified polyethylene glycol, amino acid residues, alkyl groups, substituted alkyl groups, aryl groups, substituted aryl groups, and diamines (e.g., linking groups including alkylenediamines).

[0216] In some embodiments, L 11 (If present) includes polyethylene glycol, modified polyethylene glycol, amino acid residues, alkyl groups, substituted alkyl groups, aryl groups, substituted aryl groups, or diamines. In some embodiments, L 11 It contains polyethylene glycol. In some embodiments, L 11 It contains modified polyethylene glycol. In some embodiments, L 11 It contains an amino acid residue. In some embodiments, L 11 This includes an alkyl group or a substituted alkyl group. In some embodiments, L 11 This includes an aryl group or a substituted aryl group. In some embodiments, L 11 It contains a diamine (for example, a linking group including alkylenediamine).

[0217] In some embodiments, L 12 (If present) includes polyethylene glycol, modified polyethylene glycol, amino acid residues, alkyl groups, substituted alkyl groups, aryl groups, substituted aryl groups, or diamines. In some embodiments, L 12 It contains polyethylene glycol. In some embodiments, L 12 It contains modified polyethylene glycol. In some embodiments, L 12 It contains an amino acid residue. In some embodiments, L 12 This includes an alkyl group or a substituted alkyl group. In some embodiments, L 12 This includes an aryl group or a substituted aryl group. In some embodiments, L 12 It contains a diamine (for example, a linking group including alkylenediamine).

[0218] In some embodiments, L 13 (when present) comprises polyethylene glycol, modified polyethylene glycol, amino acid residue, alkyl group, substituted alkyl, aryl group, substituted aryl group, or diamine. In some embodiments, L 13 comprises polyethylene glycol. In some embodiments, L 13 comprises modified polyethylene glycol. In some embodiments, L 13 comprises an amino acid residue. In some embodiments, L 13 comprises an alkyl group or a substituted alkyl. In some embodiments, L 13 comprises an aryl group or a substituted aryl group. In some embodiments, L 13 comprises a diamine (e.g., a linking group including an alkylenediamine).

[0219] In some embodiments, L 14 (when present) comprises polyethylene glycol, modified polyethylene glycol, amino acid residue, alkyl group, substituted alkyl, aryl group, substituted aryl group, or diamine. In some embodiments, L 14 comprises polyethylene glycol. In some embodiments, L 14 comprises modified polyethylene glycol. In some embodiments, L 14 comprises an amino acid residue. In some embodiments, L 14 comprises an alkyl group or a substituted alkyl. In some embodiments, L 14 comprises an aryl group or a substituted aryl group. In some embodiments, L 14 comprises a diamine (e.g., a linking group including an alkylenediamine).

[0220] In some embodiments, L 1 is -(L 11 ) a -(L 12 ) b -(L 13 ) c -(L 14 ) d- is the first linker, in the formula, -(L 11 ) a -but,-(T 1 -V 1 ) a -and, -(L 12 ) b -but,-(T 2 -V 2 ) b -and, -(L 13 ) c -but,-(T 3 -V 3 ) c -and, -(L 14 ) d -but,-(T 4 -V 4 ) d -and, In the formula, T 1 , T 2 , T 3 , and T 4 If present, it is a tether group. V 1 , V 2 , V 3 , and V 4 If present, it is a covalent bond or linking functional group. a, b, c, and d are each independently either 0 or 1, and the sum of a, b, c, and d is between 1 and 4.

[0221] As described above, in a particular embodiment, L 11 This is connected to a hydrazinyl-indolyl or hydrazinyl-pyrrolo-pyridinyl coupling portion (for example, as shown in formula (I) above). Therefore, in certain embodiments, T 1 This is connected to a hydrazinyl-indolyl or hydrazinyl-pyrrolo-pyridinyl coupling portion (for example, as shown in formula (I) above). In certain embodiments, V 1 It is connected to the first detachable portion. In a particular embodiment, L 12If present, it is connected to the first detachable portion. Therefore, in a particular embodiment, T 2 If present, it is connected to the first detachable portion, or V 2 If present, it is connected to the first detachable portion. In certain embodiments, L 13 If present, it is connected to the first detachable portion. Therefore, in a particular embodiment, T 3 If present, it is connected to the first detachable portion, or V 3 If present, it is connected to the first detachable portion. In certain embodiments, L 14 If present, it is connected to the first detachable portion. Therefore, in a particular embodiment, T 4 If present, it is connected to the first detachable portion, or V 4 If present, it is connected to the first detachable portion.

[0222] Tether group T 1 , T 2 , T 3 , and T 4 In relation to this, any convenient tether group can be used in the linker of the subject. In some embodiments, T 1 , T 2 , T 3 , and T 4 Each of them is (C1~C 12 ) alkyl, substituted (C1~C 12 ) alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl, (EDA) w (PEG) n , (AA) p ,-(CR 13 OH) h - comprises one or more groups independently selected from 4-amino-piperidine (4AP), acetal groups, disulfide, hydrazine, and esters, wherein w is an integer from 1 to 20, n is an integer from 1 to 30, p is an integer from 1 to 20, and h is an integer from 1 to 12.

[0223] In certain embodiments, a tether group (e.g., T 1 , T 2 , T 3 , and / or T 4 ) is (C1~C 12 ) Alkyl or substituted (C1~C 12 ) Contains alkyl. In certain embodiments, (C1~C 12 Alkyl is a linear or branched alkyl group containing 1 to 12 carbon atoms, for example, 1 to 10 carbon atoms, or 1 to 8 carbon atoms, or 1 to 6 carbon atoms, or 1 to 5 carbon atoms, or 1 to 4 carbon atoms, or 1 to 3 carbon atoms. In some cases, (C1-C 12 )Alkyl refers to alkyl or substituted alkyl, for example, (C1~C 12 ) alkyl, or (C1~C 10 ) alkyl, or (C1-C6) alkyl, or (C1-C3) alkyl. In some cases, (C1-C 12 ) Alkyl is C2-alkyl. For example, (C1~C 12 )Alkyl refers to alkylene or substituted alkylene, for example, (C1~C 12 ) Alkylene, or (C1~C 10 ) may be alkylene, or (C1-C6) alkylene, or (C1-C3) alkylene. In some cases, (C1-C 12 Alkyl is a C2-alkylene (e.g., CH2CH2).

[0224] In certain embodiments, substitution (C1~C 12 Alkyl is a linear or branched substituted alkyl group containing 1 to 12 carbon atoms, for example, 1 to 10 carbon atoms, or 1 to 8 carbon atoms, or 1 to 6 carbon atoms, or 1 to 5 carbon atoms, or 1 to 4 carbon atoms, or 1 to 3 carbon atoms. In some cases, substituted (C1-C 12 )alkyl refers to substituted alkyl, for example, substituted (C1~C 12 ) alkyl or substituted (C1~C 10 ) alkyl, or substituted (C1-C6) alkyl, or substituted (C1-C3) alkyl. In some cases, substituted (C1-C12 )alkyl is a substituted C2-alkyl. For example, substituted (C1~C 12 )Alkyl refers to substituted alkylenes, for example, substituted (C1~C 12 ) Alkylene, or substitution (C1~C 10 ) may be alkylene, or substituted (C1-C6) alkylene, or substituted (C1-C3) alkylene. In some cases, substituted (C1-C 12 Alkyl is a substituted C2-alkylene.

[0225] In certain embodiments, a tether group (e.g., T 1 , T 2 , T 3 , and / or T 4 ) includes aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, or substituted heterocyclyl. In some cases, a tether group (e.g., T) may be included. 1 , T 2 , T 3 , and / or T 4 ) includes aryl or substituted aryl. For example, aryl can be phenyl. In some cases, substituted aryl is substituted phenyl. Substituted phenyl is (C1~C 12 ) alkyl, substituted (C1~C 12 The substituents may be substituted with one or more substituents selected from alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl. In some cases, the substituted aryl is a substituted phenyl, and the substituent comprises a second cleavable moiety as described herein (e.g., an enzymatically cleavable moiety, e.g., a glycoside).

[0226] In some cases, a tether group (for example, T 1 , T 2 , T 3 , and / or T 4 ) includes heteroaryl or substituted heteroaryl groups. In some cases, a tether group (e.g., T) may be present. 1 , T 2 , T 3 , and / or T4 ) includes cycloalkyl or substituted cycloalkyl groups. In some cases, a tether group (e.g., T) may be present. 1 , T 2 , T 3 , and / or T 4 ) comprises a heterocyclyl or a substituted heterocyclyl. In some cases, a substituted heteroaryl, substituted cycloalkyl, or substituent on a substituted heterocyclyl comprises a second cleavable moiety as described herein (e.g., an enzymatically cleavable moiety, e.g., a glycoside).

[0227] In certain embodiments, a tether group (e.g., T 1 , T 2 , T 3 , and / or T 4 ) includes an ethylenediamine (EDA) moiety, for example, an EDA-containing tether. In certain embodiments, (EDA) w The EDA moiety comprises one or more EDA moieties, for example, where w is an integer from 1 to 50, e.g., 1 to 40, 1 to 30, 1 to 20, 1 to 12, or 1 to 6, e.g., 1, 2, 3, 4, 5, or 6). The linked ethylenediamine (EDA) moieties may optionally be substituted at one or more favorable positions with any favorable substituent, e.g., alkyl, substituted alkyl, acyl, substituted acyl, aryl, or substituted aryl. In certain embodiments, the EDA moiety has the following structure [ka] Described by, In the formula, y is an integer from 1 to 6, or 0 or 1, and each R 12However, independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, acyl, acyloxy, acylamino, aminoacyl, alkylamide, substituted alkylamide, sulfonyl, thioalkoxy, substituted thioalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl. In certain embodiments, y is 1, 2, 3, 4, 5, or 6. In certain embodiments, y is 1 and r is 0. In certain embodiments, y is 1 and r is 1. In certain embodiments, y is 2 and r is 0. In certain embodiments, y is 2 and r is 1. In certain embodiments, each R 12 These are independently selected from hydrogen, alkyl, substituted alkyl, aryl, and substituted aryl. In certain embodiments, any two adjacent R of EDA 12 The groups may be linked in a ring, for example, to form a piperazinyl ring. In certain embodiments, y is 1 and two adjacent R 12 The group is an alkyl group, linked cyclically to form a piperazinyl ring. In certain embodiments, y is 1, and adjacent R 12 The group is selected from hydrogen, alkyl (e.g., methyl), and substituted alkyl (e.g., lower alkyl-OH, e.g., ethyl-OH or propyl-OH).

[0228] In certain embodiments, a tether group (e.g., T 1 , T 2 , T 3 , and / or T 4 ) comprises a 4-amino-piperidine (4AP) moiety (also referred to herein as piperidine-4-amino, P4A). The 4AP moiety may optionally be substituted at one or more favorable positions with any favorable substituent, such as alkyl, substituted alkyl, polyethylene glycol moiety, acyl, substituted acyl, aryl, or substituted aryl. In certain embodiments, the 4AP moiety has the following structure [ka] Described by, In the formula, R 12 However, R is selected from hydrogen, alkyl, substituted alkyl, polyethylene glycol moiety (e.g., polyethylene glycol or modified polyethylene glycol), alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, acyl, acyloxy, acylamino, aminoacyl, alkylamide, substituted alkylamide, sulfonyl, thioalkoxy, substituted thioalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl. In certain embodiments, R 12 This is the polyethylene glycol portion. In certain embodiments, R 12 This is carboxy-modified polyethylene glycol.

[0229] In a particular embodiment, R 12 This refers to the polyethylene glycol portion (PEG) described by the following formula. k It includes the following structure [ka] It may also be expressed by, In the formula, k is an integer between 1 and 20, for example, 1 to 18, or 1 to 16, or 1 to 14, or 1 to 12, or 1 to 10, or 1 to 8, or 1 to 6, or 1 to 4, or 1 or 2, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20. In some cases, k is 2. In certain embodiments, R 17 R is selected from OH, COOH, or COOR, and R is selected from alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl. In certain embodiments, R17 COOH is.

[0230] In certain embodiments, a tether group (e.g., T 1 , T 2 , T 3 , and / or T 4 ) is (PEG) n Includes, in the formula, (PEG) n However, it is a polyethylene glycol or modified polyethylene glycol linked unit. In certain embodiments, (PEG) n The structure is as follows: [ka] Described by, In the formula, n is an integer between 1 and 50, for example, 1 to 40, 1 to 30, 1 to 20, 1 to 12, or 1 to 6, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20. In some cases, n is 2. In some cases, n is 3. In some cases, n is 6. In some cases, n is 12.

[0231] In certain embodiments, a tether group (e.g., T 1 , T 2 , T 3 , and / or T 4 ) is (AA) pThe formula includes, where AA is an amino acid residue. Any suitable amino acid may be used. The target amino acid may include, but is not limited to, L-amino acids and D-amino acids, naturally occurring amino acids, e.g., any of the 20 main alpha-amino acids and beta-alanine, or amino acids that do not exist naturally (e.g., amino acid analogs), e.g., alpha-amino acids or beta-amino acids that do not exist naturally. In certain embodiments, p is an integer from 1 to 50, e.g., 1 to 40, 1 to 30, 1 to 20, 1 to 12, or 1 to 6, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20. In certain embodiments, p is 1. In certain embodiments, p is 2.

[0232] In certain embodiments, a tether group (e.g., T 1 , T 2 , T 3 , and / or T 4 ) is formula - (CR 13 OH) h -Includes the portion described by, where h is 0 or n is an integer from 1 to 50, e.g., 1 to 40, 1 to 30, 1 to 20, 1 to 12, or 1 to 6, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12. In certain embodiments, h is 1. In certain embodiments, h is 2. In certain embodiments, R 13 is selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, acyl, acyloxy, acylamino, aminoacyl, alkylamide, substituted alkylamide, sulfonyl, thioalkoxy, substituted thioalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl. In certain embodiments, R 13 is hydrogen. In a particular embodiment, R 13 is an alkyl or substituted alkyl, for example, C 1~6 Alkyl or C1~6 Substituting alkyl, or C 1~4 Alkyl or C 1~4 Substituting alkyl, or C 1~3 Alkyl or C 1~3 It is a substituted alkyl. In certain embodiments, R 13 This refers to an alkenyl or a substituted alkenyl, for example, C 2~6 Alkenil or C 2~6 Substituting alkenyl, or C 2~4 Alkenil or C 2~4 Substituting alkenyl, or C 2~3 Alkenil or C 2~3 It is a substituted alkenyl. In certain embodiments, R 13 is an alkynyl or substituted alkynyl. In certain embodiments, R 13 is an alkoxy or substituted alkoxy. In certain embodiments, R 13 is an amino acid or a substituted amino acid. In certain embodiments, R 13 is a carboxyl or carboxyl ester. In certain embodiments, R 13 is an acyl or acyloxy. In certain embodiments, R 13 is acylamino or aminoacyl. In certain embodiments, R 13 is an alkylamide or a substituted alkylamide. In certain embodiments, R 13 is a sulfonyl. In certain embodiments, R 13 is a thioalkoxy or a substituted thioalkoxy. In certain embodiments, R 13 is an aryl or substituted aryl, for example, C 5~8 Aryl or C 5~8 Substituting aryls, for example, C5 aryls or C5-substituted aryls, or C6 aryls or C6-substituted aryls. In certain embodiments, R 13 This refers to heteroaryl or substituted heteroaryl, for example, C 5~8 Heteroaryl or C 5~8 Substituting heteroaryls, for example, C5 heteroaryls or C5-substituted heteroaryls, or C6 heteroaryls or C6-substituted heteroaryls. In certain embodiments, R13 This refers to cycloalkyl or substituted cycloalkyl, for example, C 3~8 Cycloalkyl or C 3~8 Substitutive cycloalkyls, for example, C 3~6 Cycloalkyl or C 3~6 Substituted cycloalkyl, or C 3~5 Cycloalkyl or C 3~5 It is a substituted cycloalkyl. In certain embodiments, R 13 This refers to heterocyclines or substituted heterocyclines, for example, C 3~8 Heterocycline or C 3~8 Substituting heterocyclyls, e.g., C 3~6 Heterocycline or C 3~6 Substituted heterocyclyl, or C 3~5 Heterocycline or C 3~5 It is a substituted heterocyclyl.

[0233] In a particular embodiment, R 13 R is selected from hydrogen, alkyl, substituted alkyl, aryl, and substituted aryl. In these embodiments, alkyl, substituted alkyl, aryl, and substituted aryl are R 13 As stated above,

[0234] Linking functional group V 1 , V 2 , V 3 , and V 4 Regarding this, any convenient linking functional group is the first linker L 1 It can be used in the following. The target linking functional group is not limited to amino, carbonyl, amide, oxycarbonyl, carboxy, sulfonyl, sulfoxide, sulfonylamino, aminosulfonyl, thio, oxy, phospho, phosphoramidate, thiophospholide, etc. In some embodiments, V 1 , V 2 , V 3 , and V 4 These are, independently, covalent, -CO-, and -NR bonds. 15 -, -NR 15 (CH2) q -, -NR15 (C6H4)-, -CONR 15 -, -NR 15 CO-, -C(O)O-, -OC(O)-, -O-, -S-, -S(O)-, -SO2-, -SO2NR 15 -, -NR 15 Selected from SO2- and -P(O)OH-, q is an integer from 1 to 6. In certain embodiments, q is an integer from 1 to 6 (e.g., 1, 2, 3, 4, 5, or 6). In certain embodiments, q is 1. In certain embodiments, q is 2.

[0235] Several embodiments, each R 15 These are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, acyl, acyloxy, acylamino, aminoacyl, alkylamide, substituted alkylamide, sulfonyl, thioalkoxy, substituted thioalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl.

[0236] Each R 15 Various possibilities regarding this are described in more detail below. In certain embodiments, R 15 is hydrogen. In a particular embodiment, each R 15 is hydrogen. In a particular embodiment, R 15 is an alkyl or substituted alkyl, for example, C 1~6 Alkyl or C 1~6 Substituting alkyl, or C 1~4 Alkyl or C 1~4 Substituting alkyl, or C 1~3 Alkyl or C 1~3 It is a substituted alkyl. In certain embodiments, R 15 This refers to an alkenyl or a substituted alkenyl, for example, C 2~6 Alkenil or C 2~6 Substituting alkenyl, or C 2~4 Alkenil or C2~4 Substituting alkenyl, or C 2~3 Alkenil or C 2~3 It is a substituted alkenyl. In certain embodiments, R 15 is an alkynyl or substituted alkynyl. In certain embodiments, R 15 is an alkoxy or substituted alkoxy. In certain embodiments, R 15 is an amino acid or a substituted amino acid. In certain embodiments, R 15 is a carboxyl or carboxyl ester. In certain embodiments, R 15 is an acyl or acyloxy. In certain embodiments, R 15 is acylamino or aminoacyl. In certain embodiments, R 15 is an alkylamide or a substituted alkylamide. In certain embodiments, R 15 is a sulfonyl. In certain embodiments, R 15 is a thioalkoxy or a substituted thioalkoxy. In certain embodiments, R 15 is an aryl or substituted aryl, for example, C 5~8 Aryl or C 5~8 Substituting aryls, for example, C5 aryls or C5-substituted aryls, or C6 aryls or C6-substituted aryls. In certain embodiments, R 15 This refers to heteroaryl or substituted heteroaryl, for example, C 5~8 Heteroaryl or C 5~8 Substituting heteroaryls, for example, C5 heteroaryls or C5-substituted heteroaryls, or C6 heteroaryls or C6-substituted heteroaryls. In certain embodiments, R 15 This refers to cycloalkyl or substituted cycloalkyl, for example, C 3~8 Cycloalkyl or C 3~8 Substitutive cycloalkyls, for example, C 3~6 Cycloalkyl or C 3~6 Substituted cycloalkyl, or C 3~5 Cycloalkyl or C 3~5 It is a substituted cycloalkyl. In certain embodiments, R 15This refers to heterocyclines or substituted heterocyclines, for example, C 3~8 Heterocycline or C 3~8 Substituting heterocyclyls, e.g., C 3~6 Heterocycline or C 3~6 Substituted heterocyclyl, or C 3~5 Heterocycline or C 3~5 It is a substituted heterocyclyl.

[0237] In a specific method of operation, each R 15 The substituents are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, carboxyl, carboxyl ester, acyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl. In these embodiments, the substituents are hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, carboxyl, carboxyl ester, acyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl. 15 As stated above,

[0238] In certain embodiments, the tether group includes an acetal group, a disulfide, a hydrazine, or an ester. In some embodiments, the tether group includes an acetal group. In some embodiments, the tether group includes a disulfide. In some embodiments, the tether group includes a hydrazine. In some embodiments, the tether group includes an ester.

[0239] As described above, in some embodiments, L 1 is, (T 1 -V 1 ) a -(T 2 -V 2 ) b -(T 3 -V 3 ) c -(T 4 -V4 ) d - is a first linker containing, where a, b, c, and d are each independently 0 or 1, and the sum of a, b, c, and d is between 1 and 4.

[0240] In some embodiments, the first linker L 1 In, T 1 However, (C1~C 12 ) Alkyl and substituted (C1~C 12 ) Selected from alkyl groups, T 2 , T 3 , and T 4 However, each operates independently, (C1~C 12 ) alkyl, substituted (C1~C 12 ) alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl, (EDA) w (PEG) n , (AA) p ,-(CR 13 OH) h - Selected from 4-amino-piperidine (4AP), acetal group, disulfide, hydrazine, and ester, V 1 , V 2 , V 3 , and V 4 However, each operates independently as a covalent bond, -CO-, -NR. 15 -, -NR 15 (CH2) q -, -NR 15 (C6H4)-, -CONR 15 -, -NR 15 CO-, -C(O)O-, -OC(O)-, -O-, -S-, -S(O)-, -SO2-, -SO2NR 15 -, -NR 15 Selected from SO2- and -P(O)OH-, where q is an integer from 1 to 6. During the ceremony, (PEG) n but, [ka] In the formula, n is an integer between 1 and 30. EDA has the following structure [ka] The ethylenediamine moiety has the following characteristics, where y is an integer from 1 to 6, and r is 0 or 1. 4-amino-piperidine (4AP) [ka] And, AA represents an amino acid residue, and in the formula, p is an integer from 1 to 20. Each R 15 and R 12 However, independently selected from hydrogen, alkyl, substituted alkyl, aryl, and substituted aryl, any two adjacent R 12 The groups may be linked in a ring to form a piperazinyl ring. R 13 However, it is selected from hydrogen, alkyl, substituted alkyl, aryl, and substituted aryl.

[0241] In a particular embodiment, T 1 , T 2 , T 3 , and T 4 , and V 1 , V 2 , V 3 , and V 4 The following can be selected: T 1 However, (C1~C 12 ) is alkyl, V 1 However, it is -CO-, T 2 However, it is an amino acid analog, V 2 However, it is -NH-, T 3 However, (PEG) n V 3 However, it is -CO-, d is 0 (i.e., T 4 and V 4(It does not exist).

[0242] In certain embodiments, the left side of the linker structure above is connected to a hydrazinyl-indolyl or hydrazinyl-pyrrolo-pyridinyl coupling moiety, and the right side of the linker structure above is connected to a first cleavable moiety. For example, if the first cleavable moiety contains a peptide, the right side of the linker structure above may be connected to an amino acid of the peptide containing the first cleavable moiety. In some cases, the carbonyl group on the right side of the linker structure above may form an amide bond with an amino acid of the peptide containing the first cleavable moiety.

[0243] In some embodiments, L 2 is, equation -(L 21 ) e -(L 22 ) f -(L 23 ) g -(L 24 ) h - is the second linker described by, in formula L 21 , L 22 , L 23 , and L 24 Each of these is independently a second linker subunit, where e, f, g, and h are independently either 0 or 1, and the sum of e, f, g, and h is between 0 and 4.

[0244] In certain embodiments, the sum of e, f, g, and h is 0. In these cases, the second linker L 2 It does not exist. In other words, if the sum of e, f, g, and h is 0, then the second linker L 2It is a covalent bond. In certain embodiments, the sum of e, f, g, and h is 1. In certain embodiments, the sum of e, f, g, and h is 2. In certain embodiments, the sum of e, f, g, and h is 3. In certain embodiments, the sum of e, f, g, and h is 4. In certain embodiments, e, f, g, and h are each 1. In certain embodiments, e, f, and g are each 1 and h is 0. In certain embodiments, e and f are each 1 and g and h are each 0. In certain embodiments, e is 1 and f, g, and h are each 0.

[0245] In a particular embodiment, L 21 This refers to a drug (for example, W as shown in equation (I) above). 1 ) is connected. In certain embodiments, L 22 If present, it is connected to the drug. In certain embodiments, L 23 If present, it is connected to the drug. In certain embodiments, L 24 If present, it is connected to drugs.

[0246] Any convenient linker subunit, second linker L 2 It can be used for the following. The target linker subunit is not limited to polyethylene glycol, polyethylene and polyacrylate, amino acid residues, carbohydrate polymers or their carbohydrate residues and derivatives, polynucleotides, alkyl groups, aryl groups, heterocyclic groups, and other polymer units, combinations thereof, and substitutions thereof. In some embodiments, L 21 , L 22 , L 23 , and L 24 Each of these (if present) comprises one or more groups independently selected from polyethylene glycol, modified polyethylene glycol, amino acid residues, alkyl groups, substituted alkyl groups, aryl groups, substituted aryl groups, and diamines (e.g., linking groups including alkylenediamines).

[0247] In some embodiments, L 21(If present) includes polyethylene glycol, modified polyethylene glycol, amino acid residues, alkyl groups, substituted alkyl groups, aryl groups, substituted aryl groups, or diamines. In some embodiments, L 21 It contains polyethylene glycol. In some embodiments, L 21 It contains modified polyethylene glycol. In some embodiments, L 21 It contains an amino acid residue. In some embodiments, L 21 This includes an alkyl group or a substituted alkyl group. In some embodiments, L 21 This includes an aryl group or a substituted aryl group. In some embodiments, L 21 It contains a diamine (for example, a linking group including alkylenediamine).

[0248] In some embodiments, L 22 (If present) includes polyethylene glycol, modified polyethylene glycol, amino acid residues, alkyl groups, substituted alkyl groups, aryl groups, substituted aryl groups, or diamines. In some embodiments, L 22 It contains polyethylene glycol. In some embodiments, L 22 It contains modified polyethylene glycol. In some embodiments, L 22 It contains an amino acid residue. In some embodiments, L 22 This includes an alkyl group or a substituted alkyl group. In some embodiments, L 22 This includes an aryl group or a substituted aryl group. In some embodiments, L 22 It contains a diamine (for example, a linking group including alkylenediamine).

[0249] In some embodiments, L 23 (If present) includes polyethylene glycol, modified polyethylene glycol, amino acid residues, alkyl groups, substituted alkyl groups, aryl groups, substituted aryl groups, or diamines. In some embodiments, L 23 It contains polyethylene glycol. In some embodiments, L 23It contains modified polyethylene glycol. In some embodiments, L 23 It contains an amino acid residue. In some embodiments, L 23 This includes an alkyl group or a substituted alkyl group. In some embodiments, L 23 This includes an aryl group or a substituted aryl group. In some embodiments, L 23 It contains a diamine (for example, a linking group including alkylenediamine).

[0250] In some embodiments, L 24 (If present) includes polyethylene glycol, modified polyethylene glycol, amino acid residues, alkyl groups, substituted alkyl groups, aryl groups, substituted aryl groups, or diamines. In some embodiments, L 24 It contains polyethylene glycol. In some embodiments, L 24 It contains modified polyethylene glycol. In some embodiments, L 24 It contains an amino acid residue. In some embodiments, L 24 This includes an alkyl group or a substituted alkyl group. In some embodiments, L 24 This includes an aryl group or a substituted aryl group. In some embodiments, L 24 It contains a diamine (for example, a linking group including alkylenediamine).

[0251] In some embodiments, L 2 is, -(L 21 ) e -(L 22 ) f -(L 23 ) g -(L 24 ) h - is a second linker, in the formula, -(L 21 ) e -but,-(T 5 -V 5 ) e -and, -(L 22 ) f -but,-(T 6 -V 6) f -and, -(L 23 ) g -but,-(T 7 -V 7 ) g -and, -(L 24 ) h -but,-(T 8 -V 8 ) h -and, In the formula, T 5 , T 6 , T 7 , and T 8 If present, it is a tether group. V 5 , V 6 , V 7 , and V 8 If present, it is a covalent bond or linking functional group. e, f, g, and h are each independently either 0 or 1, and the sum of e, f, g, and h is between 0 and 4.

[0252] In a particular embodiment, L 21 It is connected to the first detachable portion. Therefore, in a particular embodiment, T 5 It is connected to the first detachable portion. In a particular embodiment, V 5 This refers to a drug (for example, W as shown in equation (I) above). 1 ) is connected. In certain embodiments, L 22 If present, it is connected to the drug. Therefore, in certain embodiments, T 6 If present, it is connected to the drug or V 6 If present, it is connected to the drug. In certain embodiments, L 23 If present, it is connected to the drug. Therefore, in certain embodiments, T 7 If present, it is connected to the drug or V 7 If present, it is connected to the drug. In certain embodiments, L 24 If present, it is connected to the drug. Therefore, in certain embodiments, T 8If present, it is connected to the drug or V 8 If present, it is connected to drugs.

[0253] Tether group T 5 , T 6 , T 7 , and T 8 In relation to this, any convenient tether group can be used in the linker of the subject. In some embodiments, T 5 , T 6 , T 7 , and T 8 Each of them is (C1~C 12 ) alkyl, substituted (C1~C 12 ) alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl, (EDA) w (PEG) n , (AA) p ,-(CR 13 OH) h - comprises one or more groups independently selected from 4-amino-piperidine (4AP), acetal groups, disulfide, hydrazine, and esters, wherein w is an integer from 1 to 20, n is an integer from 1 to 30, p is an integer from 1 to 20, and h is an integer from 1 to 12.

[0254] In certain embodiments, a tether group (e.g., T 5 , T 6 , T 7 , and / or T 8 ) is (C1~C 12 ) Alkyl or substituted (C1~C 12 ) Contains alkyl. In certain embodiments, (C1~C 12 Alkyl is a linear or branched alkyl group containing 1 to 12 carbon atoms, for example, 1 to 10 carbon atoms, or 1 to 8 carbon atoms, or 1 to 6 carbon atoms, or 1 to 5 carbon atoms, or 1 to 4 carbon atoms, or 1 to 3 carbon atoms. In some cases, (C1-C 12 )Alkyl refers to alkyl or substituted alkyl, for example, (C1~C 12 ) alkyl, or (C1~C10 ) alkyl, or (C1-C6) alkyl, or (C1-C3) alkyl. In some cases, (C1-C 12 ) Alkyl is C2-alkyl. For example, (C1~C 12 )Alkyl refers to alkylene or substituted alkylene, for example, (C1~C 12 ) Alkylene, or (C1~C 10 ) may be alkylene, or (C1-C6) alkylene, or (C1-C3) alkylene. In some cases, (C1-C 12 Alkyl is C2-alkylene (e.g., CH2CH2). In some cases, (C1~C 12 Alkyl is a C1-alkylene (e.g., CH2).

[0255] In certain embodiments, substitution (C1~C 12 Alkyl is a linear or branched substituted alkyl group containing 1 to 12 carbon atoms, for example, 1 to 10 carbon atoms, or 1 to 8 carbon atoms, or 1 to 6 carbon atoms, or 1 to 5 carbon atoms, or 1 to 4 carbon atoms, or 1 to 3 carbon atoms. In some cases, substituted (C1-C 12 )alkyl refers to substituted alkyl, for example, substituted (C1~C 12 ) alkyl or substituted (C1~C 10 ) alkyl, or substituted (C1-C6) alkyl, or substituted (C1-C3) alkyl. In some cases, substituted (C1-C 12 )alkyl is a substituted C2-alkyl. For example, substituted (C1~C 12 )Alkyl refers to substituted alkylenes, for example, substituted (C1~C 12 ) Alkylene, or substitution (C1~C 10 ) may be alkylene, or substituted (C1-C6) alkylene, or substituted (C1-C3) alkylene. In some cases, substituted (C1-C 12 )Alkyl is a substituted C2 alkylene. In some cases, substituted (C1~C 12 Alkyl is a substituted C1-alkylene.

[0256] In certain embodiments, a tether group (e.g., T 5 , T 6 , T 7 , and / or T 8 ) includes aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, or substituted heterocyclyl. In some cases, the tether group includes aryl or substituted aryl. For example, aryl may be phenyl or substituted phenyl. In some cases, the tether group (e.g., T 5 , T 6 , T 7 , and / or T 8 ) includes heteroaryl or substituted heteroaryl groups. In some cases, a tether group (e.g., T) may be present. 5 , T 6 , T 7 , and / or T 8 ) includes cycloalkyl or substituted cycloalkyl groups. In some cases, a tether group (e.g., T) may be present. 5 , T 6 , T 7 , and / or T 8 ) includes heterocyclyl or substituted heterocyclyl.

[0257] In certain embodiments, a tether group (e.g., T 5 , T 6 , T 7 , and / or T 8 ) is an ethylenediamine (EDA) moiety, for example, the EDA moiety described above, for example, the EDA moiety described by the following structure [ka] Includes, In the formula, y is an integer from 1 to 6, or 0 or 1, and each R 12However, independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, acyl, acyloxy, acylamino, aminoacyl, alkylamide, substituted alkylamide, sulfonyl, thioalkoxy, substituted thioalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl. In certain embodiments, y is 1, 2, 3, 4, 5, or 6. In certain embodiments, y is 1 and r is 0. In certain embodiments, y is 1 and r is 1. In certain embodiments, y is 2 and r is 0. In certain embodiments, y is 2 and r is 1. In certain embodiments, each R 12 These are independently selected from hydrogen, alkyl, substituted alkyl, aryl, and substituted aryl. In certain embodiments, any two adjacent R of EDA 12 The groups may be linked in a ring, for example, to form a piperazinyl ring. In certain embodiments, y is 1 and two adjacent R 12 The group is an alkyl group, linked cyclically to form a piperazinyl ring. In certain embodiments, y is 1, and adjacent R 12 The group is selected from hydrogen, alkyl (e.g., methyl), and substituted alkyl (e.g., lower alkyl-OH, e.g., ethyl-OH or propyl-OH).

[0258] In certain embodiments, a tether group (e.g., T 5 , T 6 , T 7 , and / or T 8 ) refers to the 4-amino-piperidine (4AP) moiety described above, for example, the 4AP moiety described by the following structure. [ka] Includes, In the formula, R 12However, R is selected from hydrogen, alkyl, substituted alkyl, polyethylene glycol moiety (e.g., polyethylene glycol or modified polyethylene glycol), alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, acyl, acyloxy, acylamino, aminoacyl, alkylamide, substituted alkylamide, sulfonyl, thioalkoxy, substituted thioalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl. In certain embodiments, R 12 This is the polyethylene glycol portion. In certain embodiments, R 12 This is carboxy-modified polyethylene glycol.

[0259] In a particular embodiment, R 12 This refers to the polyethylene glycol portion (PEG) described by the following formula. k It includes the following structure [ka] It may also be expressed by, In the formula, k is an integer between 1 and 20, for example, 1 to 18, or 1 to 16, or 1 to 14, or 1 to 12, or 1 to 10, or 1 to 8, or 1 to 6, or 1 to 4, or 1 or 2, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20. In some cases, k is 2. In certain embodiments, R 17 R is selected from OH, COOH, or COOR, and R is selected from alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl. In certain embodiments, R 17 COOH is.

[0260] In certain embodiments, a tether group (e.g., T 5, T 6 , T 7 , and / or T 8 ) is the polyethylene glycol portion (PEG) mentioned above. n For example, it is described by the following structure (PEG) n portion [ka] Includes, In the formula, n is an integer between 1 and 50, for example, 1 to 40, 1 to 30, 1 to 20, 1 to 12, or 1 to 6, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20. In some cases, n is 2. In some cases, n is 3. In some cases, n is 6. In some cases, n is 12.

[0261] In certain embodiments, a tether group (e.g., T 5 , T 6 , T 7 , and / or T 8 ) is (AA) p The formula includes, where AA is an amino acid residue. Any suitable amino acid may be used. The target amino acid may include, but is not limited to, L-amino acids and D-amino acids, naturally occurring amino acids, e.g., any of the 20 main alpha-amino acids and beta-alanine, or amino acids that do not exist naturally (e.g., amino acid analogs), e.g., alpha-amino acids or beta-amino acids that do not exist naturally. In certain embodiments, p is an integer from 1 to 50, e.g., 1 to 40, 1 to 30, 1 to 20, 1 to 12, or 1 to 6, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20. In certain embodiments, p is 1. In certain embodiments, p is 2.

[0262] In certain embodiments, a tether group (e.g., T 5 , T 6 , T 7 , and / or T 8 ) is formula - (CR13 OH) h -Includes the portion described by, where h is 0 or n is an integer from 1 to 50, e.g., 1 to 40, 1 to 30, 1 to 20, 1 to 12, or 1 to 6, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12. In certain embodiments, h is 1. In certain embodiments, h is 2. In certain embodiments, R 13 is selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, acyl, acyloxy, acylamino, aminoacyl, alkylamide, substituted alkylamide, sulfonyl, thioalkoxy, substituted thioalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl. In certain embodiments, R 13 is hydrogen. In a particular embodiment, R 13 is an alkyl or substituted alkyl, for example, C 1~6 Alkyl or C 1~6 Substituting alkyl, or C 1~4 Alkyl or C 1~4 Substituting alkyl, or C 1~3 Alkyl or C 1~3 It is a substituted alkyl. In certain embodiments, R 13 This refers to an alkenyl or a substituted alkenyl, for example, C 2~6 Alkenil or C 2~6 Substituting alkenyl, or C 2~4 Alkenil or C 2~4 Substituting alkenyl, or C 2~3 Alkenil or C 2~3 It is a substituted alkenyl. In certain embodiments, R 13 is an alkynyl or substituted alkynyl. In certain embodiments, R 13 is an alkoxy or substituted alkoxy. In certain embodiments, R 13 is an amino acid or a substituted amino acid. In certain embodiments, R 13is a carboxyl or carboxyl ester. In certain embodiments, R 13 is an acyl or acyloxy. In certain embodiments, R 13 is acylamino or aminoacyl. In certain embodiments, R 13 is an alkylamide or a substituted alkylamide. In certain embodiments, R 13 is a sulfonyl. In certain embodiments, R 13 is a thioalkoxy or a substituted thioalkoxy. In certain embodiments, R 13 is an aryl or substituted aryl, for example, C 5~8 Aryl or C 5~8 Substituting aryls, for example, C5 aryls or C5-substituted aryls, or C6 aryls or C6-substituted aryls. In certain embodiments, R 13 This refers to heteroaryl or substituted heteroaryl, for example, C 5~8 Heteroaryl or C 5~8 Substituting heteroaryls, for example, C5 heteroaryls or C5-substituted heteroaryls, or C6 heteroaryls or C6-substituted heteroaryls. In certain embodiments, R 13 This refers to cycloalkyl or substituted cycloalkyl, for example, C 3~8 Cycloalkyl or C 3~8 Substitutive cycloalkyls, for example, C 3~6 Cycloalkyl or C 3~6 Substituted cycloalkyl, or C 3~5 Cycloalkyl or C 3~5 It is a substituted cycloalkyl. In certain embodiments, R 13 This refers to heterocyclines or substituted heterocyclines, for example, C 3~8 Heterocycline or C 3~8 Substituting heterocyclyls, e.g., C 3~6 Heterocycline or C 3~6 Substituted heterocyclyl, or C 3~5 Heterocycline or C 3~5 It is a substituted heterocyclyl.

[0263] In a particular embodiment, R13 R is selected from hydrogen, alkyl, substituted alkyl, aryl, and substituted aryl. In these embodiments, alkyl, substituted alkyl, aryl, and substituted aryl are R 13 As stated above,

[0264] Linking functional group V 5 , V 6 , V 7 , and V 8 Regarding this, any convenient linking functional group is the second linker L 2 It can be used in the following. The target linking functional group is not limited to amino, carbonyl, amide, oxycarbonyl, carboxy, sulfonyl, sulfoxide, sulfonylamino, aminosulfonyl, thio, oxy, phospho, phosphoramidate, thiophospholide, etc. In some embodiments, V 5 , V 6 , V 7 , and V 8 These are, independently, covalent, -CO-, and -NR bonds. 15 -, -NR 15 (CH2) q -, -NR 15 (C6H4)-, -CONR 15 -, -NR 15 CO-, -C(O)O-, -OC(O)-, -O-, -S-, -S(O)-, -SO2-, -SO2NR 15 -, -NR 15 Selected from SO2- and -P(O)OH-, q is an integer from 1 to 6. In certain embodiments, q is an integer from 1 to 6 (e.g., 1, 2, 3, 4, 5, or 6). In certain embodiments, q is 1. In certain embodiments, q is 2.

[0265] Several embodiments, each R 15These are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, acyl, acyloxy, acylamino, aminoacyl, alkylamide, substituted alkylamide, sulfonyl, thioalkoxy, substituted thioalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl.

[0266] Each R 15 Various possibilities regarding this are described in more detail below. In certain embodiments, R 15 is hydrogen. In a particular embodiment, each R 15 is hydrogen. In a particular embodiment, R 15 is an alkyl or substituted alkyl, for example, C 1~6 Alkyl or C 1~6 Substituting alkyl, or C 1~4 Alkyl or C 1~4 Substituting alkyl, or C 1~3 Alkyl or C 1~3 It is a substituted alkyl. In certain embodiments, R 15 This refers to an alkenyl or a substituted alkenyl, for example, C 2~6 Alkenil or C 2~6 Substituting alkenyl, or C 2~4 Alkenil or C 2~4 Substituting alkenyl, or C 2~3 Alkenil or C 2~3 It is a substituted alkenyl. In certain embodiments, R 15 is an alkynyl or substituted alkynyl. In certain embodiments, R 15 is an alkoxy or substituted alkoxy. In certain embodiments, R 15 is an amino acid or a substituted amino acid. In certain embodiments, R 15 is a carboxyl or carboxyl ester. In certain embodiments, R 15 is an acyl or acyloxy. In certain embodiments, R 15is acylamino or aminoacyl. In certain embodiments, R 15 is an alkylamide or a substituted alkylamide. In certain embodiments, R 15 is a sulfonyl. In certain embodiments, R 15 is a thioalkoxy or a substituted thioalkoxy. In certain embodiments, R 15 is an aryl or substituted aryl, for example, C 5~8 Aryl or C 5~8 Substituting aryls, for example, C5 aryls or C5-substituted aryls, or C6 aryls or C6-substituted aryls. In certain embodiments, R 15 This refers to heteroaryl or substituted heteroaryl, for example, C 5~8 Heteroaryl or C 5~8 Substituting heteroaryls, for example, C5 heteroaryls or C5-substituted heteroaryls, or C6 heteroaryls or C6-substituted heteroaryls. In certain embodiments, R 15 This refers to cycloalkyl or substituted cycloalkyl, for example, C 3~8 Cycloalkyl or C 3~8 Substitutive cycloalkyls, for example, C 3~6 Cycloalkyl or C 3~6 Substituted cycloalkyl, or C 3~5 Cycloalkyl or C 3~5 It is a substituted cycloalkyl. In certain embodiments, R 15 This refers to heterocyclines or substituted heterocyclines, for example, C 3~8 Heterocycline or C 3~8 Substituting heterocyclyls, e.g., C 3~6 Heterocycline or C 3~6 Substituted heterocyclyl, or C 3~5 Heterocycline or C 3~5 It is a substituted heterocyclyl.

[0267] In a specific method of operation, each R 15The substituents are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, carboxyl, carboxyl ester, acyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl. In these embodiments, the substituents are hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, carboxyl, carboxyl ester, acyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl. 15 As stated above,

[0268] In certain embodiments, the tether group includes an acetal group, a disulfide, a hydrazine, or an ester. In some embodiments, the tether group includes an acetal group. In some embodiments, the tether group includes a disulfide. In some embodiments, the tether group includes a hydrazine. In some embodiments, the tether group includes an ester.

[0269] As described above, in some embodiments, L 2 is, -(T 5 -V 5 ) e -(T 6 -V 6 ) f -(T 7 -V 7 ) g -(T 8 -V 8 ) h - is a second linker, where e, f, g, and h are each independently 0 or 1, and the sum of e, f, g, and h is between 0 and 4.

[0270] In some embodiments, the second linker L 2 In, T 5 , T 6 , T 7 , and T 8However, each operates independently, (C1~C 12 ) alkyl, substituted (C1~C 12 ) alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, or substituted heterocyclyl, (EDA) w (PEG) n , (AA) p ,-(CR 13 OH) h - Selected from 4-amino-piperidine (4AP), acetal group, disulfide, hydrazine, and ester, V 5 , V 6 , V 7 , and V 8 However, each operates independently as a covalent bond, -CO-, -NR. 15 -, -NR 15 (CH2) q -, -NR 15 (C6H4)-, -CONR 15 -, -NR 15 CO-, -C(O)O-, -OC(O)-, -O-, -S-, -S(O)-, -SO2-, -SO2NR 15 -, -NR 15 Selected from SO2- and -P(O)OH-, where q is an integer from 1 to 6. During the ceremony, (PEG) n but, [ka] In the formula, n is an integer between 1 and 30. EDA has the following structure [ka] The ethylenediamine moiety has the following characteristics, where y is an integer from 1 to 6, and r is 0 or 1. 4-amino-piperidine (4AP) [ka] And, AA represents an amino acid residue, and in the formula, p is an integer from 1 to 20. Each R 13 However, they are independently selected from hydrogen, alkyl, substituted alkyl, aryl, and substituted aryl. Each R 15 However, these are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, carboxyl, carboxyl ester, acyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl.

[0271] In a particular embodiment, T 5 , T 6 , T 7 , and T 8 , and V 5 , V 6 , V 7 , and V 8 It does not exist (i.e., the sum of e, f, g, and h is 0).

[0272] In a particular embodiment, T 5 , T 6 , T 7 , and T 8 , and V 5 , V 6 , V 7 , and V 8 The following can be selected: T 5 However, it is a covalent bond, V 5 However, it is -C(O)-, f is 0 (i.e., T 6 and V 6 (It does not exist), g is 0 (i.e., T 7 and V 7 (It does not exist), h is 0 (i.e., T 8 and V 8 (It does not exist).

[0273] In a particular embodiment, T 5 , T 6, T 7 , and T 8 , and V 5 , V 6 , V 7 , and V 8 The following can be selected: T 5 However, it is a covalent bond, V 5 However, -CONR 15 -and, T 6 However, it is alkyl, V 6 However, it is -CO-, g is 0 (i.e., T 7 and V 7 (It does not exist), h is 0 (i.e., T 8 and V 8 (It does not exist).

[0274] In certain embodiments, the left side of the upper linker structure is connected to the first cleavable portion, and the right side of the upper linker structure is connected to the drug.

[0275] Any of the chemical entities, linkers, and coupling components shown in the above structure may be adapted for use in the subject compound and conjugate.

[0276] Further disclosures regarding hydrazinyl-indolyl or hydrazinyl-pyrrolo-pyridinyl compounds and methods for producing conjugates can be found in U.S. Patents 9,310,374 and 9,493,413, the respective disclosures of which are incorporated herein by reference.

[0277] Compounds useful for generating conjugates This disclosure provides hydrazinyl-indolyl or hydrazinyl-pyrrolo-pyridinyl compounds useful for generating the conjugates described herein. In certain embodiments, the hydrazinyl-indolyl or hydrazinyl-pyrrolo-pyridinyl compounds may be coupling moieties useful for conjugating antibodies with drugs or active agents. For example, the hydrazinyl-indolyl or hydrazinyl-pyrrolo-pyridinyl compounds may bind to antibodies and drugs, and thus indirectly conjugate both antibodies and drugs together.

[0278] In certain embodiments, the compound comprises a cleavable linker for linking an antibody to a drug, the cleavable linker comprising a first enzymatically cleavable moiety and a second enzymatically cleavable moiety comprising a glycoside selected from the group consisting of galactosides, glucosides, mannosides, fucosides, O-GlcNAc, and O-GalNAc.

[0279] In certain embodiments, the compound is the compound of formula (II), [ka] During the ceremony, Z, CR 4 or N, X is O or NR 4 And, R 2 and R 3 However, each is independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, acyl, acyloxy, acylamino, aminoacyl, alkylamide, substituted alkylamide, sulfonyl, thioalkoxy, substituted thioalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl, or R 2 and R 3 However, they are optionally linked in a ring, forming a 5- or 6-membered heterocycline. Each R4 However, independently selected from hydrogen, halogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, acyl, acyloxy, acylamino, aminoacyl, alkylamide, substituted alkylamide, sulfonyl, thioalkoxy, substituted thioalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl, Each R 5 However, they are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl. Each R 6 However, they are independently selected from alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl. k is an integer between 1 and 10. R 7 However, this is the second part that can be enzymatically cleaved. L 1 However, it was the first linker, L 2 However, it is the second linker, W 1 However, it is a drug.

[0280] In some cases, k is 2, and the compound is the compound of formula (IIa). [ka]

[0281] For example, the compound may be the compound of formula (IIb). [ka]

[0282] In some cases, the compound may be a compound of formula (IIc). [ka]

[0283] In some cases, the compound may be a compound of formula (IId). [ka]

[0284] In some cases, the compound may be a compound of formula (IIe). [ka]

[0285] In some cases, the compound may be a compound of formula (IIf). [ka]

[0286] In some cases, the compound may be a compound of formula (IIg). [ka]

[0287] Substituents associated with the conjugate of formula (II) are described herein. References to formula (II) are intended to also encompass formulas (IIa), (IIb), (IIc), (IId), (IIe), (IIf), and (IIg).

[0288] Regarding the compound of formula (II), substituents Z and R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , L 1 , L2 , and W 1 The conjugate of equation (I) is as described above. Similarly, the first linker L of equation (II) 1 and the second linker L 2 Regarding T 1 , T 2 , T 3 , T 4 , V 1 , V 2 , V 3 , and V 4 , and T 5 , T 6 , T 7 , T 8 , V 5 , V 6 , V 7 , and V 8 The substituents are as described above with respect to the conjugate of formula (I).

[0289] In certain embodiments, the compound is a compound having the following structure. [ka]

[0290] antibody As shown above, the subject conjugate is substituent W 2The amino acids may also contain antibodies, which are modified to include a 2-formylglycine (FGly) residue. As used herein, amino acids may be referred to by their standard names, their standard three-letter abbreviations, and / or their standard one-letter abbreviations, for example, alanine or Ala or A, cysteine ​​or Cys or C, aspartic acid or Asp or D, glutamic acid or Glu or E, phenylalanine or Phe or F, glycine or Gly or G, histidine or His or H, isoleucine or Ile or I, lysine or Lys or K, leucine or Leu or L, methionine or Met or M, asparagine or Asn or N, proline or Pro or P, glutamine or Gln or Q, arginine or Arg or R, serine or Ser or S, threonine or Thr or T, valine or Val or V, tryptophan or Trp or W, and tyrosine or Tyr or Y.

[0291] In certain embodiments, the amino acid sequence of an antibody is modified to include a sulfatase motif containing a serine or cysteine ​​residue that can be converted (oxidized) to a 2-formylglycine (FGly) residue by the action of formylglycine-producing enzyme (FGE), either in vivo (e.g., during translation of an aldehyde tag-containing protein in cells) or in vitro (e.g., by contacting an aldehyde tag-containing protein with FGE in a cell-free system). Such a sulfatase motif may also be referred to herein as an FGE modification site.

[0292] Sulfatase motif The minimum sulfatase motif of an aldehyde tag is typically 5 or 6 amino acid residues long, and usually 6 or fewer amino acid residues long. The sulfatase motif provided in an Ig polypeptide is at least 5 or 6 amino acid residues, and can be 5-16, 6-16, 5-15, 6-15, 5-14, 6-14, 5-13, 6-13, 5-12, 6-12, 5-11, 6-11, 5-10, 6-10, 5-9, 6-9, 5-8, or 6-8 amino acid residues long, for example, to define a sulfatase motif with an amino acid residue length of 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, or less than 6 amino acid residues.

[0293] In certain embodiments, the polypeptide of interest includes one or more amino acid residues, for example, two or more, or three or more, or four or more, or five or more, or six or more, or seven or more, or eight or more, or nine or more, or ten or more, or eleven or eleven or twelve or thirteen or thirteen or fourteen or fifteen or fifteen or sixteen or seven or seventeen or seven or eight or nine or twenty or more amino acid residues, compared to the native amino acid sequence for providing a sequence of sulfatase motifs in the polypeptide. In certain embodiments, the polypeptide includes modifications (insertions, additions, deletions, and / or substitutions) of 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, or fewer than two amino acid residues in the amino acid sequence compared to the native amino acid sequence of the polypeptide. If the native amino acid sequence of a polypeptide (e.g., an antibody) contains one or more residues of a desired sulfatase motif, the total number of residue modifications can be reduced, for example, by site-specific modifications (insertion, addition, deletion, substitution / replacement) of amino acid residues adjacent to native amino acid residues that provide the sequence of the desired sulfatase motif. In certain embodiments, the degree of modification of the native amino acid sequence of the target antibody is minimized so as to minimize the number of amino acid residues inserted, deleted, substituted (replaced), and / or added (e.g., relative to the N-terminus or C-terminus). By minimizing the degree of modification of the amino acid sequence of the target antibody, the potential impact of such modifications on the antibody's function and / or structure can be minimized.

[0294] While aldehyde tags for specific purposes include at least one minimal sulfatase motif (also referred to as the “consensus sulfatase motif”), it should be noted that longer aldehyde tags are intended and included in this disclosure and may find applications in the compositions and methods of this disclosure. Accordingly, aldehyde tags may include a minimal sulfatase motif of five or six residues, or may be longer, and may include a minimal sulfatase motif that can be flanked at the N-terminal and / or C-terminal side of the motif by additional amino acid residues. For example, aldehyde tags of five or six amino acid residues, as well as longer amino acid sequences of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more amino acid residues, are intended.

[0295] The aldehyde tag may be located at or near the C-terminus of the Ig heavy chain. For example, the aldehyde tag may be located within the 1st, 2nd, 3rd, 4th, 5th, 6th, 7th, 8th, 9th, or 10th amino acids at the C-terminus of the natural wild-type Ig heavy chain. The aldehyde tag may be located within the CH1 domain of the Ig heavy chain. The aldehyde tag may be located within the CH2 domain of the Ig heavy chain. The aldehyde tag may be located within the CH3 domain of the Ig heavy chain. The aldehyde tag may be located within the constant region of the Ig light chain, for example, within the kappa light chain constant region or the lambda light chain constant region.

[0296] In certain embodiments, the sulfatase motif used may be described by the following formula: X 1 Z 10 X 2 Z 20 X 3 Z 30 (I') During the ceremony, Z 10 However, it is cysteine ​​or serine (which can also be represented by (C / S)), Z 20 However, it is either a proline or alanine residue (which can also be represented by (P / A)), Z 30However, basic amino acids (for example, arginine (R), lysine (K) or histidine (H), for example, lysine), or aliphatic amino acids (alanine (A), glycine (G), leucine (L), valine (V), isoleucine (I), or proline (P), for example, A, G, L, V, or I, X 1 However, whether present or absent, if present, any amino acid, e.g., aliphatic amino acid, sulfur-containing amino acid, or polar uncharged amino acid (i.e., other than aromatic amino acids or charged amino acids), e.g., L, M, V, S, or T, e.g., L, M, S, or V, provided that the sulfatase motif is at the N-terminus of the target polypeptide, X 1 There exists, X 2 and X 3 However, independently, any amino acid may be used, but usually it may be an aliphatic amino acid, a polar uncharged amino acid, or a sulfur-containing amino acid (i.e., an amino acid other than an aromatic amino acid or a charged amino acid), such as S, T, A, V, G, or C, for example, S, T, A, V, or G.

[0297] The amino acid sequence of the antibody heavy chain and / or light chain is given by formula X 1 Z 10 X 2 Z 20 X 3 Z 30 It may be modified to provide a sequence of at least 5 amino acids, in the formula, Z 10 However, it is cysteine ​​or serine, Z 20 However, it is a proline or alanine residue, Z 30 However, they are aliphatic amino acids or basic amino acids. X 1 However, it may or may not exist, and if it exists, it is any amino acid, provided that a heterologous sulfatase motif is at the N-terminus of the polypeptide, X 1 There exists, X 2 and X 3 However, each of them is an arbitrary amino acid, independently of the others.

[0298] The sulfatase motif is generally selected so as to be convertible by a selected FGE, for example, an FGE present in a host cell expressing an aldehyde-tagged polypeptide, or an FGE that is contacted with the aldehyde-tagged polypeptide in a cell-free in vitro method.

[0299] For example, if FGE is a eukaryotic FGE (e.g., mammalian FGE, including human FGE), the sulfatase motif is given by the following formula. X 1 CX 2 PX 3 Z 30 (I) It could also be a sulfatase motif. During the ceremony, X 1 However, it may or may not be present, and if present, it may be any amino acid, for example, an aliphatic amino acid, a sulfur-containing amino acid, or a polar uncharged amino acid (i.e., other than an aromatic amino acid or a charged amino acid), for example, L, M, S, or V, provided that the sulfatase motif is at the N-terminus of the target polypeptide, X 1 There exists, X 2 and X 3 However, independently, any amino acid, for example, an aliphatic amino acid, a sulfur-containing amino acid, or a polar uncharged amino acid (i.e., something other than an aromatic amino acid or a charged amino acid), for example, S, T, A, V, G, or C, for example, S, T, A, V, or G. Z 30 However, it may be a basic amino acid (for example, arginine (R), lysine (K) or histidine (H), for example, lysine), or an aliphatic amino acid (alanine (A), glycine (G), leucine (L), valine (V), isoleucine (I), or proline (P), for example, A, G, L, V, or I).

[0300] Specific examples of sulfatase motifs include LCTPSR(sequence code: / / ), MCTPSR(sequence code: / / ), VCTPSR(sequence code: / / ), LCSPSR(sequence code: / / ), LCAPSR(sequence code: / / ), LCVPSR(sequence code: / / ), LCGPSR(sequence code: / / ), ICTPAR(sequence code: / / ), LCTPSK(sequence code: / / ), MCTPSK(sequence code: / / ), VCTPSK(sequence code: / / ), LCSPSK(sequence code: / / ), LCAPSK(sequence code: / / ), LCVPSK(sequence code: / / ), LCGPSK(sequence code: / / ), LCTPSA(sequence code: / / ), ICTPAA(sequence code: / / ), MCTPSA(sequence code: / / ), VCTPSA(sequence code: / / ), LCSPSA(sequence code: / / ), LCAPSA(sequence code: / / ), LCVPSA(sequence code: / / ), and LCGPSA(sequence code: / / ).

[0301] FGly-containing sequence When FGE acts on the heavy and / or light chains of a modified antibody, serine or cysteine ​​in the sulfatase motif is modified to FGly. Therefore, the FGly-containing sulfatase motif is given by the following formula: X 1 (FGly)X 2 Z 20 X 3 Z 30 (I''') It could also be a sulfatase motif. During the ceremony, FGly is a formylglycine residue, Z 20 However, it is either a proline or alanine residue (which can also be represented by (P / A)), Z 30 However, basic amino acids (for example, arginine (R), lysine (K), or histidine (H), usually lysine is also acceptable), or aliphatic amino acids (alanine (A), glycine (G), leucine (L), valine (V), isoleucine (I), or proline (P), for example, A, G, L, V, or I, X 1However, it may or may not be present, and if present, any amino acid, for example, an aliphatic amino acid, a sulfur-containing amino acid, or a polar uncharged amino acid (i.e., other than an aromatic amino acid or a charged amino acid), for example, L, M, V, S, or T, for example, L, M, or V, provided that the sulfatase motif is at the N-terminus of the target polypeptide, X 1 There exists, X 2 and X 3 However, independently, any amino acid may be used, for example, an aliphatic amino acid, a sulfur-containing amino acid, or a polar uncharged amino acid (i.e., other than an aromatic amino acid or a charged amino acid), for example, S, T, A, V, G, or C, for example, S, T, A, V, or G.

[0302] As described above, a modified polypeptide containing an FGly residue can be conjugated to a drug (e.g., a mytansinoid) by reaction of FGly with a drug (e.g., a drug containing a hydrazinyl-indolyl or hydrazinyl-pyrrolo-pyridinyl coupling moiety, as described above) to generate an FGly'-containing sulfatase motif. As used herein, the term FGly' refers to the modified amino acid residue of the sulfatase motif coupled to a drug, e.g., mytansin or auristatin. Therefore, the FGly'-containing sulfatase motif is given by the following formula X 1 (FGly')X 2 Z 20 X 3 Z 30 (II) It could also be a sulfatase motif. During the ceremony, FGly' is the modified amino acid residue in formula (I), Z 20 However, it is either a proline or alanine residue (which can also be represented by (P / A)), Z 30However, basic amino acids (for example, arginine (R), lysine (K), or histidine (H), usually lysine is also acceptable), or aliphatic amino acids (alanine (A), glycine (G), leucine (L), valine (V), isoleucine (I), or proline (P), for example, A, G, L, V, or I, X 1 However, it may or may not be present, and if present, any amino acid, for example, an aliphatic amino acid, a sulfur-containing amino acid, or a polar uncharged amino acid (i.e., other than an aromatic amino acid or a charged amino acid), for example, L, M, V, S, or T, for example, L, M, or V, provided that the sulfatase motif is at the N-terminus of the target polypeptide, X 1 There exists, X 2 and X 3 However, independently, any amino acid may be used, for example, an aliphatic amino acid, a sulfur-containing amino acid, or a polar uncharged amino acid (i.e., other than an aromatic amino acid or a charged amino acid), for example, S, T, A, V, G, or C, for example, S, T, A, V, or G.

[0303] Modification site As shown above, the amino acid sequence of the antibody is modified to include a sulfatase motif containing a serine or cysteine ​​residue that can be converted (oxidized) to an FGly residue by the action of FGE, either in vivo (e.g., during translation of an aldehyde tag-containing protein in cells) or in vitro (e.g., by contacting an aldehyde tag-containing protein with FGE in a cell-free system). The antibody used to generate the conjugate of this disclosure includes at least an Ig constant region, e.g., an Ig heavy chain constant region (e.g., at least a CH1 domain; at least CH1 and CH2 domains; CH1, CH2, and CH3 domains; or CH1, CH2, CH3, and CH4 domains), or an Ig light chain constant region. Such an Ig polypeptide is referred to herein as a “targeted Ig polypeptide” or “tagged antibody”.

[0304] The site in the antibody to which the sulfatase motif is introduced can be any convenient site. As shown above, in some cases the degree of modification of the native amino acid sequence of the target polypeptide is kept to a minimum so as to minimize the number of amino acid residues inserted, deleted, substituted, and / or added (e.g., to the N-terminus or C-terminus). By minimizing the degree of modification of the amino acid sequence of the target antibody, the potential impact of such modifications on the antibody's function and / or structure can be minimized.

[0305] The antibody heavy chain constant region may include the Ig constant region of any heavy chain isotype, or an Ig heavy chain constant region that does not exist naturally (including the consensus Ig heavy chain constant region). The Ig constant region may be modified to include an aldehyde tag, which is located within or adjacent to the solvent-accessible loop region of the Ig constant region. The Ig constant region may be modified by insertions and / or substitutions of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 amino acids, or more than 16 amino acids, to provide the amino acid sequence of the sulfatase motif as described above.

[0306] In some cases, the aldehyde-tagged antibody comprises an aldehyde-tagged Ig heavy chain constant region (e.g., at least a CH1 domain; at least CH1 and CH2 domains; CH1, CH2, and CH3 domains; or CH1, CH2, CH3, and CH4 domains). The aldehyde-tagged Ig heavy chain constant region may comprise an IgA, IgM, IgD, IgE, IgG1, IgG2, IgG3, or IgG4 isotype heavy chain, or any allotype variant thereof, such as a human heavy chain constant region sequence or a mouse heavy chain constant region sequence, a hybrid heavy chain constant region, a synthetic heavy chain constant region, or a consensus heavy chain constant region sequence modified by FGE to include at least one sulfatase motif capable of producing an FGly-modified Ig polypeptide. Allotype variants of Ig heavy chains are known in the art. See, for example, Jefferis and Lefranc (2009) MAbs 1:4.

[0307] In some cases, an aldehyde-tagged antibody includes an aldehyde-tagged Ig light chain constant region. The aldehyde-tagged Ig light chain constant region may include a constant region sequence such as a kappa light chain, a lambda light chain, for example, a human kappa or lambda light chain constant region, a hybrid light chain constant region, a synthetic light chain constant region, or a consensus light chain constant region sequence modified by FGE to include at least one sulfatase motif capable of producing an FGly-modified antibody. An exemplary constant region includes the human gamma 1 and gamma 3 regions. Except for the sulfatase motif, the modified constant region may have a wild-type amino acid sequence, or may have an amino acid sequence that is at least 70% identical (e.g., at least 80%, at least 90%, or at least 95% identical) to the wild-type amino acid sequence.

[0308] In some embodiments, the sulfatase motif is located at a position other than the C-terminus of the Ig polypeptide heavy chain, or at a position added to the C-terminus of the Ig polypeptide heavy chain. As shown above, the isolated aldehyde-tagged antibody may contain a heavy chain constant region modified to include the sulfatase motif described above, where the sulfatase motif is located within or adjacent to a surface-accessible loop region of the antibody heavy chain constant region.

[0309] The sulfatase motif may be provided within or adjacent to one or more of these amino acid sequences at the modification site of the Ig heavy chain. For example, an Ig heavy chain polypeptide can be modified with one or more of these amino acid sequences (e.g., the modification involves the insertion, deletion, and / or substitution of one or more amino acid residues) and provide a sulfatase motif adjacent to these modification sites at the N-terminus and / or adjacent to the C-terminus. Alternatively, or in addition to the above, an Ig heavy chain polypeptide can be modified with one or more of these amino acid sequences (e.g., the modification involves the insertion, deletion, and / or substitution of one or more amino acid residues) and provide a sulfatase motif between any two residues of the Ig heavy chain modification site. In some embodiments, the Ig heavy chain polypeptide may be modified to include two motifs, which may be adjacent to each other, or separated by one, two, three, four, or more (e.g., about 1 to about 25, about 25 to about 50, or about 50 to about 100, or more amino acids). Alternatively, or in addition, if the native amino acid sequence provides one or more amino acid residues of a sulfatase motif sequence, selected amino acid residues of the modification site of the Ig heavy chain polypeptide amino acid sequence may be modified to provide a sulfatase motif at the modification site (e.g., if the modification involves the insertion, deletion, and / or substitution of one or more amino acid residues).

[0310] The antibodies used in the antibody-drug conjugates of this disclosure are not limited to, but include, for example, antigens present on cancer cells, antigens present on autoimmune cells, antigens present on pathogenic microorganisms, antigens present on virus-infected cells (e.g., human immunodeficiency virus-infected cells), and antigens present on disease cells, and may have any of the following antigen-binding specificities. For example, the antibody conjugate may bind to an antigen, and the antigen is present on the surface of a cell. The antibody conjugates of this disclosure have a suitable binding affinity, for example, 5 × 10⁻⁶ -6 M~10 -7 M, 10 -7 M~5×10 -7 M, 5×10 -7 M~10 -8 M, 10 -8 M~5×10 -8 M, 5×10 -8 M~10 -9 M, or 10 -9 It can bind to antigens with a binding affinity greater than M.

[0311] As a non-limiting example, the antibody conjugate of the subject may bind to an antigen present on cancer cells (e.g., tumor-specific antigen, antigen overexpressed on cancer cells, etc.), and the conjugated portion may be a drug, such as a cytotoxic compound (e.g., a small cytotoxic molecule, a synthetic cytotoxic peptide, etc.). For example, the antibody conjugate of the subject may be specific to an antigen on cancer cells, and the conjugated portion may be a drug, such as a cytotoxic compound (e.g., a small cytotoxic molecule, a synthetic cytotoxic peptide, etc.).

[0312] As a further non-limiting example, the antibody conjugate of the subject may bind to an antigen present on a virus-infected cell (for example, if the antigen is encoded by a virus, or if the antigen is expressed on a cell type that is infected by the virus), and the conjugated portion may be a drug, such as a viral fusion inhibitor.

[0313] Drugs for conjugation into polypeptides This disclosure provides drug-polypeptide conjugates (e.g., antibody-drug conjugates). Any of several drugs are suitable for use as a reactive partner for conjugation with an antibody, or can be modified to be suitable for use. Examples of drugs include small molecule drugs and peptide drugs.

[0314] As used herein, "small molecule drug" refers to a compound, such as an organic compound, that exhibits the desired pharmaceutically active substance and generally has a molecular weight of 800 Da or less, or 2000 Da or less, but may include molecules up to 5 kDa, or be approximately 10 kDa in size. Small inorganic molecules refer to molecules that do not contain carbon atoms, and small organic molecules refer to compounds that contain at least one carbon atom.

[0315] For example, the drug or active agent may be mytansine. "Mytansine," "mytansine moiety," "mytansine active agent moiety," and "mytansinoid" refer to mytansine, its analogues and derivatives, and the pharmaceutically active mytansine moiety and / or its portion. Mytansine conjugated to a polypeptide may be, for example, any of the various mytansinoid moieties described herein, including, but not limited to, mytansine and its analogues and derivatives (e.g., deacylmitansine). In other cases, the drug or active agent may be auristatin, or its analogues or derivatives, or the pharmaceutically active auristatin moiety and / or its portion. Auristatin conjugated to a polypeptide may be, for example, any of the various auristatin moieties described herein, including, but not limited to, auristatin and its analogues and derivatives. In other cases, the drug or active agent may be duocalmycin, or its analogues or derivatives, or the pharmaceutically active duocalmycin moiety and / or its portion. The duocalmycin conjugated to the polypeptide may be any of the various duocalmycin moieties described herein, including, but not limited to, duocalmycin and its analogs and derivatives.

[0316] In certain embodiments, the drug is selected from cytotoxins, kinase inhibitors, immunostimulants, Toll-like receptor (TLR) agonists, oligonucleotides, aptamers, cytokines, steroids, and peptides.

[0317] For example, cytotoxins may include any compound that causes cell death (e.g., necrosis or apoptosis) or a decrease in cell viability.

[0318] Examples of kinase inhibitors, though not limited to them, include adavocertib, afatinib, axitinib, bosutinib, cetuximab, cobimetinib, crizotinib, cabozantinib, dacomitinib, dasatinib, entrectinib, erdafitinib, erlotinib, fostamatinib, gefitinib, ibrutinib, imatinib, lapatinib, lenvatinib, mbritinib, nilotinib, pazopanib, pegaptanib, ruxolitinib, sorafenib, sunitinib, tucatinib, vandetanib, and vemurafenib.

[0319] Examples of immunostimulants, though not limited to them, include vaccines (e.g., bacterial or viral vaccines), colony-stimulating factors, interferons, and interleukins. Examples of TLR agonists, though not limited to them, include imiquimod and reximod.

[0320] Examples of oligonucleotide mammary glands include, but are not limited to, homivirsen, pegaptanib, mipomersen, eteplirsen, defibrotide, nusinersen, golodyrsen, viltolarsen, boranesolsen, inotercene, tofersen, and tominersen.

[0321] Examples of aptamer drugs, though not limited to them, include pegaptanib, AS1411, REG1, ARC1779, NU172, ARC1905, E10030, NOX-A12, and NOX-E36.

[0322] Cytokines include, but are not limited to, Albuinterferon alpha-2B, Aldesleukin, ALT-801, Anakinra, Ancestim, Avotermin, Valgrastim, Benpegaldesleukin, Vinetraquin, Cintredekin Besudotox, CTCE-0214, Darbepoetin alpha, Denileukin difutitox, Duranermin, Eddekin alpha, Enfilermin, Epoetin delta, Erythropoietin, Human interleukin-2, Interferon alpha, Interferon alpha-2c, Interferon alpha-n1, Interferon alpha-n3, Interferon alpha-con-1, Interferon beta-1a, Interferon beta-1b, Interferon gamma-1b, Interferon kappa, Interleukin-1 alpha, Interleukin-10, Interleukin-7, and Examples include nograstim, religistim, ripegfilgrastim, Lorukafusp alpha, Maxy-G34, methoxypolyethylene glycol-epoetin beta, moglamostim, muprestim, nagrestipen, oprelbequin, pegfilgrastim, pegrodecakine, peginterferon alpha-2a, peginterferon alpha-2b, peginterferon beta-1a, peginterferon lambda-1a, recombinant CD40-ligand, reglamostim, romiplostim, salglamostim, thrombopoietin, tucotuzumab celmoleukin, and viral macrophage-inflammatory proteins.

[0323] Examples of steroid drugs, though not limited to them, include prednisolone, betamethasone, dexamethasone, hydrocortisone, methylprednisolone, and deflazacort.

[0324] As used herein, “peptide drugs” refer to amino acid-containing polymer compounds and are intended to encompass naturally occurring and non-naturally occurring peptides, oligopeptides, cyclic peptides, polypeptides, and proteins, as well as peptide mimes. Peptide drugs may be obtained by chemical synthesis or produced from genetically encoded sources (e.g., recombinant sources). Peptide drugs may have a variety of molecular weights, ranging from 200 Da to 10 kDa or greater. Suitable peptides include, but are not limited to, cytotoxic peptides, angiogenic peptides, anti-angiogenic peptides, B cell-activating peptides, T cell-activating peptides, antiviral peptides, peptides that inhibit viral fusion, peptides that increase the production of one or more lymphocyte populations, antimicrobial peptides, growth factors, growth hormone-releasing factors, vasoactive peptides, anti-inflammatory peptides, peptides that regulate glucose metabolism, antithrombotic peptides, anti-nociceptive peptides, vasodilator peptides, platelet aggregation inhibitors, and analgesics.

[0325] Examples of drugs for which uses can be found in the conjugates and compounds described herein include, but are not limited to, tubulisin M, calicheamicin, SN-38, exatecan, STAT3 inhibitors, alpha-amanitin, aurora kinase inhibitors, berotecan, 9-aminocamptothecin (9-AC), and anthracyclines.

[0326] Other examples of drugs include small molecule drugs such as cancer chemotherapeutic agents. For example, if the polypeptide is an antibody (or fragment thereof) having specificity for tumor cells, the antibody may be modified to include modified amino acids as described herein and then conjugated to a cancer chemotherapeutic agent. Cancer chemotherapeutic agents include non-peptidic (i.e., non-proteinic) compounds that reduce the proliferation of cancer cells and encompass cytotoxic agents and cell proliferation inhibitors. Non-limiting examples of chemotherapeutic agents include alkylating agents, nitrosoureas, antimetabolites, antitumor antibiotics, plant (vinca) alkaloids, and steroid hormones. Peptidic compounds are also available.

[0327] Suitable cancer chemotherapeutic agents include drastatin and its active analogues and derivatives, and auristatin and its active analogues and derivatives (e.g., monomethyl auristatin D (MMAD), monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), etc.). See, for example, WO96 / 33212, WO96 / 14856, and US6,323,315. For example, drastatin 10 or auristatin PE may be included in the antibody-drug conjugate of this disclosure. Suitable cancer chemotherapeutic agents also include mytansinoids and their active analogues and derivatives (see, for example, EP1391213 and Liu et al (1996) Proc. Natl. Acad. Sci. USA 93:8618-8623), duocalmycin and its active analogues and derivatives (including, for example, synthetic analogues KW-2189 and CB1-TM1), and benzodiazepines and their active analogues and derivatives (for example, pyrrolobenzodiazepine (PBD)).

[0328] Drugs that act to reduce cell proliferation are known and widely used in the art. Such drugs include, but are not limited to, alkylating agents such as nitrogen mustard, nitrosourea, ethyleneimine derivatives, alkyl sulfonates, and triazenes, as well as mechloretamine, cyclophosphamide (Cytoxan®), melphalan (L-sarcolicin), carmustine (BCNU), lomustine (CCNU), semustine (methyl-CCNU), streptozotocin, chlorozotocin, uracil mustard, chlormethine, ifosfamide, chlorambucil, pipobromane, triethylenemelamine, triethylenethiophosphoramine, busulfan, dacarbazine, and temozolomide.

[0329] Examples of antimetabolites include, but are not limited to, folate analogs, pyrimidine analogs, purine analogs, and adenosine deaminase inhibitors, including cytarabine (CYTOSAR-U), cytosine arabinoside, fluorouracil (5-FU), floxuridine (FudR), 6-thioguanine, 6-mercaptopurine (6-MP), pentostatin, 5-fluorouracil (5-FU), methotrexate, 10-propargyl-5,8-dideazafolate (PDDF, CB3717), 5,8-dideazatetrahydrofolate (DDATHF), leucovorin, fludarabine phosphate, pentostatin, and gemcitabine.

[0330] Suitable natural products and their derivatives (e.g., vinca alkaloids, antitumor antibiotics, enzymes, lymphokines, and epipodophyllotoxins) include, but are not limited to, Ara-C, paclitaxel (Taxol®), docetaxel (Taxotere®), deoxycoformycin, mitomycin-C, L-asparaginase, azathioprine; brequinal; alkaloids, e.g., vincristine, vinblastine, vinorelbine, vindesine, etc.; podophyllotoxins, e.g., etoposide, teniposide, etc.; antibiotics, e.g., anthracyclines, da Examples include unorubicin hydrochloride (daunomycin, rubidomycin, serubicin), idarubicin, doxorubicin, epirubicin, and morpholino derivatives; phenoxyzombine cyclopeptides, e.g., dactinomycin; basic glycopeptides, e.g., bleomycin; anthraquinone glycosides, e.g., plicamycin (mitramycin); anthracendiones, e.g., mitoxantrone; azilinopyrroindoldiones, e.g., mitomycin; macrocyclic immunosuppressants, e.g., cyclosporine, FK-506 (tacrolimus, Prograf), rapamycin, etc.

[0331] Other antiproliferative cytotoxic agents include navelbine, CPT-11, anastrozole, letrozole, capecitabine, reloxafine, cyclophosphamide, ifosfamide, and droloxafine.

[0332] Microtubule agonists with antiproliferative activity are also suitable for use, but are not limited to: allocolchicine (NSC 406042), halichondrin B (NSC 609395), colchicine (NSC 757), colchicine derivatives (e.g., NSC 33410), dolstatin 10 (NSC 376128), mytansine (NSC 153858), rhizoxin (NSC 332598), paclitaxel (Taxol®), Taxol® derivatives, docetaxel (Taxotere®), thiocolchicine (NSC Examples include (361792) tritylcysteine, vinblastine sulfate, vincristine sulfate, natural and synthetic epothyrons including epothyron A, epothyron B, and discodermolide; estramustine, nocodazole, etc.

[0333] Suitable hormone regulators and steroids (including synthetic analogs) for use include, but are not limited to, corticosteroids such as prednisone and dexamethasone; estrogens and pregestins such as hydroxyprogesterone caproate, medroxyprogesterone acetate, megestrol acetate, estradiol, clomiphene, and tamoxifen; corticosteroids such as aminoglutethimide; 17α-ethinylestradiol; diethylstilbestrol, testosterone, fluoxymesterone, and dromostanolone propionate. Examples include (propionate), testolactone, methylprednisolone, methyl-testosterone, prednisone, triamcinolone, chlorotrianicene, hydroxyprogesterone, aminoglutethimide, estramustine, medroxyprogesterone acetate, leuprolide, flutamide (Drogenil), toremifene (Fairston), and Zoladex®. Estrogen stimulates proliferation and differentiation, and therefore, compounds that bind to estrogen receptors are used to block this activity. Corticosteroids can inhibit T cell proliferation.

[0334] Other suitable chemotherapeutic agents include metal complexes, e.g., cisplatin (cis-DDP), carboplatin, etc.; urea, e.g., hydroxyurea; and hydrazine, e.g., N-methylhydrazine; epidophyllotoxin; topoisomerase inhibitors; procarbazine; mitoxantrone; leucovorin; tegafur, etc. Other antiproliferative agents of interest include immunosuppressants, e.g., mycophenolic acid, thalidomide, desoxyspergualin, azasporine, leflunomide, mizoribine, azaspiran (SKF 105685); Iressa® (ZD 1839, 4-(3-chloro-4-fluorophenylamino)-7-methoxy-6-(3-(4-morpholinyl)propoxy)quinazoline), etc.

[0335] Taxanes are suitable for use. "Taxane" includes paclitaxel and any active taxane derivatives or prodrugs. "Paclitaxel" (which should be understood herein to include analogs, formulations, and derivatives such as docetaxel, TAXOL®, TAXOTERE® (a formulation of docetaxel), 10-desacetyl analogs of paclitaxel, and 3'N-desbenzoyl-3'Nt-butoxycarbonyl analogs of paclitaxel) is used by utilizing the technology known to those skilled in the art. It can be readily prepared (see also WO94 / 07882, WO94 / 07881, WO94 / 07880, WO94 / 07876, WO93 / 23555, WO93 / 10076, U.S. Patents 5,294,637, 5,283,253, 5,279,949, 5,274,137, 5,202,448, 5,200,534, 5,229,529, and EP 590,267), or can be obtained from various commercial sources, including, for example, Sigma Chemical Co., St. Louis, Mo. (T7402 from Taxus brevifolia, or T-1912 from Taxus yannanensis).

[0336] It should be understood that paclitaxel refers not only to the common chemically available forms of paclitaxel, but also to its analogues and derivatives (e.g., Taxotere® docetaxel as shown above), and paclitaxel conjugates (e.g., paclitaxel-PEG, paclitaxel-dextran, or paclitaxel-xylose).

[0337] The term "taxane" also includes a variety of known derivatives, including both hydrophilic and hydrophobic derivatives. Taxane derivatives include, but are not limited to, galactose and mannose derivatives described in International Patent Application WO99 / 18113, piperazino and other derivatives described in WO99 / 14209, taxane derivatives described in WO99 / 09021, WO98 / 22451, and U.S. Patent No. 5,869,680, 6-thio derivatives described in WO98 / 28288, sulfenamide derivatives described in U.S. Patent No. 5,821,263, and taxol derivatives described in U.S. Patent No. 5,415,869. Furthermore, but are not limited to, prodrugs of paclitaxel, including those described in WO98 / 58927, WO98 / 13059, and U.S. Patent No. 5,824,701.

[0338] Suitable biological modifiers for use include, but are not limited to, (1) inhibitors of tyrosine kinase (RTK) activity, (2) inhibitors of serine / threonine kinase activity, (3) tumor-associated antigen antagonists such as antibodies that specifically bind to tumor antigens, (4) apoptosis receptor agonists, (5) interleukin-2, (6) IFN-α, (7) IFN-γ, (8) colony-stimulating factors, and (9) inhibitors of angiogenesis.

[0339] Examples of drugs include small molecule drugs such as cancer chemotherapy agents. For example, if the polypeptide is an antibody (or a fragment thereof) having specificity for tumor cells, the antibody may be modified to include modified amino acids as described herein and then conjugated to cancer chemotherapy agents such as microtubule agonists. In certain embodiments, the drug is a microtubule agonist having antiproliferative activity, such as a mytansinoid.

[0340] In certain embodiments, the drug is a mytansinoid having the following structure: [ka] During the ceremony, [ka] However, in the conjugates and compounds described herein, the mytansinoid and the second linker L 2 This indicates the connection point between [the two points]. "Connection point" refers to the symbol [the symbol]. [ka] However, in the conjugates and compounds described herein, the N of the mytansinoid and the second linker L 2 This means that it shows a bond between and . For example, in equation (I), W 1 This may be a mytansinoid, for example, a mytansinoid with the structure shown above. [ka] This is the mytansinoid and the second linker L 2 This shows the connection point between them. In some cases, the mytansinoid of the above structure may be called deacylmitansin.

[0341] In certain embodiments, the drug is an antimitotic agent, such as auristatin, or an active auristatin analog or derivative thereof (e.g., monomethyl auristatin D (MMAD), monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), etc.). In certain embodiments, the drug is MMAE and has the following structure. [ka]

[0342] For example, MMAE-active agents may be included in antibody-drug conjugates such as the following: [ka] During the ceremony, [ka] However, in the conjugates and compounds described herein, auristatin and a second linker L 2 It indicates the connection point between [the two points]. For example, the symbol [...] [ka] For example, as shown in equation (I), the N of auristatin and the second linker L 2 This shows the bond between and . For example, in equation (I), W 1 This may be auristatin, for example MMAE, in the formula, in the above structure [ka] However, MMAE and the second linker L 2 This indicates the connection point between [the two points].

[0343] In certain embodiments, the drug is a DNA alkylating agent, such as duocalmycin. Examples of duocalmycin include, but are not limited to, duocalmycin A, duocalmycin B1, duocalmycin B2, duocalmycin C1, duocalmycin C2, duocalmycin D, duocalmycin SA, and CC-1065. In some embodiments, duocalmycin is a duocalmycin analog, such as, but are not limited to, adzeresin, bizeresin, or karzeresin.

[0344] In some cases, duocalmycin is a compound having the following structure. [ka]

[0345] For example, duocalmycin active agents are antibody-drug conjugates such as the following. [ka] It may be included in, During the ceremony, [ka] However, in the conjugates and compounds described herein, duocalmycin and a second linker L 2 It indicates the connection point between [the two points]. For example, the symbol [...] [ka] For example, as shown in formula (I), duocalmycin and a second linker L 2 This shows the bond between and . For example, in equation (I), W 1 This may be duocalmycin, for example, the duocalmycin shown above. [ka] This is duocalmycin and the second linker L 2 This indicates the connection point between [the two points].

[0346] As described above, in a particular embodiment, L 2 is, equation -(L 21 ) e -(L 22 ) f -(L 23 ) g -(L 24 ) h - is the second linker described by, in formula L 21 , L 22 , L 23 and L 24 Each of these is independently a second linker subunit. In a particular embodiment, L 21 It is connected to the first detachable portion. In a particular embodiment, L 21 If it exists, W 1 It is also connected to (drugs). In certain embodiments, L 22 If it exists, W 1 It is connected to (the drug). In certain embodiments, L 23 If it exists, W 1 It is connected to (the drug). In certain embodiments, L 24 If it exists, W 1 It is connected to (drugs).

[0347] As described above, in certain embodiments, the second linker-(L 21 ) e -(L 22 ) f -(L 23 ) g -(L 24 ) h - is the formula -(T 5 -V 5 ) e -(T 6 -V 6 ) f -(T 7 -V 7 ) g -(T 8 -V 8 ) h-Described by the formula, where e, f, g, and h are each independently 0 or 1, and the sum of e, f, g, and h is 0 to 4. In certain embodiments, as described above, L 21 It is connected to the first detachable portion. Therefore, in a particular embodiment, T 5 It is connected to the first detachable portion. In a particular embodiment, V 5 is, W 1 It is connected to (the drug). In certain embodiments, as described above, L 22 If it exists, W 1 It is connected to (the drug). Therefore, in certain embodiments, T 6 If it exists, W 1 (Drugs) are connected, or V 6 If it exists, W 1 It is connected to (the drug). In certain embodiments, as described above, L 23 If it exists, W 1 It is connected to (the drug). Therefore, in certain embodiments, T 7 If it exists, W 1 (Drugs) are connected, or V 7 If it exists, W 1 It is connected to (the drug). In certain embodiments, as described above, L 24 If it exists, W 1 It is connected to (the drug). Therefore, in certain embodiments, T 8 If it exists, W 1 (Drugs) are connected, or V 8 If it exists, W 1 It is connected to (drugs).

[0348] Embodiments of the present disclosure include a conjugate in which an antibody is conjugated to one or more drug moieties, for example, two, three, four, five, six, seven, eight, nine, or ten drug moieties. The drug moieties may be conjugated to the antibody at one or more sites in the antibody as described herein. In certain embodiments, the conjugate has an average drug-to-antibody ratio (DAR) (molar ratio) in the range of 0.1 to 10, or 0.5 to 10, or 1 to 10, for example, 1 to 9, or 1 to 8, or 1 to 7, or 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3, or 1 to 2. In certain embodiments, the conjugate has an average DAR of 1 to 2, for example, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, or 2. In certain embodiments, the conjugate has an average DAR of 1 to 1.5. In certain embodiments, the conjugate has an average DAR of 1.5 to 2. "Average" means the arithmetic mean.

[0349] Drugs conjugated to polypeptides can be modified to incorporate a reactive partner for reaction with the polypeptide. If the drug is a peptide drug, the reactive moiety (e.g., aminooxy or hydrazine) can be located in the N-terminal region, C-terminal region, C-terminal region, or internally relative to the peptide. For example, one method involves synthesizing a peptide drug having an aminooxy group. In this example, the peptide is synthesized from a Boc-protected precursor. The amino group of the peptide can be reacted with a compound containing a carboxylic acid group and an oxy-N-Boc group. As an example, the amino group of the peptide reacts with 3-(2,5-dioxopyrrolidine-1-yloxy)propanoic acid. Other modifications to compounds containing a carboxylic acid group and an oxy-N-protecting group may include a different number of carbon atoms in the alkylene linker and substitutions on the alkylene linker. The reaction between the amino group of the peptide and the compound containing the carboxylic acid group and the oxy-N-protecting group occurs via standard peptide coupling chemistry.Examples of peptide coupling agents that may be used include, but are not limited to, DCC (dicyclohexylcarbodiimide), DIC (diisopropylcarbodiimide), di-p-toluoylcarbodiimide, BDP (1-benzotriazolediethylphosphate-1-cyclohexyl-3-(2-morpholinylethyl)carbodiimide), EDC (1-(3-dimethylaminopropyl-3-ethyl-carbodiimide hydrochloride), cyanuryl fluoride, cyanuryl chloride, and TFFH (tetramethylphosphate). O-benzotriazole-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate, DPPA (diphenyl phosphorazidate), BOP (benzotriazole-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate), HBTU (O-benzotriazole-1-yl-N,N,N',N'-tetramethyluronium hexafluorophosphate), TBTU (O-benzotriazole-1-yl-N,N,N',N'-tetramethyluronium tetrafluoroborate) ), TSTU (O-(N-succinimidyl)-N,N,N',N'-tetramethyluronium tetrafluoroborate), HATU (N-[(dimethylamino)-1-H-1,2,3-triazolo[4,5,6]-pyridine-1-ylmethylene]-N-methylmethaneaminium hexafluorophosphate N-oxide), BOP-Cl (bis(2-oxo-3-oxazolidinyl)phosphinic chloride), PyBOP ((1-H-1,2,3-benzotriazole-1-ylmethylene) Examples include (bromotris(dimethylamino)phosphonium tetrafluorophosphate), BrOP (bromotris(dimethylamino)phosphonium hexafluorophosphate), and DEPBT (3-(diethoxyphospholyloxy)-1,2,3-benzotriazine-4(3H)-one)PyBrOP (bromotris(pyrrolidino)phosphonium hexafluorophosphate). In non-limiting examples, HOBt and DIC can be used as peptide coupling reagents.

[0350] Deprotection to expose aminooxy functionalities is performed on peptides containing N-protecting groups. Deprotection of N-oxysuccinimide groups occurs, for example, according to standard deprotection conditions for cyclic amide groups. Deprotection conditions can be found in Greene and Wuts, Protective Groups in Organic Chemistry, 3rd Ed., 1999, John Wiley & Sons, NY and Harrison et al. Specific deprotection conditions include hydrazine reagents, amino reagents, or sodium borohydride. Deprotection of Boc protecting groups can be performed using TFA. Other reagents for deprotection include, but are not limited to, hydrazine, methylhydrazine, phenylhydrazine, sodium borohydride, and methylamine. Products and intermediates can be purified by conventional means such as HPLC purification.

[0351] Those skilled in the art will understand that factors such as pH and steric hindrance (i.e., the accessibility of amino acid residues to the reaction with the desired reactive partner) are important. Modifying reaction conditions to provide optimal conjugate conditions is well within the scope of the art and is customary in the art. When conjugate is carried out with polypeptides present in or on living cells, the conditions are selected to be physiologically suitable. For example, pH may be temporarily reduced for a period sufficient for the reaction to occur but within a period tolerable by the cells (e.g., about 30 minutes to 1 hour). Physiological conditions for modifying polypeptides on the cell surface may be similar to those used in ketone-azide reactions in the modification of cells possessing cell surface azides (see, e.g., US6,570,040).

[0352] Small molecule compounds containing or modified to contain an α-nucleophilic group that serve as a reactive partner with the compounds or conjugates disclosed herein are also intended for use as drugs in the polypeptide-drug conjugates of this disclosure. General methods, chemical synthesis schemes, and conditions useful for synthesizing the compounds of interest are known in the art (see, for example, Smith and March, March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, Fifth Edition, Wiley-Interscience, 2001, or Vogel, A Textbook of Practical Organic Chemistry, Including Qualitative Organic Analysis, Fourth Edition, New York: Longman, 1978).

[0353] formulation The conjugates of this disclosure may be formulated in a variety of different ways. Generally, if the conjugate is an antibody-drug conjugate, the conjugate is formulated in a way that is appropriate to the drug, antibody, the condition being treated, and the route of administration used.

[0354] In some embodiments, a pharmaceutical composition is provided comprising one of the conjugates of the present disclosure and a pharmaceutically acceptable excipient.

[0355] The conjugate (e.g., antibody-drug conjugate) may be provided in any preferred form, for example, in the form of a pharmaceutically acceptable salt, and may be formulated for any preferred route of administration, e.g., oral, topical, or parenteral administration. Where the conjugate is provided as an injectable liquid (such as in their embodiments where they are administered intravenously or directly to tissue), the conjugate may be provided as a ready-to-use dosage form, or as a reconstituted, storage-stable powder or liquid composed of a pharmaceutically acceptable carrier and excipients.

[0356] Methods for formulating the conjugate can be adapted from those readily available. For example, the conjugate may be provided as a pharmaceutical composition comprising a therapeutically effective amount of the conjugate and a pharmacologically acceptable carrier (e.g., physiological saline). The pharmaceutical composition may optionally contain other additives (e.g., buffers, stabilizers, preservatives, etc.). In some embodiments, the formulation is suitable for administration to mammals, for example, to humans.

[0357] Treatment method The antibody-drug conjugates of this disclosure find applications in the treatment of conditions or diseases in subjects suitable for treatment by administration of the parent drug (i.e., the drug before conjugation to the antibody).

[0358] In some embodiments, methods are provided that include administering an effective amount (e.g., a therapeutically effective amount) of any of the conjugates of this disclosure to a target.

[0359] In certain embodiments, a method is provided for delivering a drug to a target site in a subject, wherein the method comprises administering a pharmaceutical composition comprising one of the conjugates of the Disclosure to the subject, and the administration is effective in releasing a therapeutically effective amount of the drug from the conjugate to a target site in the subject. For example, as described herein, the antibody-drug conjugate of the Disclosure may comprise an enzymatically cleavable linker, e.g., an enzymatically cleavable linker comprising a first enzymatically cleavable portion and a second enzymatically cleavable portion. In some cases, the cleavable linker may be cleaved under appropriate conditions to separate or release the drug from the antibody at a desired target site of action for the drug. For example, a second cleavable linker protecting the first cleavable linker from cleavage may be cleaved to enable cleavage of the first cleavable portion, thereby cleaving the cleavable linker into two or more portions, and thus releasing the drug from the antibody-drug conjugate at a desired site of action.

[0360] In certain embodiments, the first cleavable portion may be an enzymatically cleavable portion. In some cases, the enzyme that facilitates the cleavage of the first cleavable portion is an enzyme administered to the subject being treated (i.e., an exogenous enzyme to the subject being treated). For example, the first enzyme may be administered before, concurrently with, or after the administration of the antibody-drug conjugate described herein.

[0361] In certain embodiments, the second cleavable portion may be an enzymatically cleavable portion. In some cases, the enzyme that facilitates the cleavage of the second cleavable portion is an enzyme administered to the subject being treated (i.e., an exogenous enzyme to the subject being treated). For example, the second enzyme may be administered before, concurrently with, or after the administration of the antibody-drug conjugate described herein. In certain embodiments, the first enzyme and the second enzyme are different enzymes.

[0362] In other cases, the first enzyme that facilitates the cleavage of the first cleavable portion is an enzyme present in the target being treated (i.e., endogenous to the target being treated). For example, the first enzyme may be present at the desired site of action for the drug in an antibody-drug conjugate. The antibody in the antibody-drug conjugate may be specifically targeted to the desired site of action (e.g., specifically bound to an antigen present at the desired site of action), and the desired site of action also includes the presence of the first enzyme. In some cases, the first enzyme is present in excess at the desired site of action compared to other areas of the body of the target being treated. For example, the first enzyme may be overexpressed at the desired site of action compared to other areas of the body of the target being treated. In some cases, the first enzyme is present in excess at the desired site of action due to the localization of the first enzyme in a particular region or location. For example, the first enzyme may be associated with a particular structure within the desired site of action, such as a lysosome. In some cases, the first enzyme is present in excess in lysosomes compared to other areas of the body of the target. In some embodiments, the lysosome containing the first enzyme is located at the desired site of action for the drug in the antibody-drug conjugate, for example, at the site of cancer or tumor to be treated with the drug. In certain embodiments, the first enzyme is a protease such as a human protease enzyme (e.g., cathepsin B).

[0363] In certain embodiments, the second enzyme that facilitates the cleavage of the second cleavable portion is an enzyme present in the target being treated (i.e., endogenous to the target being treated). For example, the second enzyme may be present at the desired site of action for the drug in an antibody-drug conjugate. The antibody in the antibody-drug conjugate may be specifically targeted to the desired site of action (e.g., specifically bound to an antigen present at the desired site of action), and the desired site of action also includes the presence of the second enzyme. In some cases, the second enzyme is present in excess at the desired site of action compared to other areas of the body of the target being treated. For example, the second enzyme may be overexpressed at the desired site of action compared to other areas of the body of the target being treated. In some cases, the second enzyme is present in excess at the desired site of action due to localization of the second enzyme in a particular region or location. For example, the second enzyme may be associated with a particular structure within the desired site of action, such as a lysosome. In some cases, the second enzyme is present in excess in lysosomes compared to other areas of the body of the target. In some embodiments, lysosomes containing the second enzyme are located at the desired site of action for the drug in the antibody-drug conjugate, for example, at the site of cancer or tumor to be treated with the drug. In certain embodiments, the second enzyme is a glycosidase, such as galactosidase, glucosidase, mannosidase, or fucosidase.

[0364] Any suitable enzyme can be used to cleave the first and second cleavable portions of the antibody-drug conjugate described herein. Other enzymes, for example, but not limited to, those derived from other vertebrates (e.g., primates, mice, rats, cats, pigs, quail, goats, dogs, etc.), may also be suitable for cleaving the first and second cleavable portions of the antibody-drug conjugate described herein.

[0365] In certain embodiments, the antibody-drug conjugate is substantially stable under standard conditions. Substantially stable means that the cleavable linker of the antibody-drug conjugate does not undergo significant cleavage in the absence of the first and second enzymes described above. For example, as described above, the second cleavable portion can be protected from cleavage of the first cleavable portion, and therefore the cleavable linker of the antibody-drug conjugate does not undergo significant cleavage in the absence of the second enzyme described above. For example, the cleavable linker of the antibody-drug conjugate may be substantially stable such that 25% or less of the antibody-drug conjugate, e.g., 20%, or 15%, or 10%, or 5%, or 4%, or 3%, or 2%, or 1%, is cleaved in the absence of the first and / or second enzymes. In some cases, an antibody-drug conjugate is substantially stable such that its cleavable linker does not undergo significant cleavage in the absence of a first enzyme and / or a second enzyme, but can be cleaved in the presence of both the first and second enzymes. For example, an antibody-drug conjugate may be substantially stable after administration to a subject. In some cases, an antibody-drug conjugate is substantially stable after administration to a subject, and then, when the antibody-drug conjugate is in the presence of a second enzyme at a desired site of action, a second cleavable portion is cleaved from the cleavable linker, thus exposing the first cleavable portion to subsequent cleavage by the first enzyme, and subsequently releasing the drug at its desired site of action. In certain embodiments, after administration to a subject, the antibody-drug conjugate remains stable for a long period of time, for example, 1 hour or more, or 2 hours or more, or 3 hours or more, or 4 hours or more, or 5 hours or more, or 6 hours or more, or 7 hours or more, or 8 hours or more, or 9 hours or more, or 10 hours or more, or 15 hours or more, or 20 hours or more, or 24 hours (1 day) or more, or 2 days or more, or 3 days or more, or 4 days or more, or 5 days or more, or 6 days or more, or 7 days (1 week) or more, in the absence of the first enzyme and / or the second enzyme.In certain embodiments, the antibody-drug conjugate is stable for a long period of time in a certain pH range, for example, 2-10, 3-9, 4-8, 5-8, 6-8, or 7-8, in the absence of the first and / or second enzymes.

[0366] As stated above, the antibody-drug conjugates of this disclosure find use in the treatment of a condition or disease in subjects suitable for treatment by administration of the parent drug. "Treatment" means that at least a reduction of the symptoms associated with the condition the host is suffering from is achieved, and reduction is used broadly to mean at least a decrease in the magnitude of a parameter (e.g., symptoms) associated with the condition being treated. Thus, treatment also includes a situation in which a pathological condition, or at least symptoms associated therewith, is completely inhibited, for example, prevented from occurring, or stopped, for example, terminated, and as a result the host no longer suffers from that condition, or at least symptoms characterizing that condition. Thus, treatment includes (i) prevention, i.e., reducing the risk of developing clinical symptoms, including preventing the development of clinical symptoms, for example, preventing disease progression to an adverse condition; (ii) inhibition, i.e., cessation of the development or further development of clinical symptoms, for example, reducing or completely inhibiting active disease; and / or (iii) mitigation, i.e., reversing clinical symptoms.

[0367] The subjects to be treated may be subjects in need of therapy, and the subjects to be treated may be subjects suitable for treatment with the parent drug. Thus, a variety of subjects may be suitable for treatment with the antibody-drug conjugates disclosed herein. In general, such subjects are “mammals,” and humans are the subjects of interest. Other subjects may include domestic pets (e.g., dogs and cats), livestock (e.g., cattle, pigs, goats, horses, etc.), rodents (e.g., mice, guinea pigs, and rats, e.g., animal models of diseases, etc.), and non-human primates (e.g., chimpanzees and monkeys).

[0368] The amount of antibody-drug conjugate administered may be initially determined based on the dose of the parent drug and / or the dosage regimen. Generally, antibody-drug conjugates can provide targeted delivery of the conjugated drug and / or an enhanced serum half-life, and therefore provide at least one of a dose reduction or a dosage reduction in the dosage regimen. Thus, antibody-drug conjugates can provide a dose reduction and / or dosage reduction in the dosage regimen relative to the parent drug before being conjugated to the antibody-drug conjugate of this disclosure.

[0369] Furthermore, as shown above, antibody-drug conjugates can provide a controlled stoichiometry of drug delivery, so the dosage of an antibody-drug conjugate can be calculated based on the number of drug molecules delivered per antibody-drug conjugate.

[0370] In some embodiments, multiple doses of the antibody-drug conjugate are administered. The frequency of administration of the antibody-drug conjugate may vary depending on various factors, such as the severity of symptoms or the condition of the subject. For example, in some embodiments, the antibody-drug conjugate is administered once a month, twice a month, three times a month, every other week, once a week (qwk), twice a week, three times a week, four times a week, five times a week, six times a week, every other day, daily (qd / od), twice a day (bds / bid), or three times a day (tds / tid).

[0371] Methods of treating cancer This disclosure provides a method comprising delivering the conjugate of this disclosure to an individual having cancer. This method is useful for treating a wide variety of cancers, including carcinomas, sarcomas, leukemias, and lymphomas. In the context of cancer, the term “treat” includes, for example, reducing the growth of a solid tumor, inhibiting the replication of cancer cells, reducing the overall tumor burden, and alleviating one or more symptoms associated with cancer.

[0372] Cancers that can be treated using the subject method include, but are not limited to, esophageal carcinoma, hepatocellular carcinoma, basal cell carcinoma (a form of skin cancer), squamous cell carcinoma (of various tissues), bladder carcinoma including transitional cell carcinoma (malignant neoplasm of the bladder), bronchogenic carcinoma, colon carcinoma, colorectal carcinoma, gastric carcinoma, lung carcinoma including small cell and non-small cell lung carcinoma, adrenocortical carcinoma, thyroid carcinoma, pancreatic carcinoma, breast carcinoma, ovarian carcinoma, prostate carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, cystadenocarcinoma, medullary carcinoma, renal cell carcinoma, ductal carcinoma or cholangiocarcinoma, choriocarcinoma, seminoma, fetal carcinoma, Wilms' tumor, cervical carcinoma, uterine carcinoma, testicular carcinoma, bone carcinoma, epithelial carcinoma, and nasopharyngeal carcinoma.

[0373] Sarcomas that can be treated using the subject method include, but are not limited to, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, chordoma, osteogenic sarcoma, osteosarcoma, vascular sarcoma, soft tissue sarcoma, lymphangiosarcoma, intralymphatic sarcoma, synovial tumor, mesothelioma, Ewing's sarcoma, leiomyosarcoma, rhabdomyosarcoma, and other soft tissue sarcomas.

[0374] Other solid tumors that can be treated using the methods described in this subject include, but are not limited to, gliomas, astrocytomas, medulloblastomas, craniopharyngiomas, ependymomas, pineal glandomas, hemangioblastomas, acoustic neuromas, oligodendrogliomas, meningiomas, melanomas, neuroblastomas, and retinoblastomas.

[0375] Leukemias that can be treated using the subject method include, but are not limited to, a) chronic myeloproliferative syndromes (neoplastic disorders of pluripotent hematopoietic stem cells), b) acute myeloid leukemia (neoplastic transformation of pluripotent hematopoietic stem cells or hematopoietic stem cells with controlled phylogenetic potential), c) chronic lymphocytic leukemia (CLL, clonal proliferation of small, immunologically immature and dysfunctional lymphocytes), B-cell CLL, T-cell CLL (prelymphocytic leukemia), and hairy cell leukemia, and d) acute lymphoblastic leukemia (characterized by accumulation of lymphoblasts). Lymphomas that can be treated using the subject method include, but are not limited to, B-cell lymphoma (e.g., Burkitt lymphoma), Hodgkin lymphoma, non-Hodgkin B-cell lymphoma, etc.

[0376] In certain embodiments, a method is provided for treating cancer in a subject, wherein such method comprises administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of any of the conjugates of the present disclosure, and the administration is effective in treating cancer in the subject. [Examples]

[0377] The following examples are provided to those skilled in the art to provide a complete disclosure and description of the methods of preparation and use of the present invention and are not intended to limit the scope of what the inventors consider to be the invention, nor are they intended to represent that the following experiments are all or only experiments that can be performed. Efforts have been made to ensure accuracy to the figures used (e.g., quantity, temperature, etc.), but some degree of experimental error and deviation should be taken into consideration. Unless otherwise specified, parts are parts by weight, molecular weight is the weight-average molecular weight, temperature is in Celsius, and pressure is atmospheric pressure or near atmospheric pressure. "Average" means the arithmetic mean. Standard abbreviations may be used, for example, bp, base pair; kb, kilobase; pl, picoliter; s or sec, second; min, minute; h or hr, hour; aa, amino acid; kb, kilobase; bp, base pair; nt, nucleotide; im, intramuscular; ip, intraperitoneal; sc, subcutaneous, etc.

[0378] General synthesis procedure Numerous common references are available that provide generally known chemical synthesis schemes and conditions useful for synthesizing the disclosed compounds (see, for example, Smith and March, March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, Fifth Edition, Wiley-Interscience, 2001, or Vogel, A Textbook of Practical Organic Chemistry, Including Qualitative Organic Analysis, Fourth Edition, New York: Longman, 1978).

[0379] The compounds described herein can be purified by any purification protocol known in the art, including chromatography such as HPLC, preparative thin-layer chromatography, flash column chromatography, and ion-exchange chromatography. Any suitable stationary phase, including normal-phase and reverse-phase chromatography, and ionic resins, may be used. In certain embodiments, the disclosed compounds are purified via silica gel and / or alumina chromatography. See, for example, Introduction to Modern Liquid Chromatography, 2nd Edition, ed. LRSnyder and JJ Kirkland, John Wiley and Sons, 1979, and Thin Layer Chromatography, ed. E. Stahl, Springer-Verlag, New York, 1969.

[0380] During any of the processes for preparing the compound of interest, it may be necessary and / or desirable to protect any sensitive or reactive groups of the molecule of interest. This can be seen, for example, in JFW McOmie, “Protective Groups in Organic Chemistry”, Plenum Press, London and New York 1973, TW Greene and PGMWuts, “Protective Groups in Organic Synthesis”, Third edition, Wiley, New York 1999, “The Peptides”; Volume 3 (editors: E. Gross and J. Meienhofer), Academic Press, London and New York 1981. 1982, and / or Jochen Lehmann, “Chemie der This can be achieved by conventional protecting group means, as described in standard studies such as "Kohlenhydrate: Monosaccharide and Derivate," Georg Thieme Verlag, Stuttgart 1974. The protecting group may be removed at a convenient subsequent step using methods known in the art.

[0381] The subject compounds can be synthesized via a variety of different synthetic routes using commercially available starting materials and / or starting materials prepared by conventional synthetic methods. Various examples of synthetic routes that may be used to synthesize the compounds disclosed herein are described in the following scheme.

[0382] Example 1 Galactoside and Glucoside Double-Cleavage Linkers for Antibody-Drug Conjugates Introduction The usefulness of the glucuronide-dipeptide double-cleavable linker is shown, for example, in Scheme 1 below, where MMAE construct 4, having a Val-Ala-PABC linker with a glucuronide moiety attached to a self-sacrificing unit, provided an antibody-drug conjugate (ADC) that, when conjugated with an antibody, exhibited superior stability compared to common dipeptide MMAE drug linkers, while having similar efficacy in vivo. The glucuronide-based MMAE constructs were synthesized in 10 synthesis steps in good overall yield as shown in Scheme 1. This synthesis began with commercially available fully protected β-glucuronide bromide. The necessary overall deprotection of all acetate groups in the glucuronide moiety of intermediate 3, and cleavage of the methyl ester, were achieved by hydrolysis under strongly basic conditions (LiOH in methanol). [ka]

[0383] While these strongly basic conditions were suitable for MMAE drugs (especially those not sensitive to strong bases), the need for basic hydrolysis in the final step of their synthesis significantly limited the application of glucuronide-based double-cleavable linkers. Indeed, various cytotoxins frequently used to generate antibody-drug conjugates contain basic-unstable functional groups (Figure 1). For example, the primary alkyl and amide groups in duocalmycin DM5, as well as the acetate group in tubulosin M6 and the ester functional group in calichemycin 7, are highly susceptible to basic hydrolysis. Mytansinoids 8 and 9 are particularly unstable under basic conditions due to the inclusion of esters and epoxides in their structures. Similarly, the lactones in DNA topoisomerase I inhibitors, such as SN-38 10 and exatecan 11, are known to hydrolyze even under mild basic conditions.

[0384] Despite the aforementioned compatibility issues, the inventors previously found that certain mytansinoids, such as 4AP-mytansin 9 (Figure 1), could still pair with glucuronide linkers, but the synthesis of such constructs was cumbersome and inefficient (17 steps, total yield 1.8%, Scheme 2). In this synthetic route, the glucuronide linker 12 had to be prepared separately and, in a later step, to yield the synthetic sequence in a completely deprotected form, which then had to be reacted with the separately synthesized mytansin derivative 13. [ka]

[0385] While this particular mytansinoid (9) was somewhat suitable for synthetic modification, the more attractive NMC3-mytansin (8) would not be usable in a similar manner due to its structural elements. If the synthetic strategy used for 9 (Scheme 2) were to be applied to 8, a selectivity problem would inevitably arise in later stages of synthesis, requiring the differentiation of the two carboxylic acid groups in the glucuronic acid intermediate 18 (Scheme 3), necessitating an alternative and long-term protection-deprotection approach. [ka]

[0386] Results and Discussion In contrast to the examples described in the introduction, using different biologically related glycosides as double-cleavable linkers allows for the successful use of a wider range of cytotoxins in synthesis. Therefore, by using galactosides instead of glucuronides, it was possible to use NMC3-mytansin (8, Figure 1) in 11 synthesis steps (Scheme 4) to produce the P1'-galactoside construct 30 in good overall yield (7.5%). Due to the absence of a carboxylic acid group (as in compound 29, Scheme 4), the galactoside moiety in its fully deprotected form does not raise chemoselectivity issues and allows for the successful utilization of numerous base-sensitive ADC payloads. The same is expected to occur with glucosides and mannosides, as their structures are not significantly different from galactosides. [ka]

[0387] In fact, other monosaccharide derivatives with base-sensitive payloads useful for generating ADCs can be prepared, similar to galactosides. Thus, the double-cleavable glucoside linker successfully paired with the NMC3-mytansin payload, providing the corresponding construct 44 in good overall yield (4.9% in 11 steps), as shown in Scheme 5. [ka]

[0388] Furthermore, it was found that the use of galactosides or glucosides enabled more consistently efficient and higher-yield synthesis of the drug-linker compared to the glucuronide counterparts. Therefore, the synthetic route to the P1'-galactoside MMAE construct 33 shown in Scheme 6 produced the desired compound in excellent overall yield (9.4% vs. 4.2% for the glucuronide construct, Table 1). [ka]

[0389] Similarly, compared to glucuronide-containing compound 4, the glucoside homolog 46 was prepared more efficiently by starting with the corresponding monosaccharide derivative 41 and following a modified synthetic route (Scheme 7) (yields for glucuronide constructs: 7.6% vs. 4.2%, Table 1). [ka]

[0390] Furthermore, a comparison of material costs revealed that, on average, the required galactose and glucose derivatives are 10 to 20 times cheaper than their corresponding glucuronic acid derivatives (see Table 1). [Table 1]

[0391] When incorporated into a linker in close proximity to an enzymatically cleavable dipeptide, the glycoside can function as a transient protecting group, preventing premature cleavage of the circulating antibody-drug conjugate dipeptide linker. Once the ADC is trafficked into the cellular lysosomal compartment, the glycoside moiety must be cleaved by lysosomal glycosidases to expose the dipeptide linker, which is then subjected to enzymatic cleavage to release the payload. Several human glycosidases exist with different substrate preferences and expression patterns across different cells and tissues. While we have previously demonstrated that the glucuronide moiety can be efficiently removed in a wide variety of cell types as a first step toward achieving payload release, it was unclear whether the galactoside or glucoside moiety is similarly processed. To address this issue, constructs 30 and 33 were conjugated using HIPS ligation with aldehyde-tagged anti-HER2 and anti-CD79b antibodies, and constructs 44 and 46 were conjugated using HIPS ligation with aldehyde-tagged anti-FITC, anti-HER2, and anti-TROP-2 antibodies (Figure 2). The analytical characterization of the resulting conjugates is shown in Figures 3 to 10 and Figures 19 to 30.

[0392] The in vitro activity of the obtained conjugates was tested using HER2+ (NCI-N87, Sk-Br-3), CD79b+ (Granta-519, Ramos-RA), and TROP-2+ (MDA-MB-468, BxPC3) cancer cell lines. In several studies, the potency of mytansine conjugate ADCs possessing a galactoside-modified double-cleavable linker (30) was compared to the activity of the corresponding ADC generated from a single-cleavable linker payload 35 (construction 35 shown in Figure 11, in vitro potency data shown in Figures 12-15). In other studies, the potency of mytansine conjugate ADCs possessing a galactoside-modified double-cleavable linker (30) was compared to the activity of the corresponding ADC generated using a glucoside-modified double-cleavable linker 44 (in vitro potency data shown in Figures 31-34). Regarding MMAE-conjugated ADCs, the in vitro potency of galactoside-modified (33) or glucoside-modified (46) double-cleavable linkers was compared with the in vitro potency of glucuronide-modified double-cleavable linker 34 (construction 34 shown in Figure 11, and in vitro potency data shown in Figures 16-18, 35, and 36). In summary, the results showed that ADCs prepared using single-cleavable and double-cleavable linkers containing glucuronide, galactoside, and glucoside variants provided similar levels of potency across cell lines representing both solid (gastric, pancreatic, and breast cancer) and hematological malignancies. The data suggest that, despite the unknown glycosidase expression patterns and substrate specificity, galactoside and glucoside moieties were robust and efficient, and overall ADC catabolism and payload release were comparable for all linkers tested.

[0393] Materials and methods General Synthetic reagents were purchased from Sigma-Aldrich, Acros, AK Scientific, or other commercial sources and used without purification. Anhydrous solvents were obtained from commercial sources in sealed bottles. Acetobromo-α-D-galactose 21, acetobromo-α-D-glucose 36, MMAE2, and mytansin 17 were purchased from commercial sources. HIPS linker compound 32 was commercially obtained from Shanghai Medicilon and used without purification. Pentafluoroester 28 was synthesized from 32 using standard literature procedures. The synthesis of compounds 34 and 35 has been previously described. In all cases, the solvent was removed under reduced pressure using a Buchi Rotovapor R-114 equipped with a Buchi V-700 vacuum pump. Column chromatography was performed using a Biotage Isolera chromatography system. Preparative HPLC purification was performed using a Waters preparative HPLC unit fitted with a Phenomenex Kinetex 5μm EVO C18 150×21.2mm column. HPLC analysis was performed at room temperature using a 10-100% gradient of water and acetonitrile containing 0.1% formic acid on an Agilent 1100 Series Analytical HPLC system equipped with a Model G1322A Degasser, Model G1311A Quarternary Pump, Model G1329A Autosampler, Model G1314 Variable Wavelength Detector, and an Agilent Poroshell 120 SB C18, 4.6mm×50mm column. The HPLC was monitored at 254nm.

[0394] Combination of structures 30 and 33 Preparation of (2R,3S,4S,5R,6S)-2-(acetoxymethyl)-6-(5-formyl-2-nitrophenoxy)tetrahydro-2H-pyran-3,4,5-triyltriacetate (21a) A 50 mL round-bottom flask was packed with 204 mg (1.22 mmol) of 3-hydroxy-4-nitrobenzaldehyde 20 and acetobromo-α-D-galarctose 21 (500 mg, 1.22 mmol), followed by 20 mL of anhydrous acetonitrile. The solution was treated with silver(I) oxide (986 mg, 4.3 mmol), and the resulting mixture was vigorously stirred in the dark at room temperature for 24 hours. After concentrating the reaction mixture under vacuum, the residue was purified using silica gel with an ethyl acetate-hexane mixture as the eluent (0-100% gradient) to obtain 420 mg (0.85 mmol, 70% yield) of the product as a pale yellow solid. LRMS(ESI): m / z 520.0[M+Na] + , C 21 H 23 NO 13 The calculated value for m / z is 520.1.

[0395] Preparation of (2R,3S,4S,5R,6S)-2-(acetoxymethyl)-6-(2-amino-5-(hydroxymethyl)phenoxy)tetrahydro-2H-pyran-3,4,5-triyltriacetate (22) To a 3 mL solution of acetate-protected galactoside intermediate 21a (350 mg, 0.70 mmol) in ethyl acetate, 30 mg (10 wt%) of palladium on carbon and 30 μL of triethylamine were added. After removing the air, a hydrogen balloon was attached to the flask, and the reaction mixture was stirred at room temperature for 48 hours. After filtering through a Celite pad, the solvent was removed under vacuum, and the residue was dried under high vacuum to obtain 300 mg of crude product 22 as a white solid, which was used in further synthesis without further purification. LRMS (ESI): m / z 470.1 [M+H] + , C 21 H 27 NO 11 The calculated value for m / z is 470.2.

[0396] Preparation of ((2R,3R,4S,5S,6S)-2-(2-((S)-2-((S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-methylbutanamide)propanamide)-5-((((4-nitrophenoxy)carbonyl)oxy)methyl)phenoxy)-6-(acetoxymethyl)tetrahydro-2H-pyran-3,4,5-triyltriacetate (26) Boc-L-alanine (220 mg, 1.11 mmol) and aniline derivative 22 (520 mg, 1.16 mmol) were combined in 5 mL of anhydrous dichloromethane and 0.50 mL of anhydrous methanol. The resulting solution was treated with EEDQ (280 mg, 1.13 mmol) at room temperature. The reaction mixture was stirred in the dark for 1 hour, and then the solvent was removed under vacuum. The resulting crude compound 23 was dried under high vacuum for 1 hour and dissolved in 6 mL of a 1:1 TFA-DCM mixture at room temperature. After the solution was allowed to stand for 1 hour, the solvent was removed, and the resulting crude amine 24 was stored under high vacuum for several hours.

[0397] In a separate 20 mL scintillation vial, Fmoc-L-valine (375 mg, 1.1 mmol) was mixed with HATU (420 mg, 1.1 mmol) and DIPEA (375 μL, 2.15 mmol) in 3 mL of anhydrous DMF. The mixture was stirred at room temperature for 30 minutes, then combined with crude compound 24, and stirred overnight until the reaction was determined to be complete by LC-MS analysis. The reaction mixture was directly purified using a reversed-phase C18 column (CH3CN-H2O / 0.05% TFA, 0-80% gradient) to obtain compound 25 as a mixture with trace impurities. The product was thoroughly dried under high vacuum, and the next step was performed without further purification.

[0398] Compound 25 was dissolved in 6 mL of anhydrous DCM and treated with DIPEA (375 μL, 2.15 mmol), followed by the addition of 686 mg (2.26 mmol) of bis(4-entrophenyl) carbonate in a single dose at room temperature. The reaction mixture was stirred for 1 hour, then the solvent was removed under vacuum. The residue was purified by column chromatography on silica gel (siRNA-hexane, 10–100% gradient) to obtain p-nitrophenyl carbonate product 26 (640 mg, 0.62 mmol, 56% yield in 4 steps) as a yellowish solid. LRMS (ESI): m / z 1049.3 [M+Na] + , C 51 H 54 N4O 19 The calculated value for m / z is 1049.3.

[0399] Preparation of 4-((((4-((S)-2-((S)-2-amino-3-methylbutanamide)propanamide)-3-(((2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)benzyl)oxy)carbonyl)(methyl)amino)butanoic acid (27) 61 mg (0.52 mmol) of 4-(methylamino)butanoic acid, 61 μL (0.35 mmol) of DIPEA, and 1 mL of anhydrous DMF were added to a 20 mL scintillation vial. The resulting solution was combined with 180 mg (0.175 mmol) of PNP-carbonate 26 at room temperature. The reaction mixture was stirred for 1 hour until the PNP-carbonate was completely consumed, as determined by LC-MS analysis. The solvent was removed under vacuum, and the residue was dissolved in 3 mL of methanol. The resulting solution was cooled to 0°C and treated with 3 mL of 1 M aqueous lithium hydroxide solution. The reaction mixture was stirred for 30 minutes, then heated to room temperature and concentrated under vacuum. The residue was directly purified using a reversed-phase C18 column (CH3CN-H2O / 0.05% TFA, 0-50% gradient) to obtain 90 mg (0.146 mmol, 83% yield in 2 steps) of compound 27 as a yellow oil. LRMS(ESI): m / z 615.3[M+H] + , C 27 H42 N4O 12 The calculated value for m / z is 615.3.

[0400] (2S,5S,18R)-1-((4-((((4-(((S)-1-(((1 4 S,1 6 S,3 2 R,3 3 R, 2R, 4S, 10E, 12E, 14R)-8 6 -Chloro-1 4 -Hydroxy-8 5 ,14-dimethoxy-3 3 ,2,7,10-tetramethyl-1 2 ,6-Dioxo-7-Aza-1(6,4)-Oxazineana-3(2,3)-Oxirana-8(1,3)-Benzeneacyclotetradecafan-10,12-Dien-4-yl)oxy)-1-Oxopropan-2-yl)(methyl)amino)-4-oxobutyl)(methyl)carbamoyl)oxy)methyl)-2-(((2R,3R,4S,5R,6S)-3,4,5-Trihydroxy-6-( Preparation of hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)phenyl)amino)-18-(3-(2-((1,2-dimethylhydrazinyl)methyl)-1H-pyrrolo[2,3-b]pyridine-1-yl)propanamide)-5-isopropyl-2-methyl-1,4,7,17-tetraoxo-10,13-dioxa-3,6,16-triazanonadecane-19-sulfonic acid (30) Compound 27 (84 mg, 0.14 mmol), 1 mL of anhydrous DMF, and DIPEA (48 μL, 0.28 mmol) were added to a 20 mL scintillation vial, followed by 130 mg (0.14 mmol) of pentafluoroester 28. The resulting mixture was stirred for 30 minutes until coupling was deemed complete (LC-MS). Mytansine 17 (89 mg, 0.14 mmol) was added directly to the reaction mixture as a solution in 0.5 mL of DMF, followed by HATU (52 mg, 0.14 mmol). After 30 minutes, the reaction mixture was purified using a reversed-phase C18 column (CH3CN-H2O / 0.05% TFA, 10-95% gradient). After complete removal of the solvent, the resulting intermediate 29 was dissolved in 3 mL of DMF and treated with 150 μL of piperidine at room temperature. After 30 minutes, the reaction mixture was directly purified by reverse-phase preparative HPLC (C18 column, CH3CN-H2O / 0.05% TFA, 0-50% gradient). The pure fraction was lyophilized to obtain 58 mg (0.032 mmol, 23% yield in 3 steps) of compound 30. LRMS (ESI): m / z 1801.8 [M+H] + , C 82 H 118 ClN 13 O 28 The calculated value for S is m / z 1800.8.

[0401] (2R,3S,4S,5R,6S)-2-(acetoxymethyl)-6-(2-((S)-2-((S)-2-amino-3-methylbutanamide)propanamide)-5-((5S,8S,11S,12R)-11-((S)-sec-butyl)-12-(2-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropane Preparation of (2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidine-1-yl)-2-oxoethyl)-5,8-diisopropyl-4,10-dimethyl-3,6,9-trioxo-2,13-dioxa-4,7,10-triazatetradecyl)phenoxy)tetrahydro-2H-pyran-3,4,5-triyltriacetate (31) In a 4 mL glass vial, MMAE2 (13.4 mg of TFA salt, 0.016 mmol), DIPEA (3.8 μL, 0.022 mmol), and 1 mL of anhydrous DMF were mixed. The resulting solution was treated with PNP-carbonate 26 (15 mg, 0.015 mmol) and HOAt (1.0 mg, 0.008 mmol). After stirring overnight at room temperature, piperidine (30 μL) was added directly to the reaction mixture. After 30 minutes, the reaction mixture was purified by reverse-phase preparative HPLC (C18 column, CH3CN-H2O / 0.05% TFA, 0-50% gradient). The pure fraction was lyophilized to obtain 8 mg (0.006 mmol, 40% yield in 2 steps) of compound 31 as an off-white solid. LRMS (ESI): m / z 1383.5 [M+H] + , C 69 H 106 N8O 21 The calculated value for m / z is 1383.8.

[0402] (2S,5S,18R)-1-((4-((5S,8S,11S,12R)-11-((S)-sec-butyl)-12-(2-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropane-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidine-1-yl)-2-oxoethyl)-5,8-diisopropyl-4,10-dimethyl-3,6,9-trioxo-2,13-dioxa-4,7,10-triazatetradecyl Preparation of (33) - 2-(((2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)phenyl)amino)-18-(3(2-((1,2-dimethylhydrazinyl)methyl)-1H-pyrrolo[2,3-b]pyridine-1-yl)propanamide)-5-isopropyl-2-methyl-1,4,7,17-tetraoxo-10,13-dioxa-3,6,16-triazanonadecane-19-sulfonic acid Compound 31 (8 mg, 0.006 mmol), HIPS linker compound 32 (4.5 mg, 0.006 mmol), DIPEA (1.5 μL, 0.009 mmol), and 2.3 mg (0.06 mmol) of HATU were combined in 1 mL of DMF in a 4 mL glass vial. The reaction mixture was stirred at room temperature for 30 minutes, then the DMF was removed under vacuum, and the residue was dissolved in 1 mL of methanol. To this solution, 1 mL of 1 M aqueous lithium hydroxide solution was added, and the resulting mixture was stirred overnight at room temperature. The reaction mixture was directly purified by reverse-phase preparative HPLC (C18 column, CH3CN-H2O / 0.05% TFA, 10-60% gradient), and the pure fraction was lyophilized to obtain 6 mg (0.0033 mmol, 60% yield in 2 steps) of compound 33 as an off-white powder. LRMS (ESI): m / z 1770.9 [M+H] + , C 84 H 132 N 14 O 25 The calculated value for S is m / z 1769.9.

[0403] Combination of structures 44 and 46 Preparation of (2R,3R,4S,5R,6S)-2-(acetoxymethyl)-6-(2-amino-5-(hydroxymethyl)phenoxy)tetrahydro-2H-pyran-3,4,5-triyltriacetate (37). A mixture of compound 20 (5.0 g, 29.9 mmol, 1.7 equivalents) and compound 36 (7.23 g, 17.6 mmol, 1 equivalent) in anhydrous acetonitrile (100 mL) was mixed with silver(I) oxide (15.6 g, 87.9 mmol, 5 equivalents). The mixture was stirred under nitrogen in the dark at 25°C for 24 hours. The reaction mixture was diluted with HCl (100 mL), filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (0-30% hexane-HCl). Palladium on carbon (10% by weight, 800 mg, 0.75 mmol) was added all at once to a mixture of intermediate aldehyde (5.61 g, 11.3 mmol) and triethylamine (2.5 mL) in HCl (80 mL). The reaction mixture was stirred under an H2 atmosphere at 25°C for 24 hours. The solid was filtered off, and the resulting filtrate was concentrated to obtain 5.2 g (11.1 mmol, 98% yield) of product 37 as a white solid, which was used in the next step without further purification.

[0404] Preparation of (2R,3R,4S,5R,6S)-2-(acetoxymethyl)-6-(2-((S)-2-((tert-butoxycarbonyl)amino)propanamide)-5-(hydroxymethyl)phenoxy)tetrahydro-2H-pyran-3,4,5-triyltriacetate (38). A mixture of compound 37 (5.20 g, 11.1 mmol), Boc-L-Ala-OH (1.75 g, 9.25 mmol), and EEDQ (2.3 g, 9.25 mmol) in anhydrous DCM (40 mL) and MeOH (4 mL) was stirred in the dark at room temperature for 1 hour. The reaction mixture was concentrated to obtain 5.5 g of crude product 38 as a yellow solid. The crude product was used in the next step without further purification.

[0405] Preparation of (2R,3R,4S,5R,6S)-2-(acetoxymethyl)-6-(2-((S)-2-aminopropanamide)-5-(hydroxymethyl)phenoxy)tetrahydro-2H-pyran-3,4,5-triyltriacetate (39). Crude compound 38 (5.5 g, 8.6 mmol) was dissolved in TFA (23 mL). The resulting solution was stirred at room temperature for 10 minutes and concentrated under vacuum. The residue was purified by reverse-phase chromatography (C18 column, 0-75% acetonitrile-water containing 0.05% TFA). The pure fractions were combined and concentrated to obtain 4.0 g of product amine 39 as a yellow oil (7.5 mmol, 66% yield in 3 steps).

[0406] Preparation of (2S,3R,4S,5R,6R)-2-(2-((S)-2-((S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-methylbutanamide)propanamide)-5-(hydroxymethyl)phenoxy)-6-(acetoxymethyl)tetrahydro-2H-pyran-3,4,5-triyltriacetate (40). To a mixture of Fmoc-L-valine (3.1 g, 9.2 mmol) and DIPEA (3.9 mL, 22.2 mmol) in anhydrous DMF (20 mL), HATU (3.5 g, 9.2 mmol) was added all at once at room temperature. The resulting solution was stirred at room temperature for 30 minutes and then combined with amine 39 (4.0 g, 7.5 mmol). The reaction mixture was stirred for 16 hours and concentrated under vacuum. The residue was purified by silica gel chromatography (hexane: siRNA, 0-100%) to obtain compound 40 (4.5 g, 5.2 mmol, yield 70%) as a white solid.

[0407] Preparation of (2S,3R,4S,5R,6R)-2-(2-((S)-2-((S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-methylbutanamide)propanamide)-5-((((4-nitrophenoxy)carbonyl)oxy)methyl)phenoxy)-6-(acetoxymethyl)tetrahydro-2H-pyran-3,4,5-triyltriacetate (41). A mixture of alcohol 40 (4.5 g, 5.2 mmol) and DIPEA (4.5 mL, 26.1 mmol, 5 equivalents) in anhydrous THF (20 mL) was mixed with bis(4-nitrophenyl) carbonate (7.9 g, 26.1 mmol, 5 equivalents). The resulting mixture was stirred at room temperature for 24 hours and concentrated under vacuum. The residue was purified by reverse-phase chromatography (acetonitrile-water 0-70% containing 0.05% TFA) to obtain 4-nitrophenyl carbonate product 41 as a white solid (3.9 g, yield 73%). LRMS (ESI): m / z 1027.3 [M+H] + , C 51 H 54 N4O 19 The calculated value for m / z is 1027.3.

[0408] Preparation of 4-((((4-((S)-2-((S)-2-amino-3-methylbutanamide)propanamide)-3-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)benzyl)oxy)carbonyl)(methyl)amino)butanoic acid (42). A mixture of p-nitrophenyl carbonate 41 (380 mg, 0.37 mmol, 1 equivalent) and 4-(methylamino)butanoic acid (55 mg, 0.47 mmol, 1.25 equivalents) in anhydrous DMF (2 mL) was mixed with DIPEA (190 μL, 1.11 mmol, 3 equivalents). The resulting mixture was stirred for 16 hours, concentrated under vacuum, and the residue was redissolved in THF (2 mL). To the THF solution, 2 mL of 1 M LiOH aqueous solution was added at room temperature, and the mixture was stirred for 2 hours until hydrolysis was determined to be complete by HPLC analysis. The reaction mixture was quenched with 1 M HCl (2 mL), diluted with DMF (1 mL), and purified by reverse-phase chromatography (C18 column, acetonitrile-water containing 0.05% TFA, 0-75% MeCN). The pure fraction was collected, concentrated under reduced pressure, and freeze-dried to obtain compound 42 as a white solid (160 mg, 0.26 mmol, 70% yield in 2 steps). LRMS (ESI): m / z 615.3 [M+H] + , C 27H 42 N4O 12 The calculated value for m / z is 615.3.

[0409] Preparation of 4-((((4-((2S,5S,18R)-5-isopropyl-2-methyl-4,7,17,20-tetraoxo-18-(sulfomethyl)-22-(2-((1,2,2-trimethylhydrazineyl)methyl)-1H-pyrrolo[2,3-b]pyridine-1-yl)-10,13-dioxa-3,6,16,19-tetraazadocosaneamide)-3-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)benzyl)oxy)carbonyl)(methyl)amino)butanoic acid (43). To a solution of compound 32 (97 mg, 0.12 mmol, 1 equivalent) in DMF (2 mL), HATU (40 mg, 0.1 mmol, 0.85 equivalents) was added, followed by DIPEA (63 μL, 0.36 mmol, 3 equivalents) at room temperature. The resulting mixture was stirred for 1 hour and then combined with a 0.1 M solution of compound 42 in DMF (1.22 mL, 0.12 mmol, 1 equivalent). The reaction mixture was stirred for 30 minutes until all starting materials were consumed, as determined by HPLC analysis. The mixture was directly purified by reverse-phase chromatography (C18 column, acetonitrile-water with 0.05% TFA, 0-75% MeCN). The pure fraction was collected and lyophilized to obtain product 43 as a white solid (107 mg, 0.08 mmol, 67% yield). LRMS (ESI): m / z 1391.6 [M+H] + , C 65 H 86 N 10 O 22 The calculated value for S is m / z 1391.6.

[0410] (2S,5S,18R)-1-((4-((((4-(((S)-1-(((14S,16S,32R,33R,2R,4S,10E,12E,14R)-86-chloro-14-hydroxy-85,14-dimethoxy-33,2,7,10-tetramethyl-12,6-dioxo-7-aza-1(6,4)-oxazineana-3(2,3)-oxylana-8(1,3)-benzeneacyclotetradecafan-10,12-dien-4-yl)oxy)-1-oxopropane-2-yl)(methyl)amino)-4-oxobutyl)(M Preparation of (44) ethyl(carbamoyl)oxy(methyl)-2-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy(phenyl)amino)-18-(3-(2-((1,2-dimethylhydrazineyl)methyl)-1H-pyrrolo[2,3-b]pyridine-1-yl)propanamide)-5-isopropyl-2-methyl-1,4,7,17-tetraoxo-10,13-dioxa-3,6,16-triazanonadecane-19-sulfonic acid. To a mixture of compound 43 (35 mg, 25 μmol) and mytansin 17 (16 mg, 25 μmol) in DMF (2 mL), HATU (19 mg, 51 μmol, 2 equivalents) was added at room temperature, followed by DIPEA (13 μL, 76 μmol, 3 equivalents). The reaction mixture was stirred for 30 minutes until all starting materials were consumed, as determined by HPLC analysis. Then, piperzine (49 μL, 0.5 mmol, 20 equivalents) was added directly to the above solution in a single shot at room temperature, and the reaction mixture was stirred for 30 minutes. The mixture was purified by preparative HPLC (C18 column, acetonitrile-water with 0.05% TFA, 0-75% MeCN). The pure fractions were combined and lyophilized to obtain compound 44 as a white solid (21 mg, 12 μmol, 48% yield). LRMS (ESI): m / z 1800.7 [M+H] + , C 82 H 118 ClN 13 O 28 The calculated value for S is 1800.8.

[0411] 4-((S)-2-((S)-2-amino-3-methylbutanamide)propanamide)-3-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)benzyl((S)-1-(((S)-1-(((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S, Preparation of 2R)-1-hydroxy-1-phenylpropane-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidine-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)(methyl)amino)-3-methyl-1-oxobutan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)(methyl)carbamate (45). A solution of monomethyl auristatin A2 (50 mg, 70 μmol) in anhydrous DMF (2 mL) was treated with HOAt (9.5 mg, 70 μmol) and DIPEA (36 μL, 209 μmol) at room temperature. Compound 41 (72 mg, 70 μmol, 1 equivalent) was added to this mixture as a solid all at once at room temperature. The reaction mixture was stirred for 4 hours until all the starting materials were consumed, as determined by LC-MS analysis. The solvent was removed under vacuum, and the residue was redissolved in THF (2 mL). The THF solution was treated with 1 M LiOH aqueous solution (2 mL) at room temperature and stirred for 2 hours until hydrolysis was complete. The reaction mixture was quenched with 1 M HCl (2 mL), diluted with DMF (1 mL), and purified by reverse-phase chromatography (C18 column, acetonitrile-water containing 0.05% TFA, 0-75% MeCN). The pure fractions were combined, concentrated under reduced pressure, and freeze-dried to obtain product 45 as a white solid (68 mg, 56 μmol, 80% yield).

[0412] (2S,5S,18R)-1-((4-((5S,8S,11S,12R)-11-((S)-sec-butyl)-12-(2-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropane-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidine-1-yl)-2-oxoethyl)-5,8-diisopropyl-4,10-dimethyl-3,6,9-trioxo-2,13-dioxa-4,7,10-triazatetradecyl Preparation of )-2-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)phenyl)amino)-18-(3-(2-((1,2-dimethylhydrazineyl)methyl)-1H-pyrrolo[2,3-b]pyridine-1-yl)propanamide)-5-isopropyl-2-methyl-1,4,7,17-tetraoxo-10,13-dioxa-3,6,16-triazanonadecane-19-sulfonic acid (46). To a 2 mL DMF solution of carboxylic acid 32 (50 mg, 63 μmol), HATU (24 mg, 63 μmol), followed by DIPEA (33 μL, 189 μmol), was added at room temperature. The resulting mixture was stirred for 1 hour and combined with compound 45 (68 mg, 63 μmol). The reaction mixture was stirred for 5 hours until all starting materials were consumed, as determined by HPLC analysis. Piperzine (110 μL, 20 equivalents) was then added to the above solution in a single shot at room temperature. The reaction mixture was stirred for 30 minutes and diluted in 0.5 M acetate buffer at pH 4.7 until the solution became acidic. The mixture was purified by preparative HPLC (C18 column, acetonitrile water with 0.05% TFA and 0-75% MeCN). The pure fraction was collected and lyophilized to obtain compound 46 as a white solid (47 mg, 43% yield). LRMS (ESI): m / z 1769.9 [M+H] + , C 84 H 132 N 14 O 25 The calculated value for S is 1769.9.

[0413] Example 2 Bioconjugate, purification, and HPLC analysis method C-terminal aldehyde-tagged antibody (15 mg / mL) was conjugated at 0.85 mM (8 molar equivalents of drug:antibody) to linker payloads 30, 33, 44, and 46 in 20 mM sodium citrate containing 0.85% DMA and 50 mM NaCl pH 5.5 (20 / 50 buffer) at 37°C for 72 hours. Free drug was removed using a 0.5 mL Amicon spin concentrator with a 30 kD MWCO. The samples were added to the spin concentrator, centrifuged at 15,000 × g for 7 minutes, then diluted in 450 μL of 20 mM sodium citrate and 50 mM NaCl pH 5.5, and centrifuged again. This process was repeated 10 times. To determine the final product DAR, ADC was tested by analytical HIC (Tosoh #14947) using mobile phase A: 1.5 M ammonium sulfate, 25 mM sodium phosphate, pH 7.0, and mobile phase B: 25% isopropanol, 18.75 mM sodium phosphate, pH 7.0. To measure aggregation, samples were analyzed using analytical size exclusion chromatography (SEC, Tosoh #08541) with a mobile phase of 300 mM NaCl, 25 mM sodium phosphate, pH 6.8.

[0414] result αHER2 (trastuzumab) and αCD79b (polatuzumab) antibodies, modified to contain an aldehyde tag at the heavy chain C-terminus (CT), were conjugated to linker payload 30 containing mytansin and linker payload 33 containing MMAE, respectively. These reactions yielded high yields, with nearly quantitative conjugation efficiency and overall yields exceeding 95%. The resulting ADCs had drug-to-antibody ratios (DARs) of 1.79–1.89 and were primarily monomeric. Figures 3–10 show representative ADCs with respect to DAR determined by HIC and monomer integrity determined by SEC.

[0415] αHER2 (trastuzumab), αTROP-2 (sacituzumab), and an anti-FITC antibody, modified to contain an aldehyde tag at the heavy chain C-terminus (CT), were conjugated to linker payload 44 containing mytansin and linker payload 46 containing MMAE, respectively. These reactions generally yielded high yields. The resulting ADCs had drug-to-antibody ratios (DARs) of 1.15–1.79 and were predominantly monomeric. Figures 19–30 show representative ADCs with respect to DAR determined by PLRP and monomer integrity determined by SEC.

[0416] Example 3 In vitro cytotoxicity method CD79b-positive B-cell lymphoma cell lines (Granta 519 and Ramos-RA), HER2-positive gastric and breast cancer cell lines (NCI-N87 and SKBR3), and TROP-2-positive pancreatic and breast cancer cell lines (BxPC3 and MDA-MB-468) were obtained from the DSMZ and ATCC cell banks. Cells were maintained in growth medium as recommended by the suppliers. Cells were passaged 24 hours prior to plating to ensure logarithmic growth. On the day of plating, 5000 cells / well were seeded in 100 μL of standard growth medium into 96-well plates. Cells were treated with 20 μL of diluted analytes at various concentrations, and plates were incubated at 37°C in a 5% CO2 atmosphere. After 5 days, 100 μL / well of Cell Titer-Glo reagent (Promega) was added, and luminescence was measured using a Molecular Devices SpectraMax M5 plate reader. GraphPad Prism software was used for data analysis.

[0417] result Galactoside-modified double-cleavable linkers and glucoside-modified double-cleavable linkers exhibited potent (sub-nanomolecal) in vitro cytotoxicity against antigen-positive cell lines and possessed activity comparable to ADCs containing a free payload and a single-cleavable linker or a glucuronide-modified double-cleavable linker (Figures 12-18 and 31-36).

[0418] While the present invention has been described in relation to its specific embodiments, those skilled in the art will understand that various modifications may be made and equivalents may be substituted without departing from the true spirit and scope of the invention. In addition, many modifications can be made to adopt specific circumstances, materials, compositions of substances, processes, process steps or steps, in relation to the objective spirit and scope of the invention. All such modifications are intended to be within the scope of the claims appended herein.

Claims

1. A conjugate comprising: An antibody, Drugs and a cleavable linker linking the antibody to the drug and comprising a first enzymatically cleavable moiety and a second enzymatically cleavable moiety comprising a glycoside selected from the group consisting of a galactoside, a glucoside, a mannoside, a fucoside, O-GlcNAc, and O-GalNAc.

2. The conjugate is of formula (I): [Case 1] During the ceremony, Z is CR 4 or N, X is O or NR 4 and R 1 is selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl; R 2 and R 3 are each independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, acyl, acyloxy, acylamino, aminoacyl, alkylamido, substituted alkylamido, sulfonyl, thioalkoxy, substituted thioalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl; or R 2 and R 3 are optionally cyclically linked to form a 5- or 6-membered heterocyclyl; Each R 4are independently selected from hydrogen, halogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, acyl, acyloxy, acylamino, aminoacyl, alkylamido, substituted alkylamido, sulfonyl, thioalkoxy, substituted thioalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl; Each R 5 is independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, and substituted alkynyl; Each R 6 is independently selected from alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl; k is an integer from 1 to 10; R 7 comprises a second enzymatically cleavable moiety, L 1 is the first linker, L 2 is a second linker, W 1 is the drug, W 2 The conjugate of claim 1 , wherein said antibody is

3. (a) k is 2, The conjugate is of formula (Ia) [Case 2] (b) the conjugate is a conjugate of formula (Ib): [C3] (c) the conjugate is a conjugate of formula (Ic): [C4] (d) the conjugate is of formula (Id): [C5] (e) the conjugate is of formula (Ie), [C6] (f) the conjugate is a conjugate of formula (If) [C7] (g) the conjugate is a conjugate of formula (Ig); [C8] The conjugate of claim 2.

4. A compound comprising: A compound comprising a cleavable linker for linking an antibody to a drug, said cleavable linker comprising a first enzymatically cleavable moiety and a second enzymatically cleavable moiety comprising a glycoside selected from the group consisting of a galactoside, a glucoside, a mannoside, a fucoside, O-GlcNAc, and O-GalNAc.

5. The compound is a compound of formula (II): [C9] During the ceremony, Z is CR 4 or N; X is O or NR 4 ; R 2 and R 3 are each independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, acyl, acyloxy, acylamino, aminoacyl, alkylamido, substituted alkylamido, sulfonyl, thioalkoxy, substituted thioalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl; or R 2 and R 3 are optionally cyclically linked to form a 5- or 6-membered heterocyclyl; each R 4 is independently selected from hydrogen, halogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, acyl, acyloxy, acylamino, aminoacyl, alkylamido, substituted alkylamido, sulfonyl, thioalkoxy, substituted thioalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl; each R 5 is independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl; each R 6 is independently selected from alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl; k is an integer from 1 to 10; R 7 comprises said second enzymatically cleavable moiety; L 1 is a first linker; L 2 is a second linker; The compound of claim 4, wherein W 1 is a drug. (a) k is 2, The compound is of formula (IIa) [C10] (b) the compound is of formula (IIb) [C11] (c) the compound is of formula (IIc): [C12] (d) the compound is of formula (IId) [C13] (e) the compound is of formula (IIe) [C14] (f) the compound is of formula (IIf), or [C15] (g) The compound is a compound of formula (IIg), [C16] The compound according to claim 5.

7. L 1 but, - (T 1 -V 1 ) a - (T 2 -V 2 ) b - (T 3 -V 3 ) c - (T 4 -V 4 ) d - including During the ceremony, a, b, c, and d are each independently 0 or 1; T 1 , T 2 , T 3 , and T 4 each independently represents a covalent bond, (C 1 ~C 12 ) alkyl, substituted (C 1 ~C 12 ) alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl; (EDA) w , (PEG) n , (AA) p , -(CR 13 O.H. m-, 4-amino-piperidine (4AP), an acetal group, a hydrazine, a disulfide, and an ester; EDA is an ethylenediamine moiety; PEG is polyethylene glycol; AA is an amino acid residue or an amino acid analog; each w is an integer from 1 to 20; each n is an integer from 1 to 30; each p is an integer from 1 to 20; and each m is an integer from 1 to 12; V 1 , V 2 , V 3 , and V 4 each independently represents a covalent bond, —CO—, or —NR 15 --, --NR 15 (CH 2 ) q --, --NR 15 (C 6 H 4 ) -, -CONR 15 --, --NR 15 CO-, -C(O)O-, -OC(O)-, -O-, -S-, -S(O)-, -SO 2 -, -SO 2 N.R. 15 --, --NR 15 SO 2 -, -P(O)OH-, and -P(O)OH-, where each q is an integer from 1 to 6; Each R 13 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, and substituted aryl; Each R 15 is independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, carboxyl, carboxyl ester, acyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl; A conjugate according to any one of claims 1 to 3 or a compound according to any one of claims 4 to 6.

8. L 2 but, - (T 5 -V 5 ) e - (T 6 -V 6 ) f - (T 7 -V 7 ) g - (T 8 -V 8 ) h - including During the ceremony, e, f, g, and h are each independently 0 or 1; T 5 , T 6 , T 7 , and T 8 each independently represents a covalent bond, (C 1 ~C 12 ) alkyl, substituted (C 1 ~C 12 ) alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl; (EDA) w , (PEG) n , (AA) p , -(CR 13 O.H. m -, 4-amino-piperidine (4AP), an acetal group, a hydrazine, a disulfide, and an ester; EDA is an ethylenediamine moiety; PEG is polyethylene glycol; AA is an amino acid residue or an amino acid analog; each w is an integer from 1 to 20; each n is an integer from 1 to 30; each p is an integer from 1 to 20; and each m is an integer from 1 to 12; V 5 , V 6 , V 7 , and V 8 each independently represents a covalent bond, —CO—, or —NR 15 --, --NR 15 (CH 2 ) q --, --NR 15 (C 6 H 4 ) -, -CONR 15 --, --NR 15 CO-, -C(O)O-, -OC(O)-, -O-, -S-, -S(O)-, -SO 2 -, -SO 2 N.R. 15 --, --NR 15 SO 2 -, -P(O)OH-, and -P(O)OH-, where each q is an integer from 1 to 6; Each R 13 is independently selected from hydrogen, alkyl, substituted alkyl, aryl, and substituted aryl; Each R 15 is independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, carboxyl, carboxyl ester, acyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl; A conjugate according to any one of claims 1 to 3 and 7, or a compound according to any one of claims 4 to 7.

9. T 1 However, (C 1 ~C 12 ) alkyl and substituted (C 1 ~C 12 ) alkyl; T 2 , T 3 , and T 4 each independently represents aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl; (EDA) w , (PEG) n , (C 1 ~C 12 ) alkyl, substituted (C 1 ~C 12 ) alkyl, (AA) p , -(CR 13 O.H. m -, 4-amino-piperidine (4AP), an acetal group, a hydrazine, and an ester; V 1 , V 2 , V 3 , and V 4 each independently represents a covalent bond, —CO—, or —NR 15 --, --NR 15(CH 2 ) q --, --NR 15 (C 6 H 4 ) -, -CONR 15 --, --NR 15 CO-, -C(O)O-, -OC(O)-, -O-, -S-, -S(O)-, -SO 2 -, -SO 2 N.R. 15 --, --NR 15 SO 2 -, and -P(O)OH-; During the ceremony, (PEG) n but, [C17] where n is an integer from 1 to 30; EDA has the following structure: [C18] where y is an integer from 1 to 6 and r is 0 or 1; 4-amino-piperidine (4AP) [C19] and Each R 12 and R 15 are independently selected from hydrogen, alkyl, substituted alkyl, polyethylene glycol moiety, aryl, and substituted aryl, and any two adjacent R 12 the groups may be cyclically linked to form a piperazinyl ring; R 13 is selected from hydrogen, alkyl, substituted alkyl, aryl, and substituted aryl; A conjugate according to claim 7 or a compound according to claim 7.

10. (a) T 1 However, (C 1 ~C 12 ) alkyl, V 1 is -CO-, T 2 is an amino acid analogue, V 2is -NH-, T 3 But (PEG) n And V 3 is -CO-, d is 0 or (b) T 5 is a covalent bond and V 5 is —CO—; f, g, and h are 0, or (c) T 5 is a covalent bond and V 5 is —CONR 15 —; T 6 is (C 1 -C 12 )alkyl and V 6 is -CO-; g and h are 0; A conjugate according to any one of claims 7 to 9, or a compound according to any one of claims 7 to 9.

11. (a) the drug is selected from the group consisting of a cytotoxin, a kinase inhibitor, an immunostimulant, a toll-like receptor (TLR) agonist, an oligonucleotide, an aptamer, a cytokine, a steroid, and a peptide; (b) the drug is selected from the group consisting of auristatins, maytansines, and duocarmycins; or (c) the drug is selected from the group consisting of tubulysin M, calicheamicin, SN-38, exatecan, STAT3 inhibitors, alpha-amanitin, aurora kinase inhibitors, belotecan, 9-aminocamptothecin (9-AC), and anthracyclines; A conjugate according to any one of claims 1 to 3 and 7 to 10, or a compound according to any one of claims 4 to 10.

12. The second enzymatically cleavable moiety: Galactosides, Glucoside, Mannosides, Fucosides, O-GlcNAc, or Contains O-GalNAc, A conjugate according to any one of claims 1 to 3 and 7 to 11, or a compound according to any one of claims 4 to 11.

13. 1. A pharmaceutical composition comprising: A conjugate according to any one of claims 1 to 3 and 7 to 12; and a pharma- ceutically acceptable excipient.

14. A conjugate according to any one of claims 1 to 3 and 7 to 12 for use in a method of treating cancer in a subject, said method comprising: administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising the conjugate; Conjugate.